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Re´sume´
La Radiothe´rapie Interne Vectorise´e (RIV) consiste a` de´truire des cibles tumorales en
utilisant des vecteurs radiomarque´s (radiopharmaceutiques) qui se lient se´lectivement
a` des cellules tumorales. Dans un contexte d’optimisation de la RIV, une meilleure
de´termination du de´poˆt d’e´nergie dans les tissues biologiques est primordiale pour la
de´finition d’une relation dose absorbe´e - effet biologique et pour l’optimisation des traite-
ment du cancer. Cela ne´cessite une e´valuation quantitative de la distribution de l’activite´
(avec la technique d’imagerie mole´culaire la plus approprie´e) et d’effectuer le transport
du rayonnement a` l’e´chelle a` laquelle se produisent les phe´nome`nes biologiques pertinents.
Les me´thodologies a` appliquer et les proble´matiques a` e´tablir de´pendent strictement de
l’e´chelle (cellule, tissu, organe) de l’application conside´re´e, et du type de rayonnement
en cause (photons, e´lectrons, particules alpha). Mon travail de recherche a consiste´ a`
de´velopper des techniques dosime´triques de´die´es (dosime´trie mono-e´chelle) et innovantes,
capables de prendre en compte la particularite´ de diffe´rents sce´narios expe´rimentaux (cel-
lulaire, pre´-clinique, RIV clinique). Les me´thodes mises en œuvres au cours de cette the`se
(dans le cadre d’application dosime´trique re´elles) sont :
• Le de´veloppement et la validation d’un mode`le cellulaire 3D qui ont permis une
meilleure compre´hension des processus radiatifs et non radiatifs associe´s a` la mort
cellulaire dans le cadre d’expe´riences de survie clonoge´nique avec des e´metteurs beˆta.
• Une application Monte-Carlo pour le calcul des distributions de dose absorbe´e dans
les tumeurs de souris ex vivo qui a permis d’e´tablir une relation dose absorbe´e - effet
pour trois anticorps diffe´rents marque´s par un e´metteur alpha (212Pb).
• Une comparaison des diffe´rents algorithmes de calcul de dose absorbe´e dans un con-
texte de diagnostic qui a mis en e´vidence les limites potentielles des approches do-
sime´triques standards actuellement utilise´es en clinique.
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• Une approche de re´solution adaptative pour la dosime´trie clinique (dosime´trie multi-
e´chelle) e´galement propose´e afin d’augmenter la pre´cision sur la dose absorbe´e dans
de petits organes radiosensibles.
Mots-cle´s : Radiothe´rapie interne vectorise´e - dosime´trie cellulaire - dosime´trie pre´clinique
- dosime´trie clinique - mode´lisation Monte Carlo - dosime´trie multi-e´chelle.
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La Radiothe´rapie Interne Vectorise´e (RIV) consiste a` de´truire des cibles tumorales en
utilisant des vecteurs radiomarque´s (radiopharmaceutiques) qui se lient se´lectivement a`
des cellules tumorales. Comme la radiothe´rapie externe, la RIV a l’avantage de de´livrer
une tre`s haute dose absorbe´e a` une cible spe´cifique, mais, elle a en plus en commun avec
la chimiothe´rapie, la capacite´ de fournir un traitement syste´mique en attaquant des sites
multiples dans le corps. Cependant, alors que la radiothe´rapie externe est une technique
de´ja` standardise´e pour laquelle des proce´dures strictes sont suivies en amont de la the´rapie
pour la planification de la dose absorbe´e au patient, en RIV la the´rapie est les plus souvent
administre´e par des quantite´s fixes de radioactivite´. La principale limite de cette approche
est de ne´gliger l’existence des diffe´rences me´taboliques d’un patient a` l’autre, compromet-
tant ainsi l’efficacite´ du traitement. Dans la mesure ou` la re´ponse me´tabolique a` un
radiopharmaceutique donne´ est spe´cifique a` chaque individu, une meˆme activite´ injecte´e
peut re´sulter en une dose absorbe´e tre`s diffe´rente sur une population des patients. Si la
dose absorbe´e par la tumeur est insuffisante, le risque de re´cidive devient plus important.
En revanche, si la dose absorbe´e par les organes radiosensisibles sains est trop importante,
le traitement peut avoir des effets toxiques de´le´te`res.
L’optimisation de la RIV passe donc par la mise en place de traitements the´rapeutiques
personnalise´s, incluant le fractionnement et/ou l’augmentation de l’activite´ administre´e,
qui permettront de gagner en efficacite´ et de limiter la toxicite´ pour les organes sains
(Pouget et al. 2011). Afin d’atteindre une efficacite´ the´rapeutique maximale, les doses
absorbe´es par la tumeur et les organes a` risque doivent eˆtre e´value´es avant le traite-
ment, a` travers une mesure personnalise´e de la biodistribution in vivo de la radioactivite´,
a` la fois dans l’espace et dans le temps, apre`s l’injection d’une quantite´ re´duite de ra-
diopharmaceutique. Le roˆle de la dosime´trie est d’interpre´ter ces mesures pour e´tablir
la quantite´ de radioactivite´ optimale qui devrait eˆtre administre´e. Aujourd’hui, de plus
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en plus d’e´le´ments indiquent que la re´alisation d’une dosime´trie personnalise´e en pre´-
traitement est ne´cessaire, et ame´liorerait conside´rablement la qualite´ et les re´sultats de la
RIV. Les be´ne´fices cliniques de la dosime´trie pour la RIV ont de´ja` e´te´ de´montre´es pour le
traitement des maladies be´nignes et malignes de la thyro¨ıde (a` la fois pour la toxicite´ et
pour l’efficacite´), pour l’utilisation de peptides radiomarque´es a` l’yttrium 90 (pour la tox-
icite´ re´nale, et partiellement pour l’efficacite´), pour l’utilisation d’anticorps radiomarque´s
a` l’iode 131 dans le traitement des he´mopathies malignes (efficacite´), et pour l’utilisation
de microsphe`res dans le traitement du cancer du foie (toxicite´ et efficacite´) (Strigari et al.
2014). Ne´anmoins, l’optimisation de la RIV clinique doit aussi s’appuyer sur une meilleure
e´valuation de la relation dose absorbe´e-effet, via des expe´riences pre´-cliniques dont le but
est de de´terminer l’efficacite´ et la toxicite´ propre des radiopharmaceutiques. Les connais-
sances acquises lors de ces expe´riences pourraient en effet fournir de nouvelles strate´gies
plus efficaces pour l’administration des traitements en RIV. En ce sens, tout effort cher-
chant a` faire progresser la RIV devrait conside´rer a` la fois une meilleure de´termination de
la dose absorbe´e dans un contexte clinique, et le de´veloppement de la dosime´trie cellulaire
et du petit animal.
La dosime´trie a` l’e´chelle cellulaire a pour but de mieux comprendre l’action de la
radiation ionisante sur le mate´riel biologique. Les connaissances actuelles en radiobiologie
proviennent pour l’essentiel de la radiothe´rapie externe, pour laquelle les doses absorbe´es et
les de´bits de dose absorbe´e sont parfaitement connus. Cependant, en RIV, les distributions
de vecteurs radiomarque´s sont tre`s he´te´roge`nes (meˆme a` l’e´chelle cellulaire), et l’e´mission
radiative est isotrope, de diffe´rents types et a` diverses e´nergies. L’effet biologique est
en outre module´ en pre´sence d’un de´bit de dose absorbe´ faible et variable (Wheldon
et al. 1990). La de´termination de nouveaux parame`tres de re´fe´rence radiobiologiques
est re´alise´e par des expe´riences de survie sur des colonies de cellules. Dans une meˆme
colonie, les cellules peuvent avoir diffe´rentes tailles, diffe´rents niveaux d’internalisation
de la radioactivite´ et diffe´rentes distributions intracellulaires d’activite´ : ce grand niveau
d’he´te´roge´ne´ite´ refle`te celui observe´ dans les tissus biologiques in vivo. Des travaux ont
de´ja` montre´ que l’he´te´roge´ne´ite´ des parame`tres des cultures cellulaires ont un impact
significatif sur la forme des courbes de survie cellulaire (Howell et al. 2012, Uusijarvi et
al. 2008).
A l’e´chelle du petit animal, la dosime´trie est ne´cessaire pour e´tablir la relation entre
la dose absorbe´e et l’effet biologique en RIV pre´-clinique, pour caracte´riser tant l’efficacite´
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que la toxicite´ des radiopharmaceutiques. Les e´tudes de dosime´trie pre´-clinique sont, en
ge´ne´rale, base´es sur des mode`les de calcul tre`s simplifie´s (i.e. des sphe`res pour simuler la
dose auto-absorbe´e a` la tumeur), et faisant l’hypothe`se d’une absorption homoge`ne de la
radioactivite´ par les organes et la tumeur. Cette simplification est directement lie´e aux
techniques employe´es pour de´terminer l’absorption de la radioactivite´ par les diffe´rents
tissus biologiques du petit animal. En effet, les e´tudes conventionnelles de biodistribu-
tion de la radioactivite´ sont re´alise´es par l’e´chantillonnage des tissus apre`s le sacrifice de
l’animal, tissus dont on mesure ensuite l’activite´ moyenne a` l’aide de compteurs gamma.
Ceci implique que toute e´tude des effets lie´s a` l’he´te´roge´ne´ite´ de la biodistribution est
ge´ne´ralement ne´glige´e.
Si l’on conside`re maintenant l’optimisation de la RIV dans son ensemble, une do-
sime´trie pre´cise implique la mode´lisation de l’interaction entre la radiation et le tissu
vivant a` l’e´chelle caracte´ristique des phe´nome`nes biologiques d’inte´reˆt : un parame`tre
important a` prendre en compte est alors la dimension relative du milieu de propagation
(cellule, tissu, corps) par rapport a` la longueur d’interaction dans le tissu de la radiation
conside´re´e (particules α ou β, e´lectrons Auger. . . ). De ce fait, le caracte`re pe´ne´trant ou non
de la radiation ne doit pas eˆtre conside´re´ comme une proprie´te´ intrinse`que mais plutoˆt
comme une proprie´te´ contextuelle, fonction des dimensions caracte´ristiques du syste`me
biologique e´tudie´. En conse´quence, on remarquera que l’imple´mentation d’un mode`le do-
sime´trique re´aliste et de´taille´ de tre`s haut niveau n’est pas force´ment la meilleure des
solutions dans toutes les circonstances. Par exemple, alors que la mode´lisation de la dose
absorbe´e duˆ au feu croise´ des cellules est cruciale en pre´sence d’un e´metteur β a` courte
longueur d’interaction tel que le lute´tium 177 (177Lu), il est correct de faire l’hypothe`se
simple d’une absorption comple`te dans l’organe source lorsque ce meˆme radionucle´ide est
utilise´ en clinique et que seule la dose moyenne absorbe´e par l’organe est d’inte´reˆt. De
fac¸on similaire, pour le calcul de la dose absorbe´e par la tumeur sur le petit animal,
l’he´te´roge´ne´ite´ de l’absorption de la radioactivite´ dans la tumeur peut, ou non, eˆtre un
parame`tre important selon que l’on utilise des radionucle´ides e´metteurs α (courte longueur
d’interaction) ou β (grande longueur d’interaction).
Ce travail de recherche a consiste´ a` de´velopper des me´thodes de calcul dosime´trique
de´die´es (dosime´trie mono-e´chelle) et innovantes, capables de prendre en compte la par-
ticularite´ de diffe´rents sce´narios expe´rimentaux (RIV cellulaire, pre´-clinique et clinique).
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Les me´thodes mises en œuvres au cours de cette the`se on e´te´ ve´rifie´es dans le cadre
d’applications dosime´triques re´elles.
Le premier chapitre est une revue des techniques et mode`les les plus souvent utilise´s
pour la dosime´trie cellulaire, animal et clinique. Les points forts et faibles de chaque
me´thode sont de´taille´s en fonction des conditions expe´rimentales de manie`re a` identifier
des possibles strate´gies pour l’optimisation de la dosime´trie pour la RIV a` diffe´rentes
e´chelles.
Le chapitre 2 est consacre´ au de´veloppement et a` la validation d’un mode`le do-
sime´trique cellulaire 3D in silico. Sur la base de parame`tres obtenus expe´rimentalement,
le mode`le ge´ne`re une ge´ome´trie re´aliste de la culture cellulaire en prenant en compte la
tendance des cellules a` s’agre´ger en amas de diffe´rentes tailles. Dans une meˆme colonie
virtuelle, les cellules peuvent avoir diffe´rents rayons, niveaux de radioactivite´ internalise´
et diffe´rentes distributions d’activite´ intracellulaire. Ce mode`le ge´ne´rique a e´te´ utilise´
pour de´river les courbes de survie de cultures de lymphocytes B traite´s avec des anticorps
monoclonaux marque´ au lute´tium 177. L’impact important de l’irradiation par tirs croise´s
en rapport a` l’irradiation par auto-absorption a montre´ que la mode´lisation comple`te et
de´taille´e de la ge´ome´trie de la culture cellulaire est ne´cessaire pour re´ussir une analyse
dosime´trique re´aliste a` l’e´chelle cellulaire dans le cas des e´metteurs β. Plus ge´ne´ralement,
le mode`le permet une meilleure compre´hension des processus radiatifs et non-radiatifs as-
socie´s a` la mort cellulaire dans le cas d’une expe´rience de survie clonoge´nique impliquant
des e´metteurs β.
Dans le chapitre 3, il est de´montre´ qu’un calcul dosime´trique approximatif sur une
tumeur peut masquer l’existence de la corre´lation dose absorbe´e-effet, si l’on est en pre´sence
d’une grande he´te´roge´ne´ite´ de l’absorption de la radioactivite´. Trois anticorps mono-
clonaux diffe´rents, marque´s au plomb 212 (212Pb), ont e´te´ e´value´s lors d’une expe´rience
pre´clinique de radioimmunothe´rapie mene´e sur des souris ayant des carcinoses pe´ritone´ales
de volume re´duit. La dose absorbe´e moyenne, estime´e par comptage des gamma sur des
tumeurs disse´que´es, n’e´tait pas corre´le´e aux courbes de survie des souris, mesure´es au cour
d’une expe´rience pre´ce´dente. En effet, des images de coupes cryoge´niques de tumeurs, ob-
tenues par autoradiographie digitale, ont permis de mettre en e´vidence des distributions de
la radioactivite´ tre`s diffe´rentes pour les trois anticorps : en particulier, l’un d’eux n’e´tait
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pas internalise´, la radioactivite´ restant distribue´e a` la surface de la tumeur. Seule une prise
en compte pre´cise de la distribution de la dose absorbe´e, via une me´thode dosime´trique
base´e sur des simulations Monte-Carlo, a permis de pre´dire correctement l’efficacite´ des
divers anticorps.
Dans le chapitre 4, il est montre´ que le choix de l’algorithme pour le calcul de la dose
absorbe´e, et l’utilisation de mode`les anatomiques approximatifs, peuvent introduire des
biais a` l’e´chelle clinique, en particulier lorsque la radiation gamma est importante (Mar-
catili et al. 2015). Comme e´tape pre´liminaire pour la compre´hension des avantages et/ou
des limites des me´thodes dosime´triques existantes en RIV clinique, un jeu de donne´es
constitue´ de scans se´quentiels TEP/TDM de 6 patients auxquels a e´te´ injecte´ du 18F-
Flutemetamol (General Electrics), a e´te´ analyse´ en suivant trois diffe´rentes approches :
dosime´trie base´e sur les fantoˆmes (logiciel OLINDA/EXM), dosime´trie base´e sur des Voxel
Dose Kernels (VDK) (logiciel STRATOS), et dosime´trie base´e sur des simulations Monte-
Carlo (application Gate de´die´e). Le choix d’e´valuer ces techniques dans le contexte d’une
dosime´trie a` vise´e diagnostique, a permis d’e´tudier dans un meˆme cadre les effets sur la
dose absorbe´e d’e´missions a` courte (positron) et a` grande (gamma de 511 keV) longueurs
d’interaction. Si, dans un contexte diagnostique, les approches dosime´triques base´es sur
des fantoˆmes et VDK se sont montre´es rapides et ade´quates, un regard plus ge´ne´ral sur le
proble`me sugge`re que l’utilisation de ces me´thodes dans un cadre clinique ne permettrait
pas d’obtenir une dosime´trie pre´cise.
Actuellement, la me´thode la plus pre´cise pour la re´alisation d’une dosime´trie per-
sonnalise´e consiste a` exploiter les informations morphologiques obtenues a` l’e´chelle du
voxel par les techniques d’imagerie 3D, afin de re´aliser le transport direct de la radiation
e´mise par le radiopharmaceutique conside´re´ via des simulations Monte-Carlo. Cepend-
ant, le proble`me principal de cette me´thode est son manque de re´alisme pour les petites
structures radiosensibles (i.e. moelle osseuse, œil. . . ), structures pour lesquelles la dose
absorbe´e est ge´ne´ralement celle qui limite l’activite´ maximale administre´e lors du traite-
ment. Le chapitre 5 pre´sente une solution permettant de surmonter ce proble`me par
l’imple´mentation d’une technique de re´solution adaptative applique´e a` l’e´chelle clinique
(dosime´trie multi-e´chelle). Cette me´thode permet en particulier d’ame´liorer la pre´cision
de l’estimation de la dose absorbe´e dans les organes radiosensibles de petite dimension
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(Marcatili et al. 2014). Les descriptions voxelise´es et analytiques de la ge´ome´trie sont
combine´es afin de profiter a` la fois du haut niveau de personnalisation de l’imagerie 3D et
du re´alisme anatomique des me´thodes analytiques (dosime´trie multi-re´solution). En outre,
dans la mesure ou` la simulation de la distribution de la dose absorbe´e pour un corps entier
de´crit par une ge´ome´trie au maillage tre`s fin est difficilement re´alisable, on de´montrera
que cette nouvelle approche permet d’obtenir une dosime´trie pre´cise dans les structures
choisies, tout en limitant le temps de calcul total. Comme preuve de principe, l’exemple
d’une vessie contenant une distribution homoge`ne d’iode 131 (131I) a e´te´ mis a` l’e´tude :
l’estimation de la dose maximale absorbe´e par la paroi de la vessie est quatre fois plus
importante lorsque l’on utilise un mode`le haute re´solution, re´ve´lant ainsi un proble`me po-
tentiel de toxicite´ que le mode`le basse re´solution, approximatif par nature, ne peut mettre
en e´vidence.
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In Targeted Radionuclide Therapy (TRT), a radioactive isotope is usually attached to a
biological vector (to form a radiopharmaceutical) that selectively seeks out tumour cells.
As with External Beam RadioTherapy (EBRT), TRT offers the advantage of delivering
high absorbed doses to specific targets, but in common with chemotherapy, it can deliver
treatment systemically, attacking multiple sites throughout the body. However, while
EBRT treatment delivery is highly standardised and specific procedures are established
for the evaluation of patient absorbed dose before therapy, in TRT, treatments are most
often administered according to fixed amount of radioactivity. The main limitation of
this approach is to neglect the existing inter-patient variability, thus compromising the
efficacy of the treatment. Since the metabolic response to a given radiopharmaceutical is
different for each individual, the same administered activity may result in very different
absorbed doses in a population of patients. At one extreme, the absorbed dose to the
tumour may be too low, causing the occurrence of relapses; at the other, absorbed dose
to radiosensitive healthy organs may be too high inducing toxic effects.
Optimisation of TRT relies on personalized therapeutic schedules, with fractionation
and/or intensification of administered activity in order to increase efficacy, while maintain-
ing acceptable toxicity (Pouget et al. 2011). In order to attain the therapeutic efficacy,
absorbed dose to tumour(s) and organs at risk should be estimated before the treatment,
evaluating patient-specific biodistribution in vivo (both in space and time) after the injec-
tion of a reduced amount of radiopharmaceutical. The role of dosimetry is interpreting this
knowledge to establish the amount of radioactivity that should be administered. Today,
there is increasing evidence that personalised pre-treatment dosimetry is necessary and
would improve the quality and outcome of TRT. Clinical benefit of dosimetry in TRT has
already been demonstrated in the treatment of benign and malignant thyroid disease (for
toxicity and efficacy); for the use of 90Y-labelled radiopeptides (for renal toxicity and, par-
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tially, efficacy); for the use of 131I- labelled antibodies in the treatment of haematological
malignancies (efficacy); and for the use of microspheres in the treatment of liver cancers
(toxicity and efficacy) (Strigari et al. 2014). Nevertheless, clinical TRT optimisation also
relies in a better evaluation of the absorbed dose-effect relationship in pre-clinical ex-
periments aiming to assess efficacy and toxicity of radiopharmaceuticals. The knowledge
derived from these investigations may in fact provide novel and more effective strategies
for TRT treatment delivery. In this sense, any effort for the advancement of TRT should
consider, not only a better determination of the absorbed dose in a clinical settings, but
also the development of cellular and small animal dosimetry.
The goal of cell scale dosimetry is to better understand the action of ionizing radiation
on biological material. Most of the current radiobiology knowledge derives from external
beam radiotherapy, where absorbed doses and absorbed dose rate are completely char-
acterized. However, TRT results in heterogeneous distribution of radiolabelled vectors,
even at the cellular scale, with an isotropic emission of radiations of different type and en-
ergy. In addition, the biologic effect is impacted by a low and varying absorbed dose rate
(Wheldon et al. 1990). The derivation of new radiobiological parameters is performed
through survival experiments in cell colonies. Within the same colony, cells may have
different sizes, different levels of radioactivity internalization and different intracellular
activity distributions: this reflects the high level of heterogeneity displayed by a tissue
in vivo. Previous works have demonstrated that heterogeneity of cell culture parameters
produces significant effects on the shape of survival curves (Howell et al. 2012, Uusijarvi
et al. 2008).
On the other hand, small animal dosimetry is necessary to establish the relationship
between absorbed dose and biological effects during preclinical TRT, both in terms of
efficacy and toxicity. Preclinical dosimetric studies are in general based on simplistic
computing models (i.e. spheres that simulates the self-absorbed dose for a tumour) and
on the assumption of homogeneous organ/tumour uptake; this directly depends on the
techniques employed to determine animal uptake of radioactivity in different tissues. A
conventional biodistribution study will in fact rely on tissue sampling after animal sacrifice
and average activity concentration determination on gamma counters. This means that
any investigation of the heterogeneity-related effects is usually neglected.
Considering the optimisation of TRT as a whole, accurate dosimetry implies modelling
the interaction between radiation and the living tissue at the scale at which biologically
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relevant phenomena occur: an important parameter to account for is the relative dimen-
sion of the propagating medium (cell, tissue, body) with respect to the range in tissue of
the considered radiation (α- or β-particles, Augers electrons...). In this regard, the penet-
rating or non-penetrating quality of the radiation should not be interpreted as an intrinsic
property but rather considered with respect to the characteristic sizes of the biological
system of interest. This implies that implementing the most realistic and detailed dosi-
metric model is not necessarily the best solution in all circumstances. For example, while
modelling the cross-irradiation absorbed dose in a cell culture treated with a short range
β-emitter (i.e. 177Lu) is crucial to achieve realistic dosimetry, complete self-absorption
within the source organ may be safely assumed when the same radionuclide is used in
the clinics and the average organ absorbed dose is of interest. At the same time, for the
calculation of tumour absorbed dose in small animal experiments, the heterogeneity of ra-
dioactivity uptake within the tumour may, or may not, be a relevant parameter depending
on whether α- or β-emitting radionuclides are employed.
This research work consisted in developing dedicated computational dosimetric ap-
proaches (single-scale dosimetry) capable of taking into account the peculiarity of different
experimental scenarios (cellular, preclinical, clinical TRT). All methods developed were
tested in the framework of actual research applications and experiments.
The first chapter provides a review of the most common techniques and models cur-
rently available for cellular, animal and clinical dosimetry. Their strengths and weakness
are analysed in different experimental conditions in order to identify possible strategies
for TRT dosimetry optimisation at different scales.
In chapter 2, the development and validation of a 3D cellular dosimetric model (in
silico) is reported. On the basis of experimentally determined parameters, the model
generates realistic culture geometries taking into account cell tendency to aggregate into
clusters of different sizes. Within the same virtual colony, cells may have different radii,
different levels of radioactivity internalization and different intracellular activity distribu-
tions. This general-purpose model was applied to the establishment of clonogenic survival
curves for in-vitro lymphocyte B cell colonies treated with 177Lu-labeled monoclonal an-
tibodies (mAbs). The high impact of cross-irradiation with respect to self-absorption
demonstrated that a full modelling of cell culture geometry is necessary to achieve real-
istic dosimetry in the case of β-emitters, at the cellular level. More generally, the model
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allowed a better understanding of the radiative and non-radiative processes associated to
cellular death in the case of clonogenic survival experiments involving β-emitters.
An example of how approximate tumour dosimetry could mask an existing absorbed
dose-effect correlation in the case of heterogeneous radioactivity uptake, is discussed in
chapter 3. Three different mAbs labelled with 212Pb, were evaluated in a preclinical
radioimmunotherapy (α-RIT) experiment involving mice with small volume peritoneal
carcinomatosis. Average absorbed doses based on gamma counting of dissected tumours
did not correlate with mice survival curves assessed in previous experiments. Indeed, Di-
gital AutoRadiography (DAR) images of tumour cryosections highlighted a very different
radioactivity distribution for the tree mAbs: in particular, one of them did not internalise,
with all the radioactivity remaining at tumour surface. For this reason, the actual efficacy
of the three labelled-mAbs could only be predicted by considering their absorbed dose
distribution (obtained by Monte Carlo dosimetry).
In chapter 4, it was demonstrated that the choice of the absorbed dose calculation
algorithm and the implementation of approximate anatomical models may introduce a
bias, at the clinical scale, especially when gamma radiations are of importance (Mar-
catili et al. 2015). As a necessary step to understand the advantages and/or limits of
currently available dosimetric methods in clinical TRT, the same dataset, consisting of se-
quential PET/CT scans of 6 patients injected with 18F-Flutemetamol (General Electrics),
was analysed with three different approaches: phantom-based dosimetry (OLINDA/EXM
software), Dose Voxel Kernel (DVK) dosimetry (STRATOS software), and Monte Carlo
dosimetry (Gate custom application). The choice of evaluating these techniques in a
diagnostic context has allowed to consider, at the same time, the impact of both short
(positron) and long (511 keV gammas) range emissions on the absorbed dose calculation
algorithm. While in a context of diagnostic dosimetry, the phantom-based and the DVK
approaches resulted to be fast and adequate, a more general look at the problem suggested
that the use of these approaches in a therapeutic setting, could prevent the achievement
of accurate dosimetry.
Currently, the most accurate approach for the assessment of personalised dosimetry,
consists on exploiting morphological information obtained at the voxel level through 3D
imaging, to directly transport radiations emitted by the radiopharmaceutical considered
(Monte Carlo method). However, the main drawback of this approach is its lack of anatom-
ical realism for small radiosensitive structures (i.e. bone marrow, eye...) whose absorbed
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dose ultimately limits the maximum tolerated activity for the treatment. In order to
overcome this issue, in chapter 5, an adaptive resolution approach to clinical dosimetry
(multi-scale dosimetry) is also proposed to increase the accuracy of absorbed dose de-
livery in small radiosensitive organs (Marcatili et al. 2014). Voxelised and analytical
geometry descriptions are combined in order to bring together the level of personalisation
achieved through 3D imaging, and the anatomical realism of the analytical method (multi-
resolution dosimetry). Since the simulation of very finely sampled, whole body absorbed
dose distributions is not computationally feasible, this approach will allow to achieve ac-
curate dosimetry in selected structures, while keeping computation time low. In a proof
of principle example consisting of a bladder homogeneously filled with 131I, the maximum
absorbed dose to the bladder wall was four times higher when implementing a high resolu-
tion model, thus predicting potential toxicities that are hidden by the approximate nature
of a low resolution model.
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Chapter 1
Computational methods for
Targeted Radionuclide Therapy
1.1 Targeted Radionuclide Therapy
Surgical resection, either alone or in combination with External Beam RadioTherapy
(EBRT), is nowadays the most widely employed therapeutic strategy for the treatment of
locoregional tumours. In the case of diffuse systemic cancers, however, a surgical approach
is not feasible, and the applicability of EBRT is limited. In this context, chemotherapy
is, at present, the technique of choice, even if its administration results in high morbidity
and important side effects.
Targeted Radionuclide Therapy (TRT), also called Molecular RadioTherapy (MRT),
consists in the administration of radiolabelled vectors that specifically binds to tumour
cells and produce radiation-induced cytotoxic effects. TRT offers the advantage of target
selectivity achievable in EBRT treatments, while being systemic as chemotherapy. In ad-
dition, its toxicity is generally limited to the haematopoietic tissue, and few side-effects are
observed (Chatal and Hoefnagel 1999). According to the biochemical pathway selected,
and to the physical characteristics of the tumour, different vectors and radionuclides can be
used for a variety of therapeutic applications. Separate branches of TRT are usually iden-
tified depending on the targeting mechanisms employed (Dash et al. 2013). These include
cellular metabolic processess for accumulation of radioactive iodine in thyroid cancer cells,
the use of specific cell surface receptors for accumulating radiolabelled peptides (Peptide
Receptor Radionuclide Therapy, PRRT) and cell surface antigens to target monoclonal
antibodies (Radioimmunotherapy, RIT).
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Treatment of differentiated thyroid cancer (DTC), both papillary and follicular, with
131I is by far the most common and established procedure in TRT. It takes advantage
of the naturally occurring iodine uptake mediated by thyroid cells for the synthesis of
thyroid hormones. On this basis, radioactive iodine treatments are dispensed to ablate
remnant thyroid tissue after surgery in order to reduce the recurrence rate, and to treat
iodine-avid metastases. Available data show a remarkable efficacy of this therapy, with
a 5-year relative survival rates between 83 and 98% for patients with iodine-avid DTC,
while the survival drops to 66% in the case of non-avid DTC (Worden 2014).
In PRRT tumour cells are targeted with radiolabelled peptides. Peptides are molecules
consisting of two or more aminoacids linked together with peptide bond, and that regulates
many physiological processes in the human body, acting at some sites as endocrine or
paracrine signals and, at others, as neurotransmitters or growth factors (Santos 2012).
Peptides usually display favorable pharmacokinetics characterised by high concentration
in the target tissue and rapid clearance from the blood and non-target tissues. However,
high uptake in the kidneys is sometimes a concern as it may cause potential nephrotoxicity.
PRRT is mainly used for the treatment of endocrine tumour as most of them over-express
receptors that binds to somatostatin, a peptide hormone that regulates the endocrine
system. Octreotide and octreotate are somatostatin analogues that binds to somatostatin
receptors on neuroendocrine tumours. In PRRT they are usually combined with 90Y,
177Lu or 111In to deliver a lethal absorbed dose to the tumour.
Antibodies are integral agents of our immune system, primarily used to identify and
aid in the clearing of foreign pathogens. In RIT, radiolabelled monoclonal antibodies
(antibodies with monovalent affinity) are used to target specific antigens that are over-
expressed in cancer cells and under-expressed in normal cells. The concept of RIT was
initially proposed, more than a century ago by Ehrlich (Ehrlich 1899). However, his work
had a limited success due to the unavailability of specific tumour antibodies at the time. In
1976, with the development of the hybridoma technique (Breedveld 2000), the production
of monoclonal antibodies (mAbs) was made possible, increasing the scientific community
interest in RIT. Nowadays, RIT is primarily used for the treatment of haematological ma-
lignancies such as non-Hodgkin’s lymphoma (NHL). Antibody therapy with Rituximab
is commonly administered to NHL patients (immunotherapy); the use of radioimmuno-
conjugates augments the effectiveness of the cold mAbs, producing lethal effects also to
cancerous cells not expressing the targeted antigen. Currently, two commercial radiola-
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belled antibodies are available for treatment of follicular NHL, 90Y-ibritumomab tiuxetan
(Zevalin) and 131I-tositumomab (Bexxar). Both of them target the CD20 antigen expressed
at the surface of pre–B lymphocytes, mature B lymphocytes and more than 90% of B-cell
NHL (Ersahin et al. 2007); the antibodies recognise epitopes in the extracellular domain
of the CD20 antigen, and form antibody-antigen immune complexes, which induce apop-
tosis, complement-dependent cytotoxicity, and antibody-dependent cytotoxicity. RIT is
usually administered along with sufficient unlabelled antibody to saturate the non-tumour
antibody binding sites, and to potentially increase tumour to background ratio. Efficacy
of RIT was demonstrated for patients who are refractory to unlabelled anti-CD20 immun-
otherapy and chemotherapy, or have relapsed after these therapies (Goldsmith 2010).
Other forms of TRT include treatments of neuroendocrine tumours with I-131-meta-
iodobenzylguanidine (MIBG) and metastatic bone pain palliation.
MIBG structurally resembles norepinephrine and hence, it enters neuroendocrine cells
by an active uptake mechanism and is stored in the neurosecretory granules. On this basis,
131I-mIBG is mainly used to image and treat symptomatic medulla neoplasms, such as
neuroblastoma and pheochromocytoma, but also for the treatment of medullary thyroid
cancer, and carcinoid tumours.
Pain palliation with bone-seeking radiopharmaceuticals is a common practice in pa-
tients with skeletal metastases especially from advanced breast and prostate cancers, for
which more than 50% of patients develop bone metastases (Dash 2013). While the use of
radiopharmaceuticals in tumour therapy involves their binding to the tumour cells, bone
therapy targets the reactive osteoblastic reaction in the normal bone directly adjacent to
the metastasis, which is generally the cause of pain. Bone pain palliation therapy is admin-
istered either with natural boneseekers radionuclides acting as calcium analogues, or with
radionuclides chelated to organic phosphates. Traditionally, beta emitting radionuclides
are selected for this kind of treatments: 89Sr-chloride (MetastronR©) and 153Sm-EDTMP
(QuadrametR©) are the most commonly employed radiopharmaceuticals for bone pain palli-
ation. More recently, an alpha-emitter, 223Ra-dichloride (XofigoR©) has been also approved
for clinical use. Xofigo is especially promising because in addition to providing pain pal-
liation, it was shown to extend overall survival of men with metastatic prostate cancer
(Parker et al. 2013).
Like any therapy involving ionising radiation, TRT’s goal is to achieve the highest
efficacy delivering the highest possible absorbed dose to the tumour, while sparing healthy
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tissues. In order to achieve this objective, the choice of a highly specific vector, must be
combined to a careful selection of the most appropriate radionuclide according to its decay
properties and emissions.
1.1.1 Radionuclides for TRT
In TRT the radiations of primary interest are particle emissions (α, β and Auger) causing
non-reparable damage to nuclear DNA strands by radiation-induced processes as ionisa-
tion. The choice of the most appropriate radionuclide for a given therapeutic application
depends on its chemical and physical characteristics, that should be consistent with the
selected administration pathway and the type and size of tumour being treated.
Regarding its chemical properties, the radionuclide selected is expected to produce a
stable radionuclide-vector bond; to have high specific activity (i.e. the number of labels
per molecule obtainable); to be available with high purity (radionuclidic, radiochemical,
and elemental purity) and free from trace metal contamination.
For what concerns its physical characteristics, most importantly, the radionuclide half
life should be compatible with the in-vivo pharmacokinetics of the targeting molecule. A
too short half life, in fact, may produce a high number of disintegrations before radio-
pharmaceutical binding to the target, thus leading to a significant non-specific irradiation
and potential toxicity for the healthy tissues. Conversely, a too long period may lead,
to very low absorbed dose rate irradiations that would limit the treatment efficacy for
tumour control. At the same time, the consequently long radiopharmaceutical excretion
time would cause serious radioprotection issues associated to patient care and radioactive
waste disposal.
Another important parameter to consider is obviously the type of radiation emitted
by the radionuclide, with particular attention to its its Linear Energy Transfer (LET).
The LET is defined as the amount of energy deposited by the ionising radiation per unit
length of path, and it is usually expressed in keV/μm. This property depends on the type
of particle and plays an important role on radiobiological effects. In TRT applications,
radionuclides should be carefully selected on the basis of emitted particles LET, taking
into account tumour size and radiopharmaceutical internalisation properties.
Finally, the availability of a gamma emission component is a desirable characteristic as
it allows monitoring the radiopharmaceutical distributions in vivo both for pre-treatment
dosimetry and therapeutic response. Ideally, gamma radiation should be of low abundance
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to minimize the contribution to non-target organs, and low energy (100-200 keV) to provide
effective gamma camera imaging.
In the next paragraphs, the physical properties of the particle emissions of interest for
TRT application will be described in more detail. Table 1.1 provides a summary of their
main physical characteristics.
Figure 1.1: Schematic representation of Auger, α- and β-particles range in tissue, at the cellular
scale. Source: Pouget et al. 2011.
1.1.1.1 Beta emitters
Beta particles are electrons released through beta decay in combination with an antineut-
rino. Since the decay energy is shared between these two particles, the electron presents
a continuous energy spectrum between 0 and Emax, with Emax being the energy of the
transition. Typically, Emax goes from tenths to hundreds of keV, corresponding to a max-
imum electron range in water of several millimeters. Among the radionuclides employed
in TRT, 90Y is the most energetic, with a maximum range in water of 1.1 cm, even if 90%
of its energy is deposited within the first few mm (Roeske et al. 2008).
Relatively low energy electrons, as β-particles, mainly deposit their energy through
collisional losses involving excitation and ionisation of the atoms in the medium. Since
their interactions are mainly with particles of the same mass (orbital electrons in the
medium), these can result in large scattering angles. As a consequence, electrons follow a
very tortuous path. Figure 1.2(a) shows a schematic view of a typical β-particle trajectory
in the biological tissue at the cellular scale: beta range can cover hundreds of cell diameters
(cross-irradiation). The linear energy transfer for β-particles is low (0.2 - 4 keV/μm) in
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comparison to that of α-particles and Auger electrons.
All these characteristics make β-particles effective for the treatment of medium-large
size tumours (of the order of 1cm radius or less). Their range, in fact, is short enough
to keep irradiation within the neighborhood of the emission point. At the same time, the
cross-fire effect at the cellular level reduces the need of targeting each single tumour cell
in order to achieve an effective treatment. Currently, 131I, 90Y and 177Lu are among the
most widely employed β-emitters in TRT.
1.1.1.2 Alpha emitters
Alpha particles are positively charged (+2), mono-energetic helium nuclei (42He) with typ-
ical energies ranging from 3 to 9 MeV (Roeske et al. 2008). Alphas primarily interact
through Coulomb forces between their positive charge and the negative charge of orbital
electrons within the absorber atoms, causing atom ionisation and excitation. Given their
large mass (∼ 4 MeV) with respect to that of electrons (∼ 0.5 MeV), they are basically
undeviated by the interaction, and therefore follow a very straight path in tissue. Their
LET is of the order of 80 keV/μm at the beginning of their track, and increases approxim-
ately to 300 keV/μm at the end, due to electron pick-up that reduces α-particles’ charge.
Their consequent short range in tissue, varying between 5 and 10 cell diameters (50-100
μm), results in a significant amount of energy deposited near the point of emission. Figure
1.2(b) shows the typical track of α-particles in tissue at the cellular scale, compared to
that of β-particles. In figure 1.1, their range is compared to those of beta and Auger
electrons.
Alpha particles short range makes them suitable for the treatment of micrometastases
and very small tumours, allowing for localised irradiation of target cells with minimal
radiotoxicity for the sourrounding normal cells. At the same time, given the lack of cross-
fire effect, a uniform cell labelling should be achieved for the treatment to be effective.
Because of their high LET, α-particles are of great interest from a radiobiological point
of view. It has been shown, in fact, that as few as 1-3 tracks across the nucleus may
result in cell death (Roeske et al. 2008). In addition, their killing effect is independent of
dose rate, oxygenation level, and cell cycle state (Sofou 2008). However, only a handful of
α-emitters have suitable characteristics for clinical use. Many progenitors, in fact, present
a short half-life that severely limits radionuclide shipment from the site of production. At
the same time, the absence of stable daughters in most decay chains involving emissions of
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α-particles, makes it very difficult to fully characterise the radiolabelled compounds being
developed and poses important radioprotection issues. At present, 223Ra, 211At, 212Bi,
212Pb,, 213Bi and 225Ac are the most commonly used α-particles emitters in TRT.
Figure 1.2: Schematic representation of β- and α-particles tracks at the cellular scale. Source:
Couturier et al. 2005.
1.1.1.3 Auger emitters
Auger electrons are low energy, orbital electrons whose emission is usually the result of
two nuclear processess: electron capture (EC) and internal conversion (IC). In both cases,
the spectrum of the emitted electrons presents several mono-energetic emissions going
from few eV to tenths of keV. When travelling across biological material, Auger electrons
undergo the same physical processes that characterise β-particle interactions. However,
given their lower energies, they exhibit significantly higher LET (4 - 26 keV/μm) and
much shorter range (several nanometers). While α- and β-particles deposit their energy
at the cellular scale, (see figure 1.1), the energy deposition of Auger electron is confined
within the labelled cell. For this reason, Auger electrons are only effective when bound to
carriers molecules that can cross cell membrane and reach the nucleus to cause damage
to the DNA. If, on one side, their short range minimises toxicity to normal cells, on the
other, it may negatively impact on therapeutic efficacy. The application of Auger emitters
to TRT, still remains an area of research (Sofou 2008).
1.1.1.4 The role of dosimetry in TRT
Optimisation of TRT treatments relies on personalized therapeutic schedules, with frac-
tionation and/or intensification of administered activity, in order to increase efficacy while
maintaining acceptable toxicity (Pouget et al. 2011). An essential prerequisite to TRT
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Characteristic Beta Alpha Auger
Energy 0.05 – 2.5 MeV 3 – 10 MeV 10 eV – 10 keV
Range 0.2 – 11 mm 50 – 100 μm 10 nm
LET 0.2 – 4 keV/μ m 80 – 300 keV/μm 4 – 26 keV/μm
Path track Tortuous Straight Contorted
Mechanism Cross fire effect Traversed path length
in cell nuclei
Breaks in DNA
strands
Requisite Close to target/
cell surface
Binding to
cancer cells
Incorporation
into nucleus
Cross-fire effect Yes No No
Table 1.1: Summary of beta, alpha and Auger emissions characteristics. Adapted from Dash et
al. 2013.
optimization is dosimetry. Its role, in a clinical context, is to establish the amount of
radioactivity to administer, on the basis of patient biokinetics data, available from nuclear
medicine imaging. The value of dosimetry in assessing therapeutic outcome and toxicit-
ies has already been demonstrated in several clinical applications (Strigari et al. 2014).
In preclinical experiments (both at the animal and and the cellular scale) establishing
treatment efficacy is also crucial for the evaluation and comparison of novel radiophar-
maceuticals before Phase I studies on humans. Nevertheless, while the implementation of
dosimetry in EBRT is well established and has seen continuous improvements and stand-
ardisation in the past decades, dosimetry in TRT is far from reaching the same level of
advancement. Todays, TRT treatments are typically delivered with fixed level of activities,
neglecting inter-patient variability in terms of radiopharmaceutical uptake and metabolic
response. The choice of the administered activity is often made conservatively in order
to avoid potential toxicities, and on the basis of dose-limits inferred from a population
of patients (cohort-based treatment planning). This approach most commonly leads to
the delivering of sub-therapeutic treatments, eventually causing the occurrence of relapses.
On the other hand, some individuals may still develop radiation-induced toxicities because
of longer than average radiopharmaceutical retention (Glatting et al. 2013). In addition,
even when pre-therapy dosimetry is performed to optimise treatment delivery, the current
situation is that of a wide heterogeneity of implemented dosimetric approaches, which
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ultimately limits the development of patient-specific TRT (Lassmann et al. 2011). The
following sections introduce a critical review of the most commonly employed computa-
tional dosimetric methods and models in TRT. Their main advantages and drawbacks are
also identified and commented.
1.2 The MIRD schema for the calculation of the absorbed
dose
The absorbed dose (D) is defined as the energy (E) deposited in a given tissue per unit
of mass (M), and it is expressed in gray (1 Gy = 1 J/kg):
D(Gy) =
E(J)
M(kg)
(1.2.1)
In targeted radionuclide therapy, according to standard, time-independent MIRD formu-
lation (Bolch et al. 2009), the absorbed dose to a target region rT can be expressed as the
sum of the contribution from all source regions rS :
D(rT ) =
∑
rS
A˜(rS , TD)S(rT ← rS) (1.2.2)
where A˜(rS , TD) is the time-integrated activity (also called cumulated activity in Loevinger
et al. 1991) in the source region rS over the absorbed dose-integration period TD, and
S(rT ← rS) is the absorbed dose in the target per disintegration in the source (also called
S value). In the particular case source and target regions coincide, equation 1.2.2 only
includes the term for rS = rT , and the absorbed dose is generally referred to as self-
absorbed. At the same time, the absorbed dose due to the radioactivity in source regions
other than the target (rS = rT ), is identified as cross-irradiation absorbed dose.
In this section and in the following, the terms “source”and “target”are used generically
without further specifications. Indeed, despite its remarkably simple formulation, the
MIRD schema can be applied to a wide range of scenarios. Source and target regions
can hence be identified as organs, tissue subregions, voxelized tissues or organ structures,
cellular compartments and so on.
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1.2.1 Time-integrated activity
The first term of equation 1.2.2, A˜(rS , TD), expressed in units of Bq s, represents the
number of disintegrations occurring in a source regions rS during treatment time TD,
and depends on the half life of the radionuclide and its spatial and temporal distribution
in the source. These properties are specific of each radiopharmaceutical and depend, in
turns, on the metabolism of the source, its uptake (defined as the fraction of injected
activity absorbed in the region of interest) and its clearance. The amount of activity
contained in a source region changes with time. If the time-activity curve is known, the
cumulated activity for a source organ is obtained by measuring the area under this curve.
Mathematically, the time-activity curve can generally be modeled as:
A(rS , t) = A0 fS(t) e
−(λp+λb)t (1.2.3)
where A0 is the injected activity at time t = 0, fS is the fractional uptake in source rS ,
and λp and λb are the physical and biological decay constants of the radiopharmaceutical.
The cumulated activity can be calculated integrating equation 1.2.3:
A˜(rS , TD) = A0
∫ TD
0
fS(t) e
−(λp+λb)t (1.2.4)
In clinica TRT dosimetry, TD is usually set to infinite as the radiopharmaceutical acts
in the patient body until its complete biological excretion and/or physical decay. For
pre-clinical applications, as for examples cell cultures incubated with radioactivity, TD is
limited to the time frame the radiopharmaceutical interacts with the biological system
considered.
1.2.2 Absorbed dose per unit activity
The second term of equation 1.2.2, S(rT ← rS), is a radionuclide-specific quantity that
represents the mean absorbed dose to the target region, per disintegration in the source
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region, and it is expressed in units of Gy/Bq s. The S value can be written as:
S(rT ← rS) = 1
MrT
∑
i
Δi φ(rT ← rS , Ei) (1.2.5)
whereΔ i is the mean energy of the i
th transition per nuclear transformation, and φ(rT ←
rS , Ei) is the absorbed fraction, defined as the fraction of emitted energy Ei that is ab-
sorbed in the target region of mass MrT . The energy emitted per disintegrationΔ i only
depends on the radionuclide considered and can be derived from standard physics or do-
simetry tables (Eckerman and Endo 2008, Browne and Firestone 1986). Conversely, the
absorbed fraction accounts for the emission type, the energy, and the geometry of source
and target tissues. Given the impossibility of directly measuring the absorbed fraction, this
is most often determined una-tantum by Monte Carlo simulations of particle propagation
in virtual geometries presenting the same shape and composition of the tissue modelled.
In the case of simple geometries, S values have also been calculated analytically through
the integration of absorbed dose kernels over target volume. Depending on the spatial
accuracy of the geometry selected, the determination of the S values may take place at
the macroscopic level, neglecting tissue and radioactivity heterogeneity within the selec-
ted region (region-based dosimetry), or with a more refined spatial resolution that allows
modelling sub-region heterogeneities (voxel dosimetry). In any case, the establishment of
a virtual model of the biological system considered is a prerequisite for the calculation of
S values. In the next paragraphs, the principal models and methods developed for region-
or voxel-based dosimetry in clinical, pre-clinical and cellular contexts are presented.
1.3 Digital models for region-based dosimetry
For region-based TRT dosimetry, the use of digital models allows calculating region S
values for any radionuclide of interest and a large number of target-source combinations
(depending on the spatial resolution and realism of the model adopted). The primary
advantage of this approach is that the S values obtained can be stored for later use, thus
avoiding the need to perform time-consuming Monte Carlo simulation for each dosimetric
calculation.
In the last 60 years, research groups worldwide have developed virtual models of any
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kind to make it possible the generation of S values at the clinical, animal and cellular
scales.
1.3.1 Anthropomorphic models
In clinical TRT dosimetry, anthropomorphic models of different kinds are often employed
to establish organ S values that, in combination with patient-specific pharmacokinetic
information, can be used to calculate the absorbed dose delivered to the patient. However,
this strategy clearly implies that the model used is representative of patient anatomy.
The concept of Reference Man was proposed by the International Commission on Ra-
diological Protection (ICRP) after the end of the Second World War for use in radiological
protection. The Reference Man1 is an individual with a physiology and organs of size,
mass and composition representative of a given population. The use of a dosimetric model
issued from Reference Man characteristics, however, does not guarantee that the model
matches patient morphology. Because of this, tabulated S values are primarily used for
diagnostic applications where the absorbed doses are low, so that the inherent inaccuracies
in modelling a given patient are of no practical concern and largely balanced by trace-
ability and possible comparison of different radiopharmaceuticals. In principle, it would
be inappropriate to use a reference model in TRT planning, as the resulting errors can
lead to the deliver of inadequate absorbed dose to the tumour or to excess irradiation of
normal healthy tissue. However, in the absence of an approach of easy implementation,
model-based dosimetry is nowadays largely employed also for radiotherapy applications.
In the last 60 years, researcher worldwide have put considerable effort in generating
human models for the calculation of internal radiation dose. Most of them were developed
for the assessment of population-based risk of internal exposure, while others were con-
ceived for medical imaging and radiotherapy (both EBRT and TRT) applications. The
very first human model was proposed by ICRP in 1959 (ICRP 1960). It represented the
total body as a 30 cm sphere, and each organ as a sphere with different “effective radii”.
The radionuclide of interest was assumed to be located at the center, for the calculation
of the “effective absorbed energy”.
Since then, model development has seen a continous improvement, with the genera-
1Here “man ”is used in its generic sense and includes the female and the child.
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tion of models with increasing level of anatomical detail. Among them, three main types
of models can be identified (Xu 2014) on the basis of their topological characteristics
and the mathematical techniques employed for their definition: stylised, voxel-based and
Boundary REPresentation (BREP) models. This categorisation is also chronological, as
each type of model was mainly developed in a specific time frame, and goes on pair with
the advance of available computational resources at the time. Regardless of their math-
ematical representations, these models have been used to generate S values at the organ
level, assuming uniform radioactivity distribution within the organs, and thus neglecting
potential intra-organ heterogeneities of the absorbed dose.
Next sections provide a quick review of the principal models that have been employed
for TRT dosimetry. For each category, models representing adult men and women (in-
cluding pregnant women), and children of different ages, have been proposed for a better
description of actual patient anatomy. Here, the discussion will focus on adult models.
1.3.2 Stylised models
The so-called stylised or mathematical models are generated using Constructive Solid Geo-
metry (CSG). This techniques consists in creating solid objects using Boolean operators to
combine very simple shapes called primitives, in order to build organ models. Examples of
these primitives include cuboids, cylinders, prisms, pyramids, spheres, cones and ellipsoids
surfaces that are easily described by quadric equations. In figure 1.3a and 1.3b, a CSG
model of the left lung obtained from the subtraction of two ellipsoides is shown as an
example (Xu et al. 2007). The main advantage of this approach is of being very computa-
tionally efficient, as most Monte Carlo codes provide fast methods for particle propagation
through surface-equations-based geometries. Also, the use of CSG allows, in principle, the
modelling of any structure of interest, even the smallest, without imposing limits on the
model spatial resolution. Thus, currently available stylised phantoms, typically include
Monte Carlo efficient models of the skin, the red marrow, hollow organs walls, and other
small size structures that are hard to implement in voxel-based and BREP models.
Since these models were originally developed to perform radioprotection calculations,
their geometry is defined on the basis of population averaged characteristics (height, body
and organ weights). In some way, this feature represents both the strength and the
weakness of anthropomorphic stylised models, when considering their use for clinical TRT
dosimetry. On one hand, in fact, a preliminary determination of S values to be used
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Figure 1.3: A model of the left lung defined by different modeling methods. (a) The CSG-type
modeling before the Boolean operation (subtraction) is performed involving two ellipsoids A and
B. (b) After the subtraction of B from A. (c) A BREP type of modeling of the same lung using a
polygon mesh. Source: Xu et al. 2007
with any patient only makes sense if the model represents a wide range of anatomies. On
the other, however, the use of a fixed geometry does not take into account inter-patient
anatomical variability, and may significantly bias the absorbed doses obtained for some
organs.
In addition, one of the main problem of CSG geometries, is that organs are well separ-
ated (see figures 1.4b and 1.4c as an example), while in reality they touch one another. As
a result, the source organ sees the target organs under solid angles that differ significantly
from those of actual patient anatomy, especially for larger source-target distances. Several
authors (Lamart et al. 2011, Marcatili et al. 2015) have demonstrated that this difference
may cause a relevant underestimation of the absorbed dose obtained from stylised models.
The early models developed were geometrically simplistic as necessitated by the limited
computing power available at the time (1950 - 1960). In the sixties, Fisher and Snyder
(Fisher and Snyder 1966, Fisher and Snyder 1967) who worked at Oak Ridge National
Laboratory (ORNL), proposed one of the first humanoid model (in figure 1.4a, the adult
phantom) composed of three main regions: the head and neck, the trunk including the
arms, and the legs. About 120 sub-regions were defined in the model, which were used to
assign approximate values of the absorbed dose to organs located within specific regions.
The model was assumed to have homogenous tissue composition, and hence did not include
any model of lungs and bones.
The first heterogeneous, hermaphroditic adult model was developed by Snyder and
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colleagues in 1969 (Snyder et al. 1969). It was made up of three tissue types (skeletal,
lung, and soft) and its organ masses were selected to match those of the Reference Man
as described by ICRP Publication 23 (ICRP 1975). In 1978, an improved version of
the Snyder model (see figure 1.4b), including more than 20 organs and more detailed
anatomical features, was used to calculate absorbed dose fractions that appeared in the
MIRD Pamphlet No. 5, Revised (Snyder et al. 1978). Because of its adoption by the
MIRD Committee, the Snyder model is frequently referred to as the MIRD phantom.
More recently, the work of Cristy and Eckerman marked the beginning of the con-
temporary stylized models. The Cristy–Eckerman phantom family (Cristy and Eckerman
1987) is the series in most common use in current nuclear medicine dosimetry calcula-
tions. It consists of six models: the adult male and five pediatric examples (newborn,
1-, 5-, 10-, and 15-year old). The 15-year-old model was taken to be representative of
the adult female. The adult male (see figure 1.4c), which is actually hermaphroditic, was
very similar to the Fisher-Snyder model, with some minor modifications, and included
some organs that the Fisher-Snyder model did not. Absorbed dose factors for this family
of phantoms have been calculated for a large number of radionuclides, and are currently
implemented in the software OLINDA/EXM (Stabin et al. 2005) which is intended for
diagnostic dosimetry.
1.3.2.1 Voxel models
With the advent of medical imaging techniques such as CT and MRI, researchers could,
for the first time, visualize the internal structures of the body in 3D and store the im-
ages in versatile digital formats. Medical image data could hence be converted to voxel
geometry that provides a direct way of realistically describing the human anatomy. The
model derived is made up of individual voxels which can then be segmented and grouped to
isolate specific organs or suborgan structures as source and target regions. A specific ma-
terial can in principle be assigned to each voxel in order to reproduce tissue heterogeneity
encountered in the human body.
All voxel-based models developed from the 80’s are either based on CT (Computed
Tomography) and/or Magnetic Resonance (MR) images of living subjects, or on cross-
sectional photographs of cadavers. Once the image data have been acquired, organs and
tissues are consequently identified and tissue types and compositions assigned to segmen-
ted organs. For large, macroscopically-visible tissues, this segmentation, despite being
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Figure 1.4: Examples of stylised models showing a different degree of anatomical detail. From
left to right, the Snyder (Snyder et al. 1969), the MIRD (Snyder et al. 1978) and the OLINDA
(Stabin et al. 2005) models are shown.
time-consuming, is relatively easy to implement. However, for tissues with spatial dimen-
sions comparable to, or smaller than the image sampling (i.e. voxel dimension), special
interventions are required in order to model the tissue. This problem has led, so far, to
artificial solutions for the modelling of such structures. For example, the skin is often
represented by adding a single voxel layer at body surface, however, the size of voxels is
typically larger than skin actual thickness.
Indeed, the limited spatial sampling achievable is one of the main disadvantages of
voxellised models dosimetry. The spatial sampling adopted ultimately depends on the
spatial resolution of the imaging technique used to acquire the anatomical data. CT and
MR tomographic images are composed of many slices, each constituted by a 2-dimensional
pixel map of the anatomy. The typical pixel size is of the order of 1 mm2, providing a quite
accurate description of the transverse plane anatomy. However, along the longitudinal
axis, image slices are generally acquired at higher sampling (∼ 3-6 mm) in order to keep
patient absorbed dose from X-rays as low as possible in the case of CT scans, or to
reduce acquisition time in the case of MR imaging. The direct consequence of the low
longitudinal resolution is the presence of stair-stepped artefacts in modeled organs, as
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those shown in figure 1.6a (Lee et al. 2007). A possible approach to obtain improved
resolution data, is to acquire tomographic 3D images or optical photographic cryosections
from cadavers as was done in the Visible Human Project (VHP) (Xu et al. 2000). However,
even if producing very-high-spatial-sampling whole body digital models is not inherently
impossible, it should be remarked that such datasets would consist of billions of labelled
voxels. Therefore, they would be hardly manageable by standard computers because of
the required memory, and certainly nearly impossible to handle for any Monte Carlo code
currently available.
Another aspect that should be considered when using voxel-based models, is that they
are usually based on the anatomy of a single man or woman: this is the case, for example,
of VoxelMan (Zubal et al. 1994), MAX (Male Adult voXel) and FAX (Female Adult voXel)
models (Kramer et al. 2003, 2004). The generation of phantoms families that covers a
wider range of anatomical characteristics, as the GSF (German National Research Centre
for Environment and Health Gesellschaft fu¨r Strahlenforschung) phantom series (Williams
et al. 1986, Zankl et al. 1988, Smith et al. 2000, Petoussi-Henss et al. 2002, Zankl et al.
2002, Fill. et al 2004, Becker. et al 2007, Zankl et al. 2005), only partially address the
problem. A more effective solution consists in the development of voxel models based on
the Reference Man anatomy. The earliest effort in this sense, was made by Kramer et al.
(2006) who adjusted MAX and FAX models to Reference Man height and organ masses
listed in ICRP Publication 89 (ICRP 2002). In 2009, the ICRP released to the public the
Reference Male and the Reference Female (ICRP 2009) models adapted from the male
and female models of the GSF serie and based on CT images of individuals close to the
Reference Man and Woman. Body weight and height, and individual organs were adjusted
to reference values by adding and subtracting voxels: these processes were extremely time-
consuming as the voxel data format is difficult to deform, and the deformation generally
produces several artificial holes. Tissues densities and compositions were those of ICRP
Publication 89. In figure 1.5, the ICRP 110 female and male models are shown. They
present different spatial samplings: a 1.775 × 1.775 × 4.84 mm3 voxel size was used for
the women, and a 2.137 × 2.137 × 8.00 mm3 size for the man.
1.3.2.2 BREP models
The stylized and the voxel-based models represent two extremes. Clearly, the first is
simplistic and representative of a defined Reference Man. The second, on the other hand,
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Figure 1.5: Female and male reference models from ICRP Publication no. 110 (ICRP 2009).
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is far more realistic a representation of the anatomy and allows more comprehensive meas-
ures of the internal radiation dosimetry, despite being representative of the anatomy of
a single individual (with few exceptions). The recent developments of boundary repres-
entations models (Leyton 2001, Stroud 2006) seeks to preserve both the anatomic realism
of voxel phantoms and the mathematical flexibility of stylized phantoms creating mod-
els applicable to any individual. The most common technique to create a BREP-based
model involves the surface contour extraction of each organ from a tomographic image
dataset, followed by the integration of individual organs into a whole body assembly. In
essence, the contours convert the voxels into Non Uniform Rational B Splines (NURBS) or
polygonal mesh surfaces that are smooth and anatomically realistic. NURBS geometries
are flexible and computationally efficient, but fine details may be lost on certain organs
that have complex topology. On the other hand, polygonal models can be used to create
very smooth surfaces with impressive anatomical detail, by paying the price of having a
large number of vertices. As a results, NURBS are typically more efficient for real-time
applications, as the representation of cardiac and respiratory motion. Nevertheless, both
NURBS and polygonal meshes allow, through the use of mathematical transformations,
to easily model variations in anatomy and differences in organ size and morphology. Thus,
with respect to voxel-based models, they also permit a much easier construction of models
whose anatomy approaches that of a given patient.
Figure 1.6: Example of the construction and voxelization of a BREP model, starting with (A)
the original voxel model of newborn left lung, (B) its polygon mesh model, (C) its NURBS surface
model and (D), (E) voxelized models at two different isotropic voxel sampling (2 mm and 1 mm,
respectively). Source: Lee et al. 2007.
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In figure 1.6, Lee et al. (2007) show the necessary steps to build a BREP model using
the left lung as an example. Starting from a tomographic voxel dataset (A), they first
build the polygonal mesh model (B). A mesh model would be based on structures of this
type that undergo further manipulations as smoothing, to reduce the stairs-stepped arti-
facts, and volume scaling to adjust each organ to the desired mass value. Alternatively,
the polygonal mesh model can be used to generate a NURBS surface model (C), provid-
ing a smoother, more realistic representation of the organ. However, as highlighted by
Lee example, in both cases, the Monte Carlo simulation of BREP models requires their
transformation into 3D voxel models (D,E), thus sacrificing the spatial resolution of the
model itself.
Despite most modern Monte Carlo codes accepts the definition of BREP volumes,
particle tracking through this kind of geometry is still extremely inefficient. In principle,
anatomical realism could be preserved by resampling the BREP model into a high resol-
ution voxel dataset; however, the number of voxels a Monte Carlo toolkit can handle is
limited, and a too fine sampling easily results in memory faults and/or unreasonably long
computational times.
Still, the BREP approach represents the most efficient strategy to generate families
of phantoms (in figure 1.7, the RPI phantom serie) that fit the anatomical characteristics
of a wide range of individuals. It should also be noted, that the voxelization of a BREP
model allows, at least, having a uniform sampling in the three directions, thus reducing
the spatial resolution problems typical of voxel-based models along the longitudinal axis.
For these reasons, BREP models could be the ideal compromise between the need of pre-
calculated S values, and the need for patient specificity. For the end user, the dosimetric
assessment process remains simple to implement, while allowing a more personalised treat-
ment planning.
Since 2000, many research groups have started the development of BREP models, and
up to now, a total of about 200 models was reported (Xu 2014). Among the pioneers in
this filed, Segars developed the well known NCAT model (Segars 2001) originated from the
Visible Human CT dataset. The model was later extended (Segars et al. 2009) to include
cardiac and respiratory motions using tagged MRI data from a living patient (4D-NCAT).
More recently, the characteristics of the NCAT model were updated, and a family of 47 4D
models representing the cardiac and repiratory motions of multiple patients was developed.
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Figure 1.7: The RPI Adult Male (top) and Adult Female (bottom) models representing the 5th,
25th, 50th, 75th, and 95th weight percentiles (from left to right). Source: Na et al. 2010.
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The male and female model of this family are based on the high resolution Visible Male
and Female anatomical datasets. Despite these models were mainly conceived and used for
medical imaging applications, absorbed dose fractions for 177Lu and three individual voxel
models from the XCAT population were recently calculated at Lund University (Brolin et
al. 2015).
Between the many research groups involved in BREP models development, two of them
are particularly prolific.
At RPI (Rensselaer Polytechnic Institute, Troy, New York, USA), Xu et al. generated
a pair of models called RPI Adult Male and Adult Female (Zhang et al 2009), with
more than 70 organs and 45 bones adjusted to match ICRP 89 reference values. In a
subsequent work, the RPI Adult Male and Adult Female models (shown in figure 1.7)
were extended into weight-specific models representing the 5th, 25th, 50th, 75th, and 95th
weight percentiles (Na et al 2010), and to describe overweight and obese patients (Ding et
al 2012). At RPI, they also developed a set of female models at the end of three gestational
periods (3, 6 and 9 months) called RPI-P3, RPI-P6 and RPI-P9 (Xu et al 2007).
Bolch and colleagues at University of California, proposed a family of phantoms, known
as the UF family, of both genders and children of various ages (Lee et al 2007, 2008, 2010;
Bolch et al 2010), and also including fetal models (Maynard et al 2011). In 2008, ICRP
established that its future reference models for pediatric individuals would be based upon
the UF series. Recently, Zaidi and colleagues, have used the UF models for a number of
nuclear medicine absorbed dose calculations (Xie et al 2013, Xie and Zaidi 2014).
1.3.3 Small animal models
Absorbed dose assessment in rodents is a mandatory step for the evaluation of toxicity
and efficacy of novel radiopharmaceuticals before their test on humans. In the last 20
years, following the developments in human model research, several digital models have
been proposed for the calculation of organ absorbed dose in mouse and rats. Most of these
models are in the form of stylised (Hui et al. 1994, Flynn et al. 2001, Hindorf et al. 2004)
or voxel-based models (Stabin, Dogdas et al. 2007, Bitar et al. 2007), obtained either from
MR/CT tomographic images, or from photographic acquisitions of mice cryosections. As
their anthropomorphic counterparts, the first suffer of a poor anatomical realism, while
the second are usually derived from a specific subject of a given specie, and hence their
range of applicability remains limited. Using mathematical, stylized models, Hindorf et
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al. (2004) showed a notable effect on mouse dosimetry when geometric differences such as
organ mass, organ shape, and the relative locations of organs to one another are considered.
This effect is particularly pronounced for high energy β-emitters, whose particle range is
comparable to the size of mice anatomical structures.
In 2004, following the conceptual design of the human model NCAT, Segars et al.
developed the first mouse (MOBY) and rat (ROBY) 4D digital models based on NURBS
(Segars et al. 2004, Segars and Tsui 2007, Segars et al. 2010a). These models are available
through a computer program that allows deforming mouse/rat body as a whole, or each
organ separately. A 3D voxel image is then generated for its Monte Carlo implementation.
Originally conceived for imaging applications, these models have been used by several
authors to calculate organs S values for TRT dosimetry (Larsson et al. 2007, Keenan et
al. 2010, Xie and Zaidi 2013).
Figure 1.8: Examples of stylised (Hindorf et al. 2004), voxel-based (Bitar et al. 2007) and
NURBS (Segars et al. 2004) mouse models.
1.3.4 Cellular models
In a context of cellular dosimetry, cell geometry is typically represented by two concentric
homogeneous spheres of density 1 g/cm3, with the radii of the whole cell and of the nucleus
designated as Rc and Rn respectively (see figure 1.9). The radionuclide is assumed to be
uniformly distributed in one of the cellular compartment: the nucleus, the cytoplasm,
or the cell surface. This very simple model can take into account variations of cell and
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nucleus size, but neglects radioactivity distribution heterogeneity within a compartment,
and asymmetries in cellular shape. For the calculation of cross-irradiation absorbed dose
in multi-cellular systems, replicas of the single cell model are usually arranged according
to the selected spatial distribution.
Figure 1.9: Spherical symmetric model of cell geometry. Rn and Rc indicate nucleus and cell
radii respectively. Source: Roeske et al. 2008
The symmetric cellular model has been used extensively for the generation of cellular
S values. Some authors (Goddu. et al 1997, Vaziri et al. 2014, Emfietzoglou et al 2008)
implemented an analytical approach integrating particle stopping powers over cell geomet-
ries and radionuclide energy spectrum. Typically, experimentally determined relationship
between electron energy and range have been used for electrons (Cole 1969, Howell 1989),
and tabulated stopping power for α-particles (ICRU 1993). Photons and secondary elec-
trons were usually neglected in the analytical calculation. Other authors, made use of
pre-calculated Dose Point Kernels (see section 1.4.2) (Bardie`s and Chatal 1994, Bardie`s
et al. 1990, Faraggi et al. 1998, Hartman et al. 2000) or direct Monte Carlo radiation
transport (Cai et al. 2010, Bousis et al. 2010).
The work of Goddu. et al (1997) is of particular importance in this area of research,
as they generated cellular S values for different compartments and different cell/nucleus
radii, and 287 radionuclides. In the same publications, they also showed the effect of
cell model geometry on the absorbed dose to various compartments. Performing Monte
Carlo simulations of mono-energetic electron sources in ellipsoidal cells, they demonstrated
that asymmetries in the geometry may significantly impact nucleus absorbed doses, in
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particular for low energies electrons (5 keV) and for source distributed at cell surface.
For other source-target compartments, the differences between S values calculated in the
spherical and in the elliptical configurations resulted of minor importance. More recently,
a similar work by Amato et al. (2011), showed the necessity of applying geometrical
corrective factors for cell shapes that differ significantly from a sphere.
1.4 Computational methods for voxel dosimetry
While reference models are valuable for defining idealized exposures conditions and for
calculating S values for radiological protection, they are of much more limited use in
assigning organ absorbed doses for TRT treatments, especially when the individual patient
has a body morphometry far from the 50th height/weight percentile. In addition, model
based dosimetry neglects, by its own nature, heterogeneities in tissue compositions and
radioactivity distributions. The same considerations hold for small animal dosimetry. In
the specific case of cellular dosimetry, on the other hand, considering all cells as spherical
and symmetric, is the equivalent of using a Reference Man for clinical dosimetry. Also,
non-uniform radiopharmaceutical uptake within a cellular compartment may considerably
impact cell absorbed dose in the case of high LET emitters (α, Auger), in the same way
β-emitter heterogeneity can impact dosimetry at the human scale.
In order to provide means for a more accurate absorbed dose assessment in TRT ap-
plications, different computational methods have been proposed that take into account
realistic activity distributions and/or actual tissue composition with different levels of
accuracy. These techniques, valid at cellular, tissue or human scale, are based on the
availability of imaging tools capable of quantifying activity distribution and tissue dens-
ity in a given biological system. The resulting datasets are usually in the form of 2D or
3D voxel maps. In the case of clinical dosimetry, PET or SPECT images are generally
employed to assess personalised 3D radiopharmaceutical distributions, while CT is used
to produce maps of tissue compositions. For cellular and ex-vivo mouse dosimetry, digital
autoradiography (DAR) is most often used for the determination of activity uptake dis-
tributions. In the case of in-vivo small animal dosimetry, dedicate PET, SPECT or CT
scanner can also be used in analogy with the techniques implemented in the clinic.
Even if voxel-based computational methods are very attractive, as they allow in prin-
ciple a higher deegree of accuracy in the determination of the absorbed dose for a specific
39
Chapter 1. Computational methods for TRT
system, still, they all present the same weakness. These approaches demand, in fact, the
establishment of cumulated activities at the voxel level; this requires the co-registration,
with sub-voxel precision, of PET, SPECT or DAR images taken at different times. As a
matter of fact, sophisticated co-registration software that is not generally available to the
general user, would be needed to achieve this task.
1.4.1 Analytical approach
Under the assumption of homogenous propagating medium, the absorbed dose at a given
point only depends on its distance from the radiation emission point. In these conditions,
the function describing the energy deposition in a target point can be expressed analytically
and subsequently integrated over the target volume in order to obtain its average absorbed
dose.
Historically, analytical methods were the first developed for the calculation of the in-
ternal absorbed dose. In principle, they allow taking into account activity heterogeneity
in the source region, and to score the absorbed dose in complex geometries. However,
their practical implementation is mathematically challenging in most cases, with the ex-
ception of their application to simple geometrical shapes as spheres. For this reason, with
the development of the Dose Point Kernel and the Monte Carlo approaches (see next
paragraphs), analytical methods were progressively abandoned. However, their imple-
mentation in cellular dosimetry remains relevant and cellular S values calculated with this
approach are still used nowadays (Goddu et al. 1997).
In this case, given the reduced size of cells, photon emissions can be neglected and
the calculation of cellular absorbed dose can be restrained to the integration of particle
stopping powers over cell geometry. Mathematically, the absorbed fraction φ(rT ← rS , Ei)
defined in paragraph 1.2.2, can be expressed, for the ith mono-energetic particle, as:
φi(rT ← rS , Ei) =
∫ ∞
0
ΨrT←rS (x)
1
Ei
dE
dX
∣∣∣∣∣
X(Ei)−x
dx (1.4.6)
where Ei is the initial energy of the i
th particle,Ψ rT←rS (x) is the geometric reduction
factor, and dE/dX|X(Ei)−x is the stopping power evaluated at X(Ei) − x, the residual
range of particle with initial energy Ei, after passing a distance of x through the medium.
The geometric reduction factor represent the mean probability that a randomly directed
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vector of length x, starting from a random point in the source region rS , ends within the
target region rT . Its value depends on source and target geometries; explicit functions
forΨ rT←rS (x) have been derived by several authors for cellular dosimetry in self- and
cross-irradiation conditions (Howell et al. 1990, Goddu et al. 1994a, 1994b).
For electron dosimetry, the implementation of equation 1.4.6 usually reposes on the
analytical fit of stopping powers data (Cole 1969); for alpha particles, tabulated stopping
powers in water are typically used (ICRU 1993). In the case of radionuclides, equation 1.4.6
should be integrated over the radionuclide spectrum, considering both mono-energetic and
beta-particle emissions.
1.4.2 Dose point kernel approach
A Dose Point Kernel (DPK) is defined as the radial distribution of absorbed dose around
an isotropic point source in an infinite homogeneous propagation medium (Bardie`s et al.
2003). DPKs can be calculated analytically in the Continuous Slowing Down Approxim-
ation approximation2 (CSDA) (Prestwich et al. 1989a, Berger 1971) or using the Monte
Carlo technique (Berger 1973, Papadimitroulas et al. 2012, Furhang et al. 1996, Botta
2011); in both cases, a punctual source (mono-energetic photons, electrons sources or the
whole spectrum of a radionuclide) is modelled, and its energy scored in concentric spher-
ical shells. The absorbed dose in a point located at distance r from the source, is then
obtained by dividing the absorbed dose scored in the shell by the shell volume. Shell
thickness must be negligible with respect to the CSDA range of the simulated particle, in
order to avoid sampling errors.
DPKs can be used to produce 3D absorbed dose distributions from cumulated activity
maps. This requires the integration of kernels over the voxel geometry defined by the
cumulated activity map available. A simpler approach consists in assuming the source
located at the center of the source voxel, and to calculate the absorbed dose at the target
voxel center. For increased accuracy, the activity may be considered uniformly distributed
in the source voxel, to perform a volume integration over both source and target voxels.
The use of point kernel methods, however, is restricted to homogenous tissue regions.
Indeed, the shape of DPKs is significantly affected in the presence of tissue heterogeneities,
2In the CSDA regime, charged particles are assumed to lose their energy continuously at a rate given
by the stopping power. No secondary electrons (delta rays) or photons (bremsstrahlung radiation) are
considered in this approximation.
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especially at tissue interfaces (Pe´rez et al. 2011).
1.4.3 Dose voxel kernel approach
The MIRD schema described in section 1.2 for region-averaged dosimetry, can be extended
to take into account variations of the cumulated activity at the voxel level (Bolch et al.
1999). The absorbed dose to a target voxel vT due to the cumulated activities in source
voxels vS can be expressed as:
D(vT ) =
N∑
S=0
A˜(vS)S(vT ← vS) (1.4.7)
where the sum is extended to all source voxels. The voxel S value is defined as the absorbed
dose to the target voxel per unit decay in the source voxel, when they both are contained
in an infinite homogeneous medium.
According to this definition, Dose Voxel Kernels (DVK) can be obtained by Monte
Carlo simulation of voxel geometries representing an infinite medium of uniform composi-
tion; the radionuclide source is placed at the center of this geometry, and the absorbed dose
is scored in surrounding voxels. The mathematical convolution of pre-calculated DVKs
with a cumulated activity map provides the absorbed dose distribution for the biological
system considered.
A necessary condition for the application of this method, is for the DVK sampling to
match the cumulated activity image voxel size. This requires the generation of dedicate
kernels, not only for each radionuclide of interest, but also for any possible sampling.
However, in clinical TRT dosimetry for example, the variability of voxel sizes selected for
SPECT and PET images can be remarkable. Not to mention the many different voxel
sizes needed to cover dosimetric applications at the cellular, animal and clinical scales.
Several groups (Bolch et al 1999, Lanconelli et al. 2012, Amato et al. 2013) have
published DVKs for most radionuclides commonly used in TRT, and a few voxel sizes
that are supposed to reasonably cover the needs of clinical dosimetry. More recently, some
authors (Dieudonne´ et al. 2010, Ferna´ndez et al. 2013) proposed analytical methods
to scale DVKs simulated for a determined geometry sampling to the desired voxel size.
Amato et al. (2012), generalised this approach to obtain an analytical formulation of
DVKs for any radionuclide.
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An inherent limitation of the DVK approach is that, in principle, heterogeneities in
the propagation medium cannot be accounted for. Thus, its implementation in anatomical
areas including bone and lung tissue is not recommendable, as the resulting absorbed
dose could be significantly biased. On the other hand, their use in regions containing
organs with density and composition that can be assimilated to soft tissue, is generally not
problematic. In the specific case of cellular dosimetry, the biological systems considered
are usually assigned unit density compositions anyway, and a DVK approach is hence
appropriate. Still, a simple way to correct, although in part, for tissue heterogeneity has
been proposed and tested in a clinical application involving dosimetric calculations in the
abdomen (Dieudonne´ et al. 2013). With this approach, the dose voxel kernel D(vT ) in a
target voxel vT is scaled by the voxel actual tissue density ρT :
D(vT , ρT ) = D(vT )
ρ
ρT
(1.4.8)
where ρ is the material density implemented in the MC simulation of the non-corrected
kernels. Obviously this method does not account for tissue heterogeneities that are en-
countered by the particle along its track. Its applicability to highly heterogeneous ana-
tomical regions is hence questionable.
1.4.4 Monte Carlo based dosimetry
Direct Monte Carlo radiation transport in voxel geometries is considered nowadays the
most accurate approach to TRT dosimetry at any scale, as it allows taking into account
both tissue density and radioactivity heterogeneity. This kind of calculations, in fact,
is based on the acquisition of 3D voxel images describing tissue compositions (typically
CT or MR for in-vivo dosimetry) and activity distribution (PET or SPECT for in-vivo
dosimetry, DAR for ex-vivo dosimetry of tissue samples and cells) of the biological system
considered. Typically, the radioactivity distribution is assessed at different times (after
the injection of a limited amount of radioactivity in the case of clinical TRT) in order to
obtain time-activity curves (either at the voxel or at the organ level) that are employed to
build a cumulated activity voxel image. This image acts as an emission probability chart
for the definition of virtual voxel sources in the Monte Carlo simulation: homogeneously
distributed, isotropic radioactive sources are hence created in each voxel. For each radio-
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nuclide decay, the emitted radiation is typically tracked in a voxel geometry defined from
the morphological image acquired: a different tag, corresponding to a specific material,
may in principle be assigned to each voxel. The interaction between radionuclide emis-
sions and the tissue can hence be modelled taking into account all the different materials
crossed by the particle along its track.
A number of MC codes have been developed for 3D patient-specific absorbed dose
calculation in clinical TRT, implementing different approaches. Most of these codes assume
homogeneous activity distributions inside organs and lesions (Lehmann et al 2005, Yoriyaz
et al 2001), or use a partition-level approach (Song et al 2006, Yoriyaz et al 2001), while
others fully model patient’s functional and morphological images (Dewaraja et al 2005,
Dewaraja et al 2010, Hobbs et al 2009, Chiavassa et al 2006, Marcatili et al. 2013). Figure
1.10 shows the typical output of a Monte Carlo based dosimetric application. Nevertheless,
Figure 1.10: Patient-specific dosimetry obtained with the RAYDOSE software (Marcatili et al.
2013) for a 124I/131I matched-pair TRT treatment. From left to right: 124I PET/CT images at 24
hours post injection, 131I absorbed dose 3D image, and Dose Volume Histrograms in the lungs.
despite being highly promising and desirable, the direct Monte Carlo approach is still far
from being introduced in day-to-day clinical practice, and is more likely to be used for
research purposes. This lack of success depends on different factors. The main limitation
lies in the need for highly-processed input datas. The generation of the cumulated activity
map requires, in fact, a carefull co-registration of the functional images acquired with a
sub-voxel level of accuracy. Not only this process can be very time-consuming, but also,
the achievement of a viable result is not always guaranteed as the main sources of image
misalignment (patient movement and breathing) are not easily corrected via software.
Another difficulty to overcome is the resistance of patients and the medical staff to the
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acquisition of multiple SPECT or PET images for routine treatments, using the tracer
amount of activity needed to adequately characterize the dosimetry. Finally, the long
computation times needed to obtain a personalised absorbed dose distribution are often
incompatible with the tight organisation of a Nuclear Medicine department.
The Monte Carlo may, in principle, be applied to small animal in-vivo dosimetry.
The availability of dedicated PET, SPECT, CT and MRI scanners, makes it possible
to acquire sequential images of the same mouse and hence to implement Monte Carlo
based voxel dosimetry. However, this is not usually done. On one hand, in fact, the
assessment of the average absorbed dose after mouse sacrifice and biopsy is much quicker
and easier. On the other, the lack of dedicated quantitative reconstruction algorithms for
preclinical scanners, and the impossibility to implement user-defined data reconstruction
on commercial systems, results in a very approximate determination of organ uptake which
diminishes the relevance of sophisticated dosimetric calculation.
A few examples of Monte Carlo cellular dosimetry have also been reported. Despite
the need for tissue heterogeneity modelling is limited in this context, as cells are generally
assumed to be homogeneously composed by water, this approach is useful to take into
account uptake heterogeneity within the cell, or for a group of cells. Arnaud (2013) calcu-
lated the absorbed dose distribution for a realistic cell geometry and source distribution
issued from immunofluorescence microscopy, in the case of Auger electrons from 125I. His
work demonstrated that, in the case of high LET radiations, the nucleus absorbed dose
obtained in realistic conditions may be significantly different from that obtained with a
spherical symmetric cellular model. The Monte Carlo approach was also used to model
complex multi-cellular systems (Malaroda et al. 2003, Rajon et al. 2011).
In the last decades, many different Monte Carlo toolkits have been employed for TRT
dosimetry. Traditionally, codes as EGS, with its modern version EGSnrc (Kawrakow and
Rogers 2003), and MCNPx (Briesmeister 2000), have been considered the reference for the
simulation of radiotherapy experiments involving electron-photon transport at low energies
(down to 1 keV). More recently, the work undertaken by the “low energy electromagnetic
physics”work group, has made the Monte Carlo code Geant4 a most valuable tool for the
simulation of electromagnetic interactions of photons, electrons, hadrons and ions with
matter, down to very low energies (eV scale). In 2004 Gate, a user-friendly MC toolkit
based on Geant4 and dedicated to medical physics applications, was developed. Since
45
Chapter 1. Computational methods for TRT
then, Geant4 and Gate are being increasingly used and trusted by the medical physics
community.
1.4.4.1 Geant4
Geant4 (Geometry and tracking) is a general-purpose, open-source Monte Carlo toolkit
originally developed at CERN (European Organization for Nuclear Research) for the sim-
ulation of high energy physics experiments (Agostinelli et al. 2003). Nowadays, it is also
used for nuclear and accelerator physics, as well as studies in medical and space science.
Geant4 allows modelling complex geometries and particle source characteristics to virtually
reproduce any possible experimental condition. The user can build his/her own applic-
ation on the basis of predefined C++ classes that handle geometry and source definition,
and particle tracking and interaction at a lower level. Geant4 also offers numerous physics
models to describe the interaction of radiation with matter in different energy ranges. Of
particular interest for radiotherapy applications, are the Livermore models (Chauvie et al
2004) for the simulation of electromagnetic interactions down to 250 eV. These models
are based on the evaluated tables from LLNL (Lawrence Livermore National Laboratory):
EPDL97 (Cullen et al 1997), EEDL (Perkins et al 1991a) and EADL (Perkins et al 1991b),
and they have already been validated by several authors for TRT applications (Maigne
et al 2011, Papadimitroulas et al 2012, Amato et al 2013, Mauxion et al 2013). More
recently, the Geant-4 DNA collaboration also developed physics models for the simulation
of early biological damage induced by ionising radiation at the DNA scale (Chauvie et al.
2006).
1.4.4.2 Gate
The MC toolkit Gate (Geant4 Application for Emission Tomography) is an open source
code originally dedicated to nuclear medicine imaging, and based on the Geant4 generic
MC toolkit (Jan et al. 2004). It currently supports modelling of Emission Tomography
(PET and SPECT) and Computed Tomography (CT). Since version 6.0 it also allows
scoring absorbed doses in defined volumes or voxels for radiotherapy applications. In
particular, Gate permits an accurate description of time-dependent phenomena that are
not possible to include in a single Geant4 simulation.
Gate is conceived as a layer of C++ classes built on top of the Genat4 core, in order to
allow a more straightforward description of medical physics experiments (both for imaging
46
1.5. TRT dosimetry optimisation at different scales
and radiotherapy applications). The same physics models available in Geant4 are hence
maintained, while the definition of source and geometry is made easier for the end user.
Unlike Geant4, the use of Gate does not require any particular coding skill, since the
simulation can be set up by simple macro scripting.
1.5 TRT dosimetry optimisation at different scales
Depending on the size of the source and target regions identified, and depending on the
particles range in tissue for the radionuclide selected, the dosimetric model adopted may
rely on different hypotheses/approximations. Next sections provide a quick review of the
peculiarities of TRT dosimetry in different experimental contexts. The most common
issues encountered at the cellular, animal and clinical scales, and their possible solutions
are analysed, providing means for TRT optimisation.
1.5.1 Cellular dosimetry
The derivation of new radiobiological parameters is performed through survival exper-
iments in cell colonies. Survival curves are usually expressed in terms of administered
activity. However, establishing cell survival in terms of absorbed dose is crucial to in-
vestigate the absorbed dose-effect relationship, especially at very low doses: the lack of
correlation could, for example, indicate the presence of bystander effect (Chouin et al.
2009). To a first approximation, cell absorbed dose can be calculated, on the basis of
MIRD schema, summing up the contribution of cell self-absorption and cross-irradiation,
plus the contribution of radioactivity in the culture medium, when relevant. However, this
approach only offers an absorbed dose estimation of limited accuracy. Within the same
colony, cells may have different sizes, different levels of radioactivity internalisation and
different intracellular activity distributions: this reflects the high level of heterogeneity
displayed by a tissue in vivo. Therefore, depending on the type of emissions involved, the
dosimetric calculation should attain different levels of “realism”. So, while for β-emitters
it is usually not essential to model cellular uptake heterogeneity and actual cell shape/size,
in the case of alpha and Augers this is crucial in order to obtain sound dosimetric results
(Arnaud 2013, Roeske 2008). Conversely, β-emitters dosimetry requires a special attention
to the calculation of the cross-irradiation absorbed dose, since this may be significantly
higher than self-absorbed dose, especially for large colonies or clusters of cells (Goddu et
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al. 1994b). Moreover, since the cross-irradiation strictly depends on the spatial distri-
bution of cells within the culture, realistic modelling of the experimental conditions are
generally required, as demonstrated in chapter 2.
Another aspect to consider for dosimetry at the cellular scale, is also the stochastic
nature of energy deposition. Use of the average absorbed dose to an individual cell, in
fact, assumes that equilibrium conditions are satisfied with respect to the number and
type of particles entering and exiting a given calculation volume. For low LET radiation,
this condition is generally verified, as a large number of decays is required to deposit
a considerable dose. However, this assumption may not be valid when there is a very
inhomogeneous cellular uptake or the cellular absorbed dose is low. In the case of α-
particles, for which only a few cellular decays are required to cause radiation-induced effects
(Roeske 2008), this assumption may also not be appropriate. In these cases, stochastic
dosimetric methods (micro-dosimetry) may be required (Bardie`s and Pihet 2000).
1.5.2 Small animal dosimetry
Small animal absorbed dose assessment is required during radiopharmaceuticals develop-
ment to document and compare the risks associated with the use of unsealed sources of
radiations. In addition, small animal dosimetry may be necessary to establish the rela-
tionship between absorbed dose and biological effect during preclinical TRT. Conventional
pharmacokinetics assessment is usually performed by counting radioactivity present in tis-
sues samples after animal sacrifice, at various time points after the administration of the
radiopharmaceutical. Organ S values obtained from Monte Carlo mouse models are then
used to obtain the organ absorbed dose. For tumours, in analogy with model-based clinical
dosimetry, water sphere S values are employed.
However, this approach is limited (but simple to implement) as it only provides mean
activity concentration in a given sample, thus restraining absorbed dose determination
to whole organs or tumours (activity heterogeneity within the tissue/organ is not taken
into account). In addition, the radiopharmaceutical kinetics is extracted from different
mice at different time points: this technique is not ideal as inter-subjects variability could
possibly bias the shape of the biodistribution. Even if each point of the time-activity
curve is generally averaged over kinetic data from a few mice, the resulting curve is not
necessarily the same one would obtain averaging mouse-specific biodistributions (as it is
usually done in Phase I human studies).
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A possibly more rigorous method would consist in performing longitudinal mouse ima-
ging studies employing small animal PET or SPECT scanner. However, the technical
difficulties associated to small animal scanner calibration for quantitative imaging, makes
this approach difficult to implement for non-experts.
As described in section 1.2, the absorbed dose to an organ is computed as the sum of the
contributions of radioactivity in the organ itself (self-absorbed dose) and in surrounding
structures (cross-absorbed dose). In clinical applications, the cross-absorbed dose mainly
depends on photon irradiation: as a consequence, for most radionuclides employed in
therapy, its values is low compared to the self-absorbed component. On the contrary, for
small animals, whose organ’s size is of the same order of the range of particles involved,
the cross-irradiation may be substantial, especially for long range β-emitters. As the
cross-absorbed dose depends on the shape and size of organs, as well as on their relative
placement in the virtual model adopted for the simulation, any approximation introduce
at this level may remarkably impact the dosimetry (Boutaleb et al. 2009, Hindorf et al.
2004). The higher level of organ cross-irradiation, also produces indirect consequences
to the absorbed dose extrapolated to humans, for experiments aiming at evaluating novel
radiopharmaceuticals: the preclical study, in fact, may potentially predict higher toxicities
for non-source organs, that are not going to be observed in the Phase I study.
At the same time, given the relative dimensions of organ size and β-particle range,
the self-absorption approximation generally adopted in preclinical experiments, is not al-
ways appropriate, as demonstrated by Konijnenberg et al. (2007) for energetic β-particles
from 90Y. Irradiation from surrounding tissue can, in fact, play a relevant role in tumour
absorbed dose, making the use of mice models including tumour models recommendable
(Larsson et al. 2011). On the other hand, however, the impact of heterogeneous dis-
tributions of β-emitting radiopharmaceuticals can generally be neglected, as long range
particles contribute to the irradiation of tumours areas where the pharmaceutical is not
directly bound, thus producing smooth absorbed dose distributions.
This is not necessarily true for high LET radiations (Auger electrons, α-particles) that
deposits their energy locally. The particle range is, in fact, much shorter than typical
tumour sizes encountered in mice experiments. As a consequence, any heterogeneity evid-
enced in the radioactivity distribution persist in the absorbed dose distribution. Tumour
dosimetry based on average activity determination (i.e. through gamma counting) may
lead, in this case, to a wrong interpretation of the efficacy of the radiopharmaceutical
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under investigation, as shown in chapter 3.
1.5.3 Clinical dosimetry
In a typical clinical scenario, 2D (planar scintigraphy) or 3D (SPECT or PET) patient
images acquired at different times after radiopharmaceutical injection, are used to build
time-activity curves for the organs of interest and the tumour(s), and to calculate the
corresponding cumulated activities. Generally, a uniform uptake within each Volume Of
Interest (VOI) is assumed. Then, the absorbed dose to each VOI is computed from the
MIRD formula (equation 1.2.2) using tabulated organ S values. For tumour dosimetry,
water spheres S values are typically employed.
In the case of organ dosimetry, S values are often calculated by Monte Carlo simula-
tion of anthropomorphic models. For these calculations, radionuclide emissions are usually
categorised in two groups according to their absorption properties: α, β and Auger emis-
sions are usually assumed to release all their energy within the tissue of origin; photons,
depending on their energy, are absorbed in both source organ and surrounding tissues.
While the self-absorption hypothesis is certainly valid, at the human scale, for Auger and
α-emissions having a range in tissue from nanometers to ∼100 μm, for β-particles this is
not necessarily true. High energy β-particles, as those from 90Y , can have ranges up to
a cm, and hence produce a measurable absorbed dose in adjacent organs. Nevertheless,
because of their limited range, their irradiation may only affect a restricted area of the
target organs. Also, the probability of an energetic beta particle escaping the source organ
remains low, thus leading to very slow statistical convergence of the MC simulation. Under
these conditions, the calculation of the average beta absorbed dose to the target organ
may be critical, and the relevance of averaging the absorbed dose over the whole volume
may be questionable. As a consequence, considering the small absorbed doses involved,
beta cross-irradiation is usually neglected.
Another approximation that is often adopted, is to neglect the effect of bremsstrahlung
radiation on the cross-dose. However, as demonstrated by Stabin et al. (1994), although
the bremsstrahlung-related absorbed dose can be much smaller than that due to the β-
particles themselves (e.g., by a factor of 1,000 at a distance of 1 mm from the source in
soft tissue), the absorbed doses of both mechanisms equate at distances of about 1 cm for
90Y . Hence, depending upon the β-particle kinetic energy spectrum and the amount of
activity of the β-emitting radionuclide, energy deposition to surrounding organs due to
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bremsstrahlung may not be negligible (Williams et al. 1989). Since the bremsstrahlung
cross section scales as m−2, where m is the charged particle’s mass, the radiation emitted
by a decelerating α-particle at the energies typical of a decay, may be safely neglected.
On the other hand, positrons emit bremsstrahlung, but their radiative yield becomes com-
parable to those of electrons only at kinetic energies exceeding about 75 keV (McParland
2010).
As seen in section 1.4.4, a more personalised approach to clinical dosimetry can be
achieved through direct radiation transport in voxel geometries representing patient-
specific tissue compositions and activity distributions. Monte Carlo simulation can easily
be configured to take into account all physical processes of interest, without the need of
making approximations on the radionuclide emission spectrum and particles penetration.
Still, the use of MC dosimetry in clinical routine is limited for the reasons previously
discussed.
1.5.3.1 Multi-resolution dosimetry
One of the limiting factors to the achievement of accurate personalised dosimetry is the
use of low resolution anatomical models either coming from patient-specific imaging or
anthropomorphic models. In the first case the spatial sampling is limited by the intrinsic
resolution of the imaging technique used to assess tissue (∼ 1 mm) and activity (∼ 1 cm)
distributions in vivo. In the case of virtual models, even when they are highly anatomically
realistic in their NURBS form, when used in their voxel form they present the same limit-
ations as patient images. The ultimate problem is, in fact, that currently available Monte
Carlo codes, are not optimised for the simulation of BREP geometries, thus requiring the
implementation of voxel geometries. At the same time, only a limited number of voxels can
be defined within a single simulation in order to keep computation times reasonably low
and mostly to avoid saturating the computer memory. Even if these constraints are not
impedimental in the vast majority of clinical applications, they pose obvious difficulties
in the determination of the absorbed dose to small (with respect to the spatial sampling
of the model adopted) anatomical structures. This is particularly true for a small radio-
sensitive organ as the red marrow, but also for the eye, the skin, and hollow organ walls in
general. In chapter 5, a multi-resolution approach is proposed, to obtain high resolution
absorbed dose distributions in selected organs of interest, while keeping simulation time
and memory consumption low. This method is based on the use of voxels of different
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sizes to represent regions of different anatomical interest, and was validated as a proof of
principle example involving beta dosimetry to the bladder wall.
1.6 Conclusions
Several approaches are currently available for the calculation of the internal absorbed dose
in different TRT applications. Some of them are quite approximate as they only allow
establishing average absorbed doses to macroscopic regions on the basis of pre-defined vir-
tual geometries (model-based dosimetry), but offer the advantage of being of easy and fast
implementation. Other methods allow increasing dosimetric accuracy at different levels,
offering the possibility to take into account activity and/or tissue density heterogeneities
(voxel-based dosimetry), and actual geometry of the biological system considered. Nev-
ertheless, all dosimetric strategies described in this chapter are in principle equally valid
and it would be incorrect to establish a priori which method is the best, without contex-
tualising its application. Indeed, the pertinence of a given dosimetric approach is strictly
related to the penetrating or non-penetrating character of the radiation involved, with re-
spect to the characteristic size of the propagating medium considered. In this sense, TRT
dosimetry optimisation implies choosing the most appropriate approach for the particular
experimental conditions analysed.
In this thesis, different dosimetric procedures are investigated in the context of cel-
lular (chapter 2), small animal (chapter 3) and clinical (chapter 4) targeted radionuclide
therapy applications, involving α- and β-emitting radionuclides. Considering the peculiar-
ities of each experiment, it is shown that different levels of accuracy are required to reach
sound dosimetric results. In the last chapter, an original multi-resolution approach is also
proposed to optimise Monte Carlo based absorbed dose calculations in small anatomical
structures.
52
Chapter 2
Realistic multi-cellular dosimetry
for 177Lu labelled antibodies:
model and application
2.1 Introduction
Radiopharmaceutical development is a growing research field: new molecules for the treat-
ment of cancer through TRT are regularly proposed and tested (clinical, preclinical exper-
iments). Cellular behaviour of administered radiopharmaceuticals is commonly studied
using in vitro radiobiological experiments. Correct absorbed dose quantification is re-
quired for the evaluation of observed radiobiological effects and to predict or compare the
therapeutic efficacy of different radiopharmaceuticals. Absorbed dose calculations are also
needed to establish the absorbed dose-effect relationship (or the lack thereof) in clonogenic
survival experiments and to better understand cell death mechanism.
Following the MIRD schema (Bolch et al. 2009), the in-vitro absorbed dose to a
given cell depends on the radioactivity internalised by the target cell itself (self-absorbed
dose) and the surrounding cells (cross-absorbed dose), and by the radioactivity in the
culture medium (non-specific absorbed dose). Traditional MIRD dosimetry applied at the
clinical scale, generally assumes uniform distribution of radioactivity within the source
organ. However, within the same colony, cells may have different sizes, different levels
of radioactivity internalization and different intracellular activity distributions. All these
variables, that in turns reflect the high level of heterogeneity displayed by a tissue in
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vivo, can make it difficult to predict the response of cell populations to a given radiophar-
maceutical. Nevertheless, previous works demonstrated that heterogeneity of cell culture
parameters produces significant effects on the shape of survival curves (Howell et al. 2012,
Uusija¨rvi et al. 2008).
In addition, in clinical dosimetry, α, Auger and β-particles are usually considered as
non-penetrating radiations, and their contribution to the absorbed dose of non-source
organs is often neglected. However, considering the cell-to-cell distances typical of in-vitro
experiments (from a few to few hundreds of um), and the particle range in water for
this type of radiations (from few um to few mm), this assumption no longer holds true,
and the relevant cross-dose should be calculated for the specific geometry and radiation
considered. In the last decades, many researchers have developed digital models for the
calculation of cellular absorbed dose for in-vitro experiments using both Monte Carlo and
analytical methods. Most of these works focuses on the study of α and Auger emitters and
therefore considers cell culture geometries of limited sizes: typically, cell clusters in closed
packed geometry are generated for the calculation of the cell cross absorbed dose (Faraggi
et al. 1998, Cai et al. 2010). Goddu et al. 1994b, calculated the self-dose-to-cross-dose
ratios to cell nucleus for different cluster sizes (up to 400 um) considering α, Auger and
β-emitters: for β-emitters they demonstrated that the cross-absorbed dose is important
irrespectivly of cluster size and sub-cellular source distribution, and increases as the cluster
size increases. Other authors, performed cellular dosimetry for more realistic geometries
in the case of β-emitters (Freudenberg et al. 2011) and mono-energetic electrons up to
1 MeV (Rajon et al. 2011). In most of these works, however, the contribution of the
non-specific irradiation is usually disregarded since they focus on in-vivo applications.
Despite the great research interest in cellular dosimetry, still, the availability of pre-
calculated cellular S values is limited to the self-absorption contribution (Goddu et al.
1997). The only exception is represented by the MIRDcell software (Vaziri er al. 2014)
that is freely available online and allows the user to predict cell survival curves for many
radionuclides and mono-energetic radiations of different types. Unfortunately, only few
specific geometrical configurations (single clusters of cells and cell monolayers in closed
packed geometry) are implemented in MIRDcell: as a consequence, the complexity of
certain in vitro experiments cannot be appropriately modelled.
This chapter reports the development of an in-silico model for the determination of
the average cell absorbed dose in 3D colonies. On the basis of experimentally determined
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parameters (cell density, cluster density, average cluster size, cell cumulated activity), the
model generates realistic, randomised culture geometries taking into account cell tend-
ency to aggregate into isolated clusters of different sizes. Within the same virtual colony,
cells may have different radii, different levels of radioactivity internalization and different
intracellular activity distributions. The physical size of the modelled experiment is not
limited in order to cover the range in water of β-emitters. A mixture of Monte Carlo
and analytical approach was applied to achieve as accurate as possible results while re-
ducing calculation time. This general-purpose cellular model was applied to the in-vitro
dosimetry of lymphocyte B cells (Ramos and DOHH2 cells) treated with 177Lu-labelled
monoclonal Antibodies (mAbs). The aim was to investigate the therapeutic efficacy of
a novel radiopharmaceutical (177Lu-HH1, also called BetalutinTM ) in human lymphoma
cells and to compare it with those of 177Lu-Rituximab and of the irrelevant 177Lu-IgG,
namely 177Lu-Erbitux, that targets epidermal growth factor receptors (EGFR). In the
next sections, the application of the dosimetric model developed to these experiments is
discussed in details.
2.2 Materials and Methods
2.2.1 Experiments
All cell experiments listed in this section were performed by colleagues at “Institut de
Recherche en Cance´rologie de Montpellier”(IRCM), U1194 INSERM, Montpellier, France.
2.2.1.1 Cell lines and radiolabelled monoclonal antibodies
Ramos and DOHH2 cell line were obtained from American Tissue Culture Collection.
Cells were grown at 37◦C in a humidified atmosphere of 95% air/5% CO2 in RPMI (Life
technologies) medium supplemented with 10% heat-inactivated fetal bovine serum, 1%
Geneticin, 100 g/ml L-glutamine and antibiotics (0.1 U/ml penicillin and 100 g/ml strep-
tomycin). Cell diameter and area were determined after propidium iodide staining and
observation under a fluorescence microscope.
Ramos and DOHH2 cells, both expressing CD20 and CD37 cell surface receptors were
targeted with Rituximab or HH1 mAbs. Rituximab is a chimeric antibody established from
the murine monoclonal antibody (mAb), namely ibritumomab, targeting CD20 receptors
expressed by B cells lymphoma. HH1 is a murine mAb targeting CD37 receptors also
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expressed by B cells lymphoma. Cetuximab (or Erbitux, using its commercial name) is
a chimeric antibody directed against type I human epidermal receptor (HER1) which is
not expressed by lymphoma cells. It was used as non-specific mAb for control purposes.
All mAbs were conjugated with p-SCN-benzyl-DOTA and radiolabelled with 177Lu at
a concentration of 10 mg/mL (1 mL). They were radiolabelled with 177LuCl3 (Perkin
Elmer, Boston) at specific activity of 200 MBq/mg. Radiochemical purity was > 97%,
with radionuclidic purity > 99.94%.
2.2.1.2 Determination of time-activity curves
The uptake of radioactivity was determined in Ramos and DOHH2 cells exposed to 177Lu-
HH1 (BetalutinTM ), 177Lu-Rituximab or 177Lu-Erbitux. Typically, 106 cells/mL of culture
medium were incubated for 18 hours with increasing activities (0, 0.5, 1, 2, 4 and 6
MBq/mL) of 177Lu-labelled mAbs. Then, cells were washed twice and seeded in 12 micro-
well plates containing 1 mL of culture medium at a concentration of 200 103 cells/mL.
At different times (2h, 24h, 48h, 72h and 144h), cells were collected, washed twice with
phosphate buffered saline (pbs), and re-suspended in 1 mL pbs. An aliquot fraction (8
μL) was used for cells numbering using a cell counter (Muse, Merck Millipore), while the
radioactivity of the remaining volume was determined using a gamma counter (Hewlett
Packard, Palo Alto, CA). The activity per cell (Bq/cell) was next obtained for each time
point. The total average cell cumulated activity was obtained from the integration of
the time-activity curves in the relevant time range. For all cell lines and each mAb,
experiments were done in triplicates and repeated at least three times, allowing for the
extrapolation of a statistical error on the average cellular cumulated activities. Figure 2.1
shows a schematic representation of the protocol used for determining cell activity.
2.2.1.3 Clonogenic survival experiments
Therapeutic efficacy of radiolabelled and unlabelled mAbs was assessed using clonogenic
assay. A concentration of 106 cells/mL was grown in 12 micro-well plates containing 1 mL
of RPMI medium before being incubated for 18 h at 37◦C/5% CO2: a) with increasing test
activities (0, 0.5, 1, 2, 4 and 6 MBq/mL) of 177Lu-mAbs (177Lu-HH1, 177Lu-Rituximab
and 177Lu-Erbitux) or b) with increasing test concentrations (0, 5, 10, 15, 25, 40 μg/mL)
of unlabelled mAbs (HH1, Rituximab and Erbitux). Next, cells were collected, centrifuged
and washed twice, before being suspended in 5 mL of RPMI medium and counted. 1500
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Figure 2.1: Schematic representation of the protocol used for determining the cellular uptake of
radioactivity. Courtesy of A. Pichard and JP. Pouget.
cells were mixed with 4.5 mL of MethoCult R© (Stem cell Technologies) medium and seeded
at increasing concentrations for increasing test activities (500 – 10000 cells/petri dish
containing 1.5 mL medium). Petri dishes were next kept for 12 to 16 days for determining
the number of colonies. Colonies containing 50 or more cells were scored and the surviving
fraction was calculated. All the experiments were repeated at least three times in triplicate.
Figure 2.2 shows a schematic representation of the protocol used for clonogenic survival
experiments.
Survival curves issued from experiments with labelled mAbs were corrected for anti-
body toxicity in order to identify purely radiative effects. The activity concentration in
the medium (MBq/mL) used in the experiments with the labelled mAbs was expressed in
terms of antibody concentration (ug/mL). Then, cell survival curves, supposedly including
only radiative effects (CSrad), were obtained by subtracting survival curves obtained with
labelled mAbs (CS), from survival curves obtained with cold mAbs (CScold)
CSrad = 100− (CScold − CS) (2.2.1)
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Figure 2.2: Schematic representation of the protocol used for clonogenic survival experiments.
Courtesy of A. Pichard and JP. Pouget.
under the assumption that radiative and non-radiative cell death mechanisms are inde-
pendent phenomena.
2.2.1.4 Determination of culture cell geometry
During incubation (between 0 and 18 hours), Ramos and DOHH2 cells showed the tend-
ency to accumulate at the centre of the culture well: within this macro-aggregate they
mainly formed clusters of different sizes with some cell remaining isolated. Cell spatial
distribution was highly heterogeneous and cell were organised in few layers in suspension.
Since the average absorbed dose to the cell strictly depends on the geometrical configura-
tion of the cell culture, a preliminary determination of the relevant geometrical parameters
was performed on the basis of pictures acquired by optical microscopy. Four sets of pic-
tures were acquired, corresponding to Ramos and DOHH2 cells treated with 177Lu-HH1
and 177Lu-Rituximab. Three concentric regions were identified in the cylindrical culture
well of radius rw= 3.4 cm as shown in figure 2.3: centre (a cylindrical region of radius
rc), halfway (a cylindrical shell with rc < r < rh) and edge (a cylindrical shell with
rh < r < rw). For each region, cell line and for both antibodies, two planar pictures
were taken at ×5 and ×20 magnifications, in order to measure the cell density in each
area. In figure 2.4, the ×20 pictures acquired for Ramos cells treated with Betalutin and
Rituximab are shown as an example. For each picture acquired, the following parameters
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were extracted: density of isolated cells (cell/cm2); clusters density (clusters/cm2); aver-
age cluster radius in μm and its relative standard deviation. Culture thickness of three,
two and one cell diameters was assumed for the central, halfway-through and edge regions
respectively. The extracted parameters were used to estimate the total number of cells in
each region. The size of the central region (rc) was determined directly segmenting the
cell macro-aggregate (visible by eye) which laid approximately at the centre of the culture
well. The outer radius of the halfway region (rh) was tuned in order to obtain an overall
number of cells in the culture of the order of the nominal value (4 millions of cells). Micro-
scope observation of culture suspensions in flasks did not reveal any significant difference
in geometrical arrangement according to whether cells were exposed to 177Lu-Erbitux,
177Lu-HH1 or 177Lu-Rituximab. Hence, for further modelling of cell suspension analysis,
the parameters obtained with 177Lu-HH1 were arbitrarily used for 177Lu-Erbitux.
Figure 2.3: Left: picture of the culture well (3.4 cm radius) for Ramos cells treated with 177Lu-
HH1. At the centre a cell macro-aggregate is visible by eye. Right: schematic representation of
the three regions identified in the culture well.
After 18 hours of incubation in radioactive medium, between 500 and 10000 cells were
seeded in petri dishes containing 1.5 mL medium. Under this conditions, cells exhibited
an approximately uniform and isotropic spatial distribution. A maximum density of 6667
cells/cm3 was found for DOOH2 cells treated with 177Lu-Rituximab.
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2.3 Dosimetric model
According to the standard MIRD schema (Bolch et al. 2009), the absorbed dose to a
target cell (Dt) can be obtained summing up the contribution of the activity in the target
cell (Dself ) itself, in the cells other than the target (Dcross) and in the culture medium
(Dm):
Dt = Dself +Dcross +Dm (2.3.2)
Each of these components can be calculated as the product of the S value corresponding
to the appropriate source/target combination (St←s), and the cumulated activity in the
source:
Dt = A˜t St←t +
N−1∑
s
A˜s St←s(ds) + A˜m St←m (2.3.3)
In equation 2.3.3, A˜t, A˜s and A˜m respectively indicate the cumulated activities in the
target cell, in the sth source cell and in the culture medium.
In next paragraphs, the techniques implemented for the calculation of self-absorption,
cross-irradiation and non-specific irradiation S values are described. S values are obtained
via Monte Carlo simulation and then used for the calculation of the average cell absorbed
dose according to equation 2.3.2.
2.3.1 Self-irradiation absorbed dose
Cell geometry was modelled with two concentric homogeneous unit density spheres rep-
resenting the cell and the nucleus. Each cell was hence composed by three compartments:
cell nucleus (N), cell cytoplasm (Cy) and cell surface (CS) (see picture 1.9 in chapter
1). Cell sizes were defined according to experimentally determined cell (RC = 5.1 um)
and nucleus (RN = 4.0 um) radii. The cell model was implemented in Geant4.9.6 patch
04 (Agostinelli et al. 2003) in order to calculate cell S values for different hypotheses
of antibody internalisation and different target regions. For this and all MC simulation
performed for this work, the whole 177Lu spectrum was considered as defined in the MIRD
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radionuclide data and decay schemes (Eckerman and Endo 2008). The Livermore physics
list was selected as it allows tracking particle down to an energy of 250 eV: this corres-
ponds to a cut in range of 10 nm, which is adequate for energy deposition in cells of few
microns. 106 primary particles were generated for the simulation of each self-irradiation
S value, in order to obtain a statistical uncertainty below 1%.
The self-irradiation absorbed dose factor (Sself ) assumes different values depending on
the localization of the labelled mAbs within the cell. Here, absorbed dose in the whole cell,
the nucleus and the cytoplasm was scored for two different radioactivity distribution hypo-
theses: 100% of the source uniformly distributed in the cytoplasm (internalising antibody)
and 100% of the source uniformly distributed in the cell membrane (non-internalising an-
tibody). In general, for any target compartment considered (nucleus, cytoplasm or the
whole cell), if ACy and AC are the activities in the cytoplasm and in the whole cell at a
given time of measurement, Sself can be expressed as a function of the S values corres-
ponding to a source in the cytoplasm (SCy) and to a source at cell surface (SCS):
Sself =
ACy
AC
SCy + (1− ACy
AC
)SCS (2.3.4)
Sub-cellular localisation of radioactivity in Ramos and DOHH2 cells was experiment-
ally determined from immunofluorescence images. On this basis, a 50% CS + 50% Cy
radioactivity distribution was assumed for 177Lu-HH1, and a 100% CS distribution for
177Lu-Rituximab and 177Lu-Erbitux. Equation 2.3.4 was used to derive Sself for Ramos
cell treated with 177Lu-HH1. Subsequently, the experimentally determined cell cumulated
activities were multiplied by the corresponding S values, in order to obtain the absolute
cell absorbed dose due to self-irradiation. The error associated to the self-absorbed dose
was obtained propagating the standard deviations of cell cumulated activities applying
conventional error propagation rules.
2.3.2 Cross-irradiation absorbed dose
In principle, the most accurate approach for the calculation of cross-irradiation cellular S
values consists in the direct MC simulation of a couple of source and target cells, since
it allows taking into account the contribution of all secondary electrons. Even if this is
feasible for short cell-to-cell distances (with respect to cell radius), at larger distances the
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simulation may not converge for ballistic reasons.
Beta particles emitted by 177Lu have a maximum range in tissue of 1.76 mm (Berger
et al. 2009), hence, for the calculation of the absorbed dose to a cell in the culture, the
contribution of all source cells placed at distances between two cell radii and at least 1.76
mm should be taken into account. This requires the knowledge of cross-irradiation S values
up to a cell-to-cell distance of 1.76 mm or larger, that are impossible to obtain via direct
MC simulation.
In this work, three different approaches for the calculation of cross-irradiation S values
were implemented: direct MC simulation at short cell-to-cell distances, the use of MIRDcell
software, and the generation of S values from DPKs (Dose Point Kernels). The comparison
of results obtained with these three approaches served as a validation benchmark.
2.3.2.1 Generation of cross-irradiation S values
Monte Carlo simulation of cross-irradiation S values. The same simulation set-up im-
plemented for the generation of self-irradiation S values was used for the generation of
cross-irradiation S values. In this case, however, the absorbed dose was scored in the
nucleus, the cytoplasm and the whole volume of a target cell placed at a variable surface-
to-surface distance from the source cell (0.0, 5.1, 10.2, 15.3, 20.4 and 51.75 um). Ramos
cell experimentally determined nucleus and cell sizes were considered (RC = 5.1 um and
RN = 4.0 um).
MIRDcell software for the generation of cross-irradiation S values. The “Cell Source/Target
tab”of the MIRDcell applet (Vaziri et al. 2014) was used for the calculation of cross-
irradiation S values for two cells placed at a variable centre-to-centre distance ranging
from 10 (adjacent cells) to 1578 um. The upper limit roughly corresponds to the Continu-
ous Slowing Down Approximation (CSDA) range of 177Lu β-particles in water and is set
by the software. 5 um radius cells with a 4 um radius nucleus were considered for both
cell lines, as in MIRDcell, cell radii can only be defined as integers. In MIRDcell, the
177Lu beta spectrum is defined according to MIRD radionuclide data and decay schemes
as in the MC simulations implemented for this study. The absorbed dose is calculated
analytically in the CSDA.
Generation of cross-irradiation S values from DPKs. 177Lu Dose Point Kernels (DPKs)
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were simulated using MCNPX (Briesmeister 2000): the energy deposited by a punctual
177Lu source (spectrum defined according to Eckerman and Endo 2008) was scored in
concentric spherical shells. MNCPX is the natural choice for the generation of DPKs as
it easily allows scoring the deposited energy in concentric spherical shells through macro
scripting. On the contrary, the implementation of the same geometry in Geant4 would
require the development of user-defined C++ classes. A shell thickness of 17.6 um was used
to generate DPKs between 17.6 and 2552 um, simulating 800 millions of primary particles.
800 millions additional particles were also generated for the simulation of DPK between
17.6 and 228.8 um on a shell thickness of 8.8 um, in order to increase DPK sampling
accuracy in the steepest region of the curve at low distances from the source. The DPKs
obtained were subsequently used to calculate the absorbed dose (S values) to a target
sphere (representing the cell) placed at variable distance from the source. For this calcu-
lation the source and the target cells were assumed to be punctual, so the DPKs and the
S values basically coincide except for a change in units (MeV cm−3/Bq s versus Gy/Bq s).
This approximation is easily verified for cell-to-cell distances much greater than cell size.
At shorter distances, a validation of S values obtained from DPK is required: the DPK
S values were hence compared to cross-irradiation S values obtained with direct Monte
Carlo simulation and with MIRDcell.
2.3.2.2 Generation of multi-cellular geometries
The cross-irradiation S value (St←s(ds)) allows calculating the contribution to the absorbed
dose of a single source cell located at a fixed distance (ds) from the target cell. In a
culture well containing N labelled cells, the average cross-absorbed dose to a given cell
(Dcross) is obtained summing up all the contributions from the N-1 source cells having
a cumulated activity A˜s (c.f. the second term of equation 2.3.3). In order to calculate
Dcross, the knowledge of the 3D spatial distribution of cells in the culture is required for
the determination of ds and hence St←s(ds). According to cell incubation experiments
(0<t<18 hours), in each region of the culture well, both isolated cells and cell clusters of
different sizes may be present during the incubation time. The calculation of the cross-
absorbed dose to a given target cell was hence separated into three contributions:
• the absorbed dose due to the activity in isolated cells (DIC , Dose from Isolated
Cells);
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• the absorbed dose due to the activity in cells of the cluster the target cell belongs
to (DTC , Dose from Target Cluster);
• the absorbed dose due to the activity in cells of surrounding clusters (DSC , Dose
from Surrounding Clusters).
Since the experiments indicated that Ramos and DOHH2 cells tend to aggregate, the
target cell was arbitrarily assumed to belong to a cluster. Three separate models for the
description of cell culture geometry were developed in order to allow the calculation ofDIC ,
DTC and DSC . Since the maximum range in water of
177Lu β-particles is 1.76 mm, the
contribution of cells located at much larger distances was neglected. Moreover, considering
that cells are arranged in few layers along the vertical axis (Z) of the culture well, the
geometrical models were restricted to cylindrical volumes (from here on called Model
Volume) having radius of 2550 um (= 500 Ramos cell radii) and height corresponding
to the number of observed cell layers (NLayers) times cell diameter (2RC) expressed in
microns. The Model Volume is arbitrarily determined so that its radius in the XY plane is
larger than the maximum beta range in water, to include also Bremsstrahlung contribution;
this volume is small enough to fit into all well regions defined in this study. In this volume,
random distributions of non-overlapping isolated cells and clusters were generated with a
series of C++ classes implemented in ROOT1 (Brun and Rademakers 1997).
For the calculation of cross-irradiation absorbed dose after 18 hours, only isolated cells
contribution was modelled. In this case, the Model Volume was a cylinder of radius 2550
um and height 1.6 mm, corresponding to the full height of culture medium in the Petri
dishes.
3D model of isolated cells. Randomly distributed, non-overlapping, isolated cells were
modelled. The minimum allowed distance between two cells was equal to two cell radii.
The software takes as input cell density (cell/cm2) and computes the number of cells to
be placed in the Model Volume. Then, it generates random X, Y, and Z coordinates (cell
centres) within the established limits: if the current cell does not overlap to any other
previously created cell, its coordinates are stored. The output of this piece of software is
a list (in txt format) of distances (ds) between source cells and the target cell arbitrarily
placed at the barycentre of the Model Volume. Even if, in principle, the model can be
1https://root.cern.ch
65
Chapter 2. Realistic multi-cellular dosimetry for 177Lu labelled antibodies
used to calculate the absorbed dose to a cell placed anywhere in the Model Volume, the
calculation was restricted to the central cell. The resulting error in the final absorbed dose
is expected to be negligible since most of cells in any culture well region can be inscribed
into a circle having a 2.5 mm radius.
Different isolated cell models were generated for each antibody/cell line combination
and for each region of the culture well where the presence of isolated cells was experiment-
ally detected. For example, in the case of Ramos cells treated with 177Lu-HH1, isolated
cells were not detected in the central region and this case was hence not included in the
model. In addition, for each eligible configuration of antibody, cell line and region, 50 dif-
ferent geometrical arrangements of isolated cells were created running the software with
different random seeds.
3D model of target cell cluster. In analogy with the 3D isolated cell model, cell clusters
of different sizes were modelled in ROOT. Fifty clusters were generated in order to es-
tablish an average absorbed dose (and the corresponding standard deviation) that does
not depend on the specific geometrical configuration modelled. Clusters radii (on the XY
plane) were randomly sampled according to a Gaussian distribution having the mean and
the standard deviation equal to the experimentally determined values. The maximum
cluster thickness was set to NLayers× 2RC . Assuming a packing factor of 0.74 (typical of
hexagonal close packing lattices), randomly distributed, non-overlapping cells were gen-
erated to cover the cluster volume. In figure 2.5, a 17.6 um radius and a 35.4 um radius
clusters are represented as an example.
Subsequently, within each cluster generated, the relative distances between each cell
and the others was computed and stored in a txt file. This approach allowed obtaining an
average cell absorbed dose independent from the specific position of the target cell. This
was felt necessary as, at short cell-to-cell distances, the difference between the absorbed
doses of two cells placed at the centre or at the edge of the cluster may, in principle, be
significant.
3D model of surrounding cell clusters. The many clusters present in the Model Volume
were modelled as non-overlapping cylinders with a thickness of NLayers × 2RC , and a
randomly selected radius obtained from the sampling of a Gaussian distribution having a
mean and a standard deviation equal to the experimentally measured values. The number
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Figure 2.5: Graphical representations of a 17.6 um radius (left) and a 35.4 um (right) radius cell
clusters. Cell positions and radii are shown in a realistic scale.
of clusters to be generated was determined according to the experimental cluster density
(cluster/cm2). The number of cells (Ncells) comprised in each cluster was calculated as
the ratio of the given cluster volume (Vcluster) and the cell volume (Vcell), and assuming a
packing factor (PF ) of 0.74:
Ncells =
Vcluster
Vcell
PF (2.3.5)
The target cell was placed at the barycentre of the volume model and included in a cluster
of random size. For each cluster, its distance to the target cell (calculated from the
cluster barycentre to the Model Volume barycentre), its radius and the number of cells
included, are stored for the subsequent calculation of cell absorbed dose. For each cell line,
antibody and well region combination, 50 geometrical configurations of multiple clusters
were generated to obtain average absorbed doses independent from the specific geometry
modelled.
2.3.2.3 Cell cumulated activities
The cumulated activity A˜s for the s
th source cell (c.f. the second term of equation 2.3.3)
was randomly assigned sampling a Lognormal distribution of the form:
L(A˜s) =
1√
2π lnk
1
A˜s
exp(−(ln(A˜s/μ))
2
2(lnk)2
) (2.3.6)
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with k = (σ/m) + 1 and μ = m (Cousins 2010), where m and σ are the experimentally
determined average cell cumulated activities (in the time frame of interest) and standard
deviations.
The Lognormal distribution represents a random variable whose logarithm follows a
normal distribution. It is typically used to model the errors of a process involving many
small multiplicative errors (Limpert et al. 2001). Here, it was used alternatively to a Gaus-
sian distribution in order to avoid selecting negative cumulated activities (the Lognormal
distribution is defined for x > 0). Nevertheless, when the measured standard deviations
are small, the choice made for μ and k parameters (equations 2.3.6) allows approximately
reproducing the shape of a Gaussian distribution having a mean equal to m and a stand-
ard deviation equal to σ. In figure 2.6, the Lognormal and the Gaussian distributions
corresponding to m=1041.49 and σ=230.25 and to m=1795.09 and σ=1312.90 are shown
as an example.
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Figure 2.6: Lognormal (red) and Gaussian (blue) distributions corresponding to different average
cumulated activities and standard deviations. For smaller standard deviations, the shape of the
Lognormal distribution approaches that of the Gaussian distribution.
2.3.2.4 Calculation of cross-irradiation absorbed dose between 0 and 18 hours
In order to obtain the average cell absorbed dose for the whole cell culture, absorbed doses
obtained for each region were first computed separately and then summed up, using the
total number of cells belonging to each region (estimated from experiments) as weights.
The cross-irradiation absorbed dose was calculated according to the second term of
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equation 2.3.3. Cell cumulated activities (A˜s) between 0 and 18 hours were randomly
sampled according to equation 2.3.6. The cross-irradiation S value (St←s(ds)) was evalu-
ated for each source-to-target distance ds, linearly interpolating the merged S values data
obtained from the DPKs and the direct MC simulation at very short distances.
For the calculation of the absorbed dose from surrounding clusters (DSC), the St←s(ds)
term was assumed to slowly vary within a given cluster. The cross-irradiation absorbed
dose to the target cell (Dcross) can hence be written as:
Dcross =
N−1∑
s
A˜s St←s(ds) ≈ St←cluster(dcluster)
Nc−1∑
i
A˜cluster (2.3.7)
where St←cluster(dcluster) is the cross-irradiation S value estimated at the centre of the
cluster, and A˜cluster is the total cumulated activity in the cluster between 0 and 18 hours;
A˜cluster was directly generated randomly sampling the Lognormal distribution in equation
2.3.6. In the first part of equation 2.3.7 the sum is extended to all cells (N) from all
clusters, while in the second part, it is extended to the number of clusters generated (Nc).
The three contributions to the cross-irradiation absorbed dose DIC , DTC and DSC
were averaged over the 50 geometrical configurations generated for each model. The
absorbed dose calculated for the target cluster (DTC) is also averaged over the possibility
of each cell of the cluster being the target. It was hence possible to associate a standard
deviation to the average absorbed doses obtained for each well region, which reflects the
variability introduced by the geometrical model, and which takes into account the different
labelling of the various cells. The average cross-irradiation absorbed doses DIC , DTC and
DSC for any cell in the culture, were subsequently calculated summing up the values
obtained at the edge, halfway-trough and at the centre of the culture well, and weighting
for the total number of cells in each region. Then, the average cross-irradiation absorbed
dose was calculated summing up the contributions of isolated cells, target cluster and
surrounding clusters. At each stage, the standard deviation for the absorbed dose was
obtained according to standard error propagation rules.
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2.3.2.5 Calculation of cross-irradiation absorbed dose between 18 hours and
14 days
The calculation of the cross-irradiation absorbed dose for cells seeded in Petri dishes after
18 hours was much more straightforward as the cells were uniformly distributed throughout
the dish volume. Ten different geometrical configurations of isolated cells were generated
to model the conditions of maximum cell density (6667 cells/cm3), for which the highest
cross-absorbed dose was expected. The stored isolated cell positions were subsequently
used to calculate the cross-absorbed dose according to the second term of equation 2.3.3. A
lognormal cumulated activity distribution was also assumed: average cumulated activities
and standard deviations were obtained from the integration of cells time-activity curves
between the time of cell rinsing (18 hours) and the time of cell counting (on average 14
days = 336 hours). Since the cross-irradiation absorbed dose found for the maximum cell
density conditions was irrelevant (4.38 10−5 ± 5.16 10−6 Gy), the cross-absorbed dose
after 18 hours was neglected for all cell line/mAb combinations.
2.3.3 Non-specific irradiation absorbed dose
2.3.3.1 Generation of non-specific S values
Given 177Lu β-particles range in water, all radioactivity incorporated in a spherical volume
of 1.76 mm radius surrounding the target cells, potentially contributes to its absorbed dose.
Therefore, the non-specific irradiation S value was simulated with Geant4, modelling a
homogeneous spherical water medium of 2.55 mm radius uniformly filled with 177Lu and
surrounding the target cell. Sphere’s radius was arbitrarily selected larger than 1.76 mm
in order to account for Bremsstrahlung radiation. The presence of cells other than the
target was not modelled since the volume they occupy is negligible with respect to the total
culture volume (1 million Ramos cells per mL corresponds to 0.007% of the culture volume
occupied by cells). The same source and physics parameters used for the generation of
cellular S values, were also adopted for this simulation. The absorbed dose was scored in
three regions of the target cell: the whole cell having a radius of 5.1 um (Ramos cell), the
nucleus (radius=4.0 um) and the cytoplasm. 3.7 109 events were simulated to achieve a
statistical uncertainty below 5%. Simulation time was about three weeks on a single CPU
(3.1 GHz Intel Core i5).
In order to validate the results obtained, the MIRDcell software was employed as well
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to calculate the non-specific irradiation S value, using the tool for the calculation of the
self-irradiation S value. Despite MIRDcell has not been conceived for the implementation
of this kind of geometry, the option for the calculation of the nucleus S value for a source
distributed in the cytoplasm (SCy←N ) can be adapted to the calculation of cell S value for
a source located in a spherical shell of any size (2.55 mm in this case). In fact, these two
configurations present the same geometry: it is sufficient to identify the nucleus as the
whole cell, and the cytoplasm as the medium. Since the MIRDcell program only accepts
integers for the definition of cell dimensions, two cells of 4 and 5 um radii were considered.
2.3.3.2 Calculation of non-specific absorbed dose
The nominal cumulated activity concentration in the culture medium was calculated in-
tegrating the initial activity concentrations (0.5, 1, 2, 4, 6 MBq/mL) over the incubation
time (18 hours). Multiplying this value by the total volume non occupied by cells, the
nominal cumulated activity in the medium was obtained. The volume occupied by cells
was calculated for Ramos and DOHH2 cells treated with the three antibodies, taking into
account experimentally determined cell and cluster densities in each well region. In order
to obtain the actual cumulated activity in the medium, the total cumulated activity in
the cells at 18 hours was subtracted from the nominal cumulated activity, for each region
separately.
Subsequently, for each combination of cell line, antibody and well region, the medium
cumulated activities were multiplied for the non-specific irradiation S value issued from
the MC simulation, in order to obtain the absorbed dose to the whole cell and to the
nucleus. The three absorbed dose values obtained for each cell line/antibody combination
in each region, were summed up using the total number of cells in each region as weights.
Standard error propagation was applied throughout the calculation.
2.3.4 Total absorbed dose and clonogenic survival
For each combination of cell line and mAbs, the average absorbed dose to a target cell
placed at the centre of the Model Volume was calculated as the sum of three contributions:
i) the self-absorbed dose, ii) the non-specific absorbed dose and iii) the cross-irradiation
absorbed dose. Table 2.1 provides a summary of the models used and the integration
times considered for the determination of each contribution. As in cellular dosimetry it is
generally recognized that radiosensitive sites are associated to DNA (Humm et al. 1994),
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Abs. dose
contribution
Incubation time
0 < t < 18 h
Clonogenic experiments
0 < t < 336 h
Dosimetric model
Self Symmetric sphere
Cross IC, TC, SC (3 regions)
negligible IC
Non-specific Uniform sphere (3 regions)
Table 2.1: Summary table of the dosimetric models adopted for the calculation of the self-, cross-
and non-specific irradiation cross absorbed doses. Gray cells visually highlight the integration time
considered for the assessment of each contribution.
when the absorbed dose to other compartments was available, the nucleus was selected as
the target region for the construction of cell survival curves. The squared error on the total
absorbed dose was computed as the squared sum of the errors of the single components.
The dosimetric results obtained for Ramos and DOHH2 cells treated with 177Lu-HH1,
177Lu-Rituximab and 177Lu-Erbitux, were applied to clonogenic survival curves in order
to express cell survival in terms of the average nucleus absorbed dose.
2.4 Results
2.4.1 Experiments
2.4.1.1 Determination of cell cumulated activities
Time activity curves obtained for Ramos and DOHH2 cells exposed to 177Lu-HH1, 177Lu-
Rituximab and 177Lu-Erbitux (initial activity concentration ranging from 0 to 6 MBq)
are reported in figure 2.7 and in the first graphs of figures 2.8 and 2.9. Between 0 and 18
hours, they describe the uptake of radioactivity within the cells; after 18 hours, when cell
are rinsed, the radioactivity begins to fade, following a simple mono-exponential decay
that depends on both 177Lu physical half life and biological wash-out. In order to assess
cell cumulated activities, time-activity curves should be integrated over the experiment
time (0 - 336 hours), however, when their shape is not know, this process may not be
straightforward. A possible solution would be to integrate the curves using the parallelo-
gram rule. However, in this particular case, the result may be significantly biased by the
limited number of time points available (only 2 for the uptake phase). In particular, the
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lack of an experimental data point at 18 hours, immediately before cell rinsing, makes it
very difficult to extrapolate the time of maximum uptake.
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Figure 2.7: Time-activity curves for Ramos (left) and DOHH2 (right) cells treated with 177Lu-
Rituximab (top) and 177Lu-Erbitux (bottom). Each plot contains the data relative to different
initial activity concentrations in the medium (from 0.5 to 6 MBq/mL).
To make the most out of the available points, time-activity curves were fitted using
two separate functions for the incubation and wash-out phases. For the latter, a mono-
exponential function was used to fit the 4 time points (24, 48, 72, 144 h) at t > 18 hours,
allowing the extrapolation of cell activity at t = 18 hours. This point was subsequently
added to the curve and included in the fit for t ≤ 18 hours. In principle, in fact, only the
radioactivity present in the culture medium is removed when cells are rinsed, while the
labelled mAbs bound to cell receptors are not eliminated. In other words, cell activity
versus time is expected to be described by a continous function. For both cell lines and all
mAbs, all the activities extrapolated at t = 18 resulted inferior to activities measured at
t = 2 hours. Thus, assuming that maximum uptake took place between before 18 hours,
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the incubation phase was modelled with a function describing un uptake phase followed
by a mono-exponential decay phase. In summary, time activity curves were fitted with
the following equations:
A(t) = A1 (e
−λat − e−λbt) for 0 < t < 18 h (2.4.8)
A(t) = A2 e
−λct for 18 < t < 336 h (2.4.9)
Figures 2.8 and 2.9 show fit results for Ramos and DOHH2 cells treated with 177Lu-HH1;
time-activity curves are plotted in the same vertical scale to facilitate the comparison.
Curves shapes obtained for the other mAbs were very similar; for most experiments, the
maximum uptake resulted between 5 and 10 hours. In the case of cells treated with 177Lu-
Erbitux, for which cell activity was very low, most of fits performed at t < 18 hours did
not converge. For those curves, cumulated activity before 18 hours was estimated using
the parallelogram rule, while for t > 18 hours, the mono-exponential fitted function was
integrated. For all experiments, the error on cumulated activity was obtained propagating
the fit parameters errors using the dedicate function in ROOT.
Average cumulated activities obtained in Ramos cells exposed to 177Lu-HH1, 177Lu-
Rituximab and 177Lu-Erbitux are reported in figure 2.10 for the different activity con-
centrations introduced in the culture medium. The large error bars are due to the fact
that the number of parameters for the fit equals the number of experimental points, and
thus the fit cannot bit well constrained. Cumulated activities in cells treated with 177Lu-
Rituximab are always significantly higher than those obtained for 177Lu-HH1, which is
most probably explained by the highest number of CD20 receptors, compared with CD37
receptors at the surface of Ramos and DOHH2 cells. As expected, cells treated with the
non-specific mAb 177Lu-Erbitux exhibited the lower level of internalisation: except for
the highest medium activity concentrations tested, their cumulated activities were almost
negligible from a dosimetric point of view.
2.4.1.2 Clonogenic survival experiments
Ramos cell survival curves obtained with the radiolabelled mAbs and expressed as a func-
tion of the activity concentration in the medium are reported in figure 2.11. For the same
test activity, 177Lu-Rituximab resulted in the highest therapeutic efficacy, 177Lu-Erbitux
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Figure 2.8: Top left: time activity curves obtained for Ramos cells treated with 177Lu-HH1, and
for the five different initial activity concentrations in the culture medium. In the other plots, each
single time-activity curves is fitted with equations 2.4.8.
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Figure 2.9: Top left: time activity curves obtained for DOHH2 cells treated with 177Lu-HH1,
and for the five different initial activity concentrations in the culture medium. In the other plots,
each single time-activity curves is fitted with equations 2.4.8. In this figure and in figure 2.8, the
same vertical scale was selected in order to facilitate the comparison.
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Figure 2.10: Ramos (top) and DOHH2 (bottom) cells cumulated activity as a function of the
initial activity concentration in the medium (MBq/mL) for the three mAbs. The plots on the left
correspond to time-activity curves integrated between 0 and 336 hours. For plots on the right, the
integration was performed between 0 and 18 hours.
in the lowest while 177Lu-HH1 was in between. It must be kept in mind that Erbitux does
not bind to the cells. In figure 2.12, survival curves obtained with the labelled and the
unlabelled version of HH1 and Rituximab are expressed in terms of mAb concentration
(ug/mL) in the medium for direct comparison. The high cytotoxicity of Rituximab is
evidenced in figure 2.12, right, where approximately half of the cell population is killed
by the treatment. On the contrary, HH1 (figure 2.12, left) showed a lower (although not
negligible) cytotoxicity with only 10% of cells killed.
2.4.1.3 Determination of culture cell geometry
The relevant parameters describing Ramos and DOHH2 cells cultures geometry are repor-
ted in tables 2.2 and 2.3 for the three regions considered. They were obtained from cells
treated with 177Lu-HH1 and 177Lu-Rituximab, and they were subsequently used as input
to the dosimetric model. As expected, the values found for cluster size and cell/cluster
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Figure 2.11: Ramos (left) and DOHH2 (right) cells clonogenic survivals as a function of the
initial activity concentration in the medium (MBq/mL).
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Figure 2.12: Ramos (top) and DOHH2 (bottom) cells clonogenic survivals as a function of the
initial mAb concentration (ug/mL) in the medium. Cell survivals on the left are obtained with the
labelled and unlabelled versions of HH1, and those on the right with the labelled and unlabelled
versions of Rituximab.
density do not differ significantly for the two mAbs.
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Ramos cells
Region Cluster radius (um) St. Dev.(um) Isolated cell/cm2 Clusters/cm2 Nlayers
177Lu-HH1
centre 23.87 4.88 none 2.72 104 3
halfway 21.46 6.50 negligible 2.31 104 2
edge 21.62 9.90 1.20 105 2.17 104 1
177Lu-Rituximab
centre 28.52 4.03 none 2.29 104 3
halfway 28.31 10.06 1.09 105 1.10 104 2
edge 21.64 7.75 5.89 104 1.06 104 1
Table 2.2: Geometrical parameters derived from Ramos in-vitro experiments.
DOHH2 cells
Region Cluster radius (um) St. Dev.(um) Isolated cell/cm2 Clusters/cm2 Nlayers
177Lu-HH1
centre 24.91 4.59 none 3.36 104 3
halfway 32.35 15.32 negligible 6.12 103 2
edge 14.08 1.11 2.52 104 1.02 103 1
177Lu-Rituximab
centre 26.85 3.87 none 2.35 104 3
halfway 23.08 9.28 9.78 104 9.15 103 2
edge 19.28 6.43 5.13 104 6.35 103 1
Table 2.3: Geometrical parameters derived from DOHH2 in-vitro experiments.
2.4.2 Dosimetry
2.4.2.1 Self-irradiation
Self-irradiation S values are reported in table 2.4 for the three different target regions and
the three source distributions considered. S values corresponding to 50% of radioactivity
in the cytoplasm and 50% in the cell surface were calculated using equation 2.3.4. These
results were compared to MIRD cellular S values (Goddu et al. 1997) for validation
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purposes. MIRD S values are calculated analytically using electron stopping powers in
the CSDA, and neglecting photon contribution. Percentage differences of few percents were
found, which are most probably due to the fact that secondary electrons and photons are
not considered in the analytical calculations.
Self-irradiation S values (Gy/Bq s)
Ramos cells
Source
Target 100% CS 100% Cy 50% Cy + 50% CS
Cell 6.51 10−4 9.32 10−4 7.91 10−4
Cytoplasm 9.07 10−4 1.28 10−3 1.09 10−3
Nucleus 3.75 10−4 5.61 10−4 4.68 10−4
DOHH2 cells
Source
Target 100% CS 100% Cy 50% Cy + 50% CS
Cell 6.19 10−4 8.25 10−4 7.22 10−4
Cytoplasm 1.11 10−3 1.50 10−3 1.30 10−3
Nucleus 4.02 10−4 5.26 10−4 4.64 10−4
Table 2.4: Self-irradiation S values for Ramos and DOHH2 cells.
Variations on cell and nucleus size have the highest impact when the absorbed dose is
scored in the cytoplasm: percentage differences between Ramos and DOHH2 cells S values
are in this case 22% and 17% for a 100% CS and a 100% Cy source respectively. The
influence of source localisation is rather pronounced for all target regions considered and
both cell lines: percentage difference of 45% and 33% are found for Ramos and DOHH2
cells respectively, when the source is localised in the cytoplasm or on the cell surface.
2.4.2.2 Cross-irradiation
In figure 2.13, cross-irradiation S values obtained from direct MC simulation are reported
as a function of the cell-to-cell distance calculated at cell surface, for the three target
regions (Nucleus, Cytoplasm and the whole cell from left to right). In each plot, results for
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the three source distributions considered are presented. The cross-irradiation contribution
is about one order of magnitude lower than self-irradiation when the cells are in contact.
At 4 radii distance (surface-to-surface distance of 20.4 um) the ratio between self- and
cross-irradiation S values for the whole cell is of the order of 100.
The radioactivity localisation in the source cell has not a significant impact on the
absorbed dose to the target cell: the highest discrepancy (∼7%) is found between a 100%
CS and a 100% Cy source distributions in the case of contiguous cells and when considering
the cytoplasm as target volume. Under the same conditions, the percentage difference
between S values for two cells placed at 4 radii distance is about 0.5%. These results
justify the use, at higher cell-to-cell distances, of cross-irradiation S values not taking into
consideration the radioactivity heterogeneity within the cell.
Figure 2.13: Cross-irradiation S values obtained from direct MC simulation for three different
targets (nucleus, cytoplasm and whole cell). In each plot, S values are reported for different
cell-to-cell distances, and for difference radioactivity internalisation hypotheses.
In figure 2.14 (left), cross-irradiation S values derived from 177Lu DPKs are represented
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by a blue dashed line, together with those calculated with MIRDcell (continuous red line).
Data points (green) represent 177Lu cross-irradiation S values obtained via direct MC
simulation. The direct MC approach is assumed to produce the most accurate absorbed
doses with respect to MIRDcell, for which secondary electrons are neglected, and the DPK
approach based on a punctual source and target approximation. In the range 22.0 – 61.95
um, where three of the simulated S values superpose the DPK S values, the percentage
difference between the two datasets is below 5% (c.f. figure 2.14, triangular points). Their
agreement at short cell-to-cell distances validates the assumption of punctual target and
source made for the generation of DPK S values. At the same time, at rather short cell-
to-cell distances, MIRDcell and DPK data visually show the same behaviour. However,
MIRDcell S values display an artificial periodicity that increases with cell-to-cell distance,
and that most probably depends on a bug in the MIRDcell applet. Even in the range 22.0
– 120 um, where the MIRDcell periodic response is less evident, the percentage differences
between the DPK and the MIRDcell datasets (DPK - MIRDcell)x100/MIRDcell) are quite
high: a maximum and an average percentage difference of 28.8% and 20.0% are observed
respectively (see figure 2.14, circular points).
Figure 2.14: On the left plot: cross-irradiation S values obtained from MIRDcell (red), from
DPKs (blue), and via direct MC simulation (green). On the right: percentage differences between
MIRDcell and MC data with respect to S values derived from DPKs.
Calculation of cross-irradiation absorbed dose.
Cross-irradiation average absorbed doses obtained from isolated cells (DIC), single tar-
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get cluster (DTC) and surrounding multiple clusters models (DSC) in each region of the
counter well, were summed up using the total numbers of cells in each region as weights.
For each combination of cell line and antibody considered in this study, a specific aver-
age cross-irradiation absorbed dose values was found. The separate contributions of DIC ,
DTC and DSC are shown in figure 2.15 in the case of Ramos (top) and DOHH2 (bottom)
cells treated with the two specific antibodies (177Lu-HH1 and 177Lu-Rituximab). In all
experiments, the highest absorbed dose comes from radioactivity in the cluster the target
cell belongs to; DTC is about two times DSC . On the other hand, the impact of radio-
activity in isolated cells is low but generally not negligible (of the order of 0.5 Gy for
Ramos cell treated with 177Lu-Rituximab), with the exception of DOHH2 cells treated
with 177Lu-HH1 for which it is almost null. The higher absorbed doses obtained for cells
treated with 177Lu-Rituximab are mostly due the highest measured cumulated activity
per cell. Cross-irradiation absorbed doses for cell treated with the non-specific antibody
(177Lu-Erbitux) resulted negligible with respect to 177Lu-HH1 and 177Lu-Rituximab ab-
sorbed doses: at 6 MBq/mL, 177Lu-HH1 cross-irradiation absorbed dose is about 3 and
7 times higher for Ramos and DOHH2 cell respectively, while 177Lu-Rituximab absorbed
dose is 7 times higher for both cell lines.
For all mAbs and both cell lines considered, the relative standard deviation on the
total cross-irradiation absorbed dose was on average 24%. This value directly depends on
the randomisation of cellular uptake of radioactivity and geometrical configurations imple-
mented in the dosimetric model; in turn, it provides a measure of the great heterogeneity
of parameters characterising a cellular systems both in vitro and in vivo.
2.4.2.3 Non-specific irradiation
Non-specific irradiation S values obtained from direct MC simulation of a single Ramos
cell (5.1 um cell radius and 4.0 um nucleus radius) are reported in table 2.5 for the three
target regions considered. In the same table, S values calculated with MIRDcell for a 4
and 5 um radius cells, are also shown.
The non-specific irradiation cell S value obtained for the 4 um radius cell in MIRDcell
could be approximately considered as the nucleus S value if assuming that the medium
activity included (or missing) in the spherical shell between 4 and 5 um does not have a
significant contribution to the nucleus/cell absorbed dose. In these conditions it is possible
to compare nucleus S values obtained with MIRDcell and the direct MC simulation, for
83
Chapter 2. Realistic multi-cellular dosimetry for 177Lu labelled antibodies
Initial activity concentration (MBq/mL) 
0 1 2 3 4 5 6
A
bs
. D
os
e 
(G
y)
0
1
2
3
4
5 Total cross dose
Multiple clusters
Single cluster
Isolated cells
Cross irradiation absorbed dose - Ramos cells - 177Lu-HH1
Initial activity concentration (MBq/mL) 
0 1 2 3 4 5 6
A
bs
. D
os
e 
(G
y)
0
1
2
3
4
5 Total cross dose
Multiple clusters
Single cluster
Isolated cells
Cross irradiation absorbed dose - Ramos cells - 177Lu-Rituximab
Initial activity concentration (MBq/mL) 
0 1 2 3 4 5 6
A
bs
. D
os
e 
(G
y)
0
1
2
3
4
5 Total cross dose
Multiple clusters
Single cluster
Isolated cells
Cross irradiation absorbed dose - DOHH2 cells - 177Lu-HH1
Initial activity concentration (MBq/mL) 
0 1 2 3 4 5 6
A
bs
. D
os
e 
(G
y)
0
1
2
3
4
5 Total cross dose
Multiple clusters
Single cluster
Isolated cells
Cross irradiation absorbed dose - DOHH2 cells - 177Lu-Rituximab
Figure 2.15: The different contributions of DIC , DSC and DMC are shown for the two specific
mAbs (177Lu-HH1 on the left and 177Lu-Rituximab on the right) and the two cell lines (Ramos on
top, DOHH2 at bottom.)
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Non-specific irradiation S values
Target Cell Cytoplasm Nucleus
MC (Ramos cell) 3.10 10−10 3.19 10−10 3.01 10−10
MIRDcell (4 um radius cell) 3.44 10−10 - -
MIRDcell (5 um radius cell) 3.43 10−10 - -
Table 2.5: Non-specific irradiation S values obtained via direct MC simulation and from MIRD-
cell.
which a 14% difference was found. At the same time, the percentage difference between
nucleus and cell S values obtained with Geant4 was 3%, while a 0.3% differences was
found between S values calculated with MIRDcell for cells of 4 and 5 um radius. Besides,
the difference between the S values obtained with MIRDcell and the direct simulation is
about 10% for the 5 um radius cell. The direct MC simulation is a priori more realistic
and provides in principle the more accurate result. For this reason, in this work, the
non-specific irradiation nucleus S value issued from the MC simulation was used for the
calculation of the total absorbed dose. However, considering the huge spare of time al-
lowed by the analytical approach, the use of MIRDcell or another equivalent method is
recommended for future applications.
2.4.2.4 Total absorbed dose
In figure 2.16, self-, cross- and non-specific absorbed doses to the nucleus are reported
as a function of the initial activity concentration in the medium, for Ramos and DOHH2
cells treated with 177Lu-HH1, 177Lu-Rituximab and 177Lu-Erbitux. In general, most of
the absorbed dose to the target cell is due to non-specific irradiation. For both cell
lines treated with the non-specific mAb (177Lu-Erbitux), the non-specific absorbed dose
augments with increasing activity concentration in the medium, at approximately constant
rate. A quite similar behaviour is also observed for Ramos cells treated with the two
specific mAbs. In the case of DOHH2 cells, instead, at high initial activities, non-specific
irradiation is lower (for 177Lu-HH1) or of the same order (for 177Lu-Rituximab) of the
cross-irradiation contribution. This effect is a direct consequence of the higher cumulated
activities found for DOHH2 cells. Indeed, if more labelled mAb is internalised in the
cells, the activity in the medium, and hence the corresponding absorbed dose, is reduced
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accordingly. Furthermore, at low activity concentrations, for which cellular receptors are
not saturated, the cross- and the self-irradiation absorbed doses are higher than the non-
specific absorbed dose, for both cell lines treated with 177Lu-Rituximab. Conversely, for
cells treated with 177Lu-HH1, the non-specific irradiation becomes dominant at quite low
initial activities (> 1 MBq/mL).
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Figure 2.16: The Different contributions of self-, cross- and non-specific irradiation absorbed
doses are shown for the three mAbs and the two cell lines (Ramos on the left, DOHH2 on the
right).
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Despite the self-absorbed dose is calculated over a larger temporal frame with respect
to the cross-absorbed dose (336 hours vs. 18 hours), its contribution is, on average, the
smallest. However, for DOHH2 cells treated with 177Lu-Rituximab, the self-absorbed dose
is higher than the cross-absorbed dose, most probably because of the high mAb uptake
for this configuration. The results here presented correspond to specific internalisation
hypotheses for the three antibodies (50% CS + 50% Cy for 177Lu-HH1, and a 100% CS
for 177Lu-Rituximab and 177Lu-Erbitux). Other possibilities have been explored, reaching
compatible absorbed dose values, since in the dosimetric model implemented the intern-
alisation only impacts the self-irradiation absorbed dose.
2.4.3 Clonogenic survival
In figures 2.17 and 2.18, Ramos and DOHH2 survivals are presented as a function of nuc-
leus absorbed dose for the three 177Lu-mAbs considered, before (top) and after (bottom)
correction for mAb toxicity. A Linear Quadratic (LQ) model (Dale 1985) was considered
for the fit of all datasets. Errors on both axes were considered, using a generalised version
of the χ2 method (effective variance method) as implemented in ROOT. Fit results are
displayed in each plot: the parameter p0 and p1 correspond to the α and β parameters of
the LQ model.
For Ramos cells, 177Lu-HH1 data not corrected for toxicity showed a linear behaviour
(β = 0), while for 177Lu-Rituximab and 177Lu-Erbitux, β was different from zero. Ac-
cording to these results, the combination of radiation damages and biological toxicity was
more effective for 177Lu-Rituximab than for the non specific 177Lu-mAb (177Lu-Erbitux),
with 177Lu-HH1 being in between. After correction for antibody toxicity, both 177Lu-HH1
and 177Lu-Rituximab displayed a linear behaviour, with β compatible to zero. The effect
of the correction on 177Lu-HH1 survival curves was to approximately double the D37 value
(the absorbed dose required to achieve 37% survival) from 7.2 Gy to 12.9 Gy without
directly impacting on the shape of the curve. Conversely, 177Lu-Rituximab survival was
shifted from a LQ response with a D37 = 4.6 Gy, to a linear response with D37 =18.3 Gy.
For the non-specific antibody, which was supposed non-cytotoxic, survival curves followed
the LQ model with a D37 = 9.9 Gy and α/β = 3.7 Gy.
An interesting effect of toxicity correction is that survival curves of the three mAbs get
closer: in particular at low absorbed doses, where the experimental errors are relatively
low, the three curves almost perfectly superpose. If the hypothesis that cell deaths by
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Figure 2.17: Ramos cells clonogenic survival as a function of nucleus absorbed dose.Survival
curves on top include both cytotoxic and radiative effect, while those at bottom are corrected for
antibody toxicity.
radiation and by cytotoxicity are additive phenomena is correct, the curves at bottom of
figures 2.17 and 2.18 only account for radiative effects, hence, a similar absorbed dose-
response relationship is expected for the three 177Lu-mAbs. In order to determine if the
treatment has a significant effect on the curve shape, the three corrected survivals have
been compared with an F-test (Motulsky and Christopoulos 2005), which is appropriate
for nested data. For each couple of datasets, the null hypothesis is that the same curve
fits both data points and the difference is purely due to chance. The high p-value (0.27)
found for the couple 177Lu-Rituximab/177Lu-HH1 demonstrated that, given the errors in-
troduced by the experiments and the absorbed dose model, it is not possible to reject
the null hypothesis. A similar conclusion can be drawn for the couple 177Lu-HH1/177Lu-
Erbitux, for which the p-value was 0.28. Conversely, the non-specific antibody survival
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Figure 2.18: DOHH2 cells clonogenic survival as a function of nucleus absorbed dose. Survival
curves on top include both cytotoxic and radiative effect, while those at bottom are corrected for
antibody toxicity.
resulted significantly different from 177Lu-Rituximab survival (p-value = 0.03), if consid-
ering a 5% significance.
For DOHH2 cells, the overall efficacies of 177Lu-HH1 and 177Lu-Rituximab seemed to
be comparable when both cytotoxic and radiative effects were taken into account. The
two specific antibody also showed a higher efficacy than 177Lu-Erbitux’s. Both 177Lu-HH1
and 177Lu-Erbitux curves could be fitted with a LQ model, obtaining D37 values of 1.9
and 2.1 Gy respectively. At the same time, an α/β ratio of 39.2 Gy was found for cells
treated with 177Lu-Erbitux, which confirmed the higher radiosensitivity of DOHH2 cells
with respect to Ramos. Conversely, 177Lu-HH1, showed a linear behaviour with D37 =
1.6 Gy. After correction for antibody toxicity, 177Lu-HH1 and 177Lu-Rituximab survival
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curves displayed a saturation effect even at low absorbed doses. In both cases, it was not
possible to fit the data neither with a linear nor with a LQ model. According to figure
2.18 (bottom), DOHH2 cell treatment with 177Lu-HH1 resulted more effective than with
177Lu-Rituximab, when considering only radiation effects.
2.5 Discussion
Paradigm of radiobiology is that radiation-induced biological effects are proportional to the
delivered absorbed dose. Therefore in conventional External Beam RadioTherapy (EBRT)
linear or linear quadratic response is generally established for survival of cells exposed to
radiation. However, such an assumption is not straightforward in targeted radionuclide
therapy (TRT) in particular because cell irradiation between EBRT and TRT differs in
many ways. In TRT, cells are irradiated at low absorbed dose rate (< 1 Gy h−1 in
the experiment here described) and therefore, they have more time to repair; irradiation
may be highly heterogeneous at the cellular level; and finally the contribution of the
unlabelled cytotoxicity associated with the radiopharmaceutical needs to be considered
to extract purely radiative effects and thus establish an absorbed dose-effect relationship.
Clonogenic assay is the reference technique for investigating biological effects of radiation
on cells: the relationship between clonogenic survival and nucleus absorbed dose allows
comparing differences in efficacy of various treatments. Calculating nucleus absorbed dose
in TRT is much more complex than in EBRT. Many variables can affect the absorbed dose
to a given cell in a colony in vitro: sub-cellular and intra-cellular radioactivity distribution,
cell spatial distribution, cell size. Taking into account this level of variability can make the
dosimetry a challenge, especially for what concerns the calculation of the cross-absorbed
dose. In particular, when considering beta emitting radiopharmaceuticals with a range in
water of few millimetres, the average cell cross-absorbed dose depends on the heterogeneous
characteristics of a large number of cells.
2.5.1 Dosimetric model
The dosimetric model developed allows calculating the average cell absorbed dose for
in-vitro experiments taking into consideration realistic culture characteristics (cell size,
isolated cell/cluster density, cluster size, average cell cumulated activity). Intracellular
variability of these parameters is further taken into account randomising the geometrical
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properties of the modelled colony, and calculating a standard deviation for the resulting
cell absorbed dose. The approach used is generic and can be applied to any type of
radiation, provided that the relevant self-absorbed dose S values and DPKs are known.
The firsts are easily found in the literature for most common radionuclides (Goddu et al.
1997), while the seconds are available for some β-emitters (Papadimitroulas et al. 2012,
Prestwich et al. 1989b) and mono-energetic electrons (Cross et al. 1982).
In this work, the model was applied to the dosimetry of two different cell lines treated
with three monoclonal antibodies (mAbs) radiolabelled with a β-emitter (177Lu). For this
particular scenario, the highest contribution to cell absorbed dose was in general due to
non-specific irradiation associated to the radioactivity in the culture medium (with the
exception of DOHH2 cells treated with 177Lu-Rituximab). Clearly, this outcome is specific
of in-vitro experiments where cells and cell clusters are well spaced and most of the culture
volume is occupied by the incubation medium. In vivo, cells are closers and the non-specific
activity is expected to contribute less. Disregarding non-specific irradiation, most of cell
absorbed dose was associated to cross-irradiation from cells other than the target. Cross-
absorbed dose contribution from the cluster the target cell belongs to, was about two
times the cross-absorbed dose due to other clusters (of the order of 2 Gy for Ramos and
DOHH2 cells treated with 177Lu-Rituximab, at 6 MBq/mL of medium activity). At the
same time, cross-absorbed dose contribution from isolated cells was the lowest but, in some
cases, not negligible (i.e. ∼0.7 Gy and ∼0.6 Gy for Ramos and DOHH2 cells treated with
177Lu-Rituximab, at 6 MBq/mL of medium activity). Both contributions of cell clusters
and isolated cells are large enough to produce measurable modification of survival curves
if neglected, which proves the necessity of modelling the whole culture geometry when
β-emitters are involved. On average, cross- and self-irradiation absorbed doses were of the
same order.
Results obtained also evidenced a little dependence of the total absorbed dose on cell
size and sub-cellular radioactivity distribution in the case of 177Lu. In fact, both these
variables, are only included in the calculation of the self-absorbed dose, which only partly
contributes to the total cell absorbed dose. At the same time, 177Lu cross-irradiation
S values have been demonstrated to be independent on sub-cellular uptake for cell-to-
cell distances larger than 20.4 um (4 cells radii). Moreover, cross-irradiation S values
calculated in the punctual approximation were able to well reproduce (within 5%) the S
values obtained via direct Monte Carlo simulation and taking into account actual cell size.
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In order to avoid even this level of approximation, the use of MIRDcell cross-irradiation
S values was initially considered, but this path was abandoned because of the artificial
periodicity found in MIRDcell data. Even if the 20% difference found between cross-
irradiation S values calculated in this study and MIRDcell’s may seem inconsequential
considering the small absolute values of the data involved, it should be noted that, summed
up over thousands cells the difference may become considerable.
The aim of this approach was to generate a multi-cellular model as realistic as possible.
Still, some approximations had to be made in order to keep it reasonably simple. The
main assumption was to consider constant the number of cells in the colony during the
18h-incubation time with radioactivity, while proliferation may occur with a direct impact
on cell/cluster density and cluster size. Also, the computation of the cross-absorbed dose
was limited to a target cell placed at the centre of the Model Volume. This restriction was
considered appropriate since the Model Volume (whose size is of the order of 177Lu beta
range in water) is much smaller than the culture well volume. As a consequence, most
of cells in the colony can be safely considered as “central”: many Model Volumes can, in
fact, be inscribed in the well volume.
Furthermore, a non-conventional approach was used to take into account cell labelling
heterogeneity. While in many works (Rajon et al. 2011, Vaziri et al. 2014) only a
fixed fraction of cells is assumed to be labelled, and hence considered in the dosimetric
calculation, here all modelled cells were included in the dosimetry. In this work, in fact,
the experimental determination of cell cumulated activity (and its standard deviation), is
performed on samples of about 8000 cells; in principle, within these cells, different levels of
radioactivity uptakes are achieved, with some cells being unlabelled. Therefore, randomly
sampling cell cumulated activity on the basis of these variables, indirectly guarantees to
adequately model cell labelling heterogeneity.
Nevertheless, the establishment of cell cumulated activities remains the main weakness
of this work. The limited number of experimental points available for the cells time-activity
curves made it very difficult to determine the time of maximum uptake. A two-function-
fit approach was hence proposed to estimate the shape of the curve during incubation.
However, the consequent need to fit a three parameters function on three data points,
made the convergence of the fit very unstable, and the errors associated to the cumulated
activities considerably large. In addition, for most experiments, a maximum uptake time
between 5 and 10 hours was found, which is earlier than expected. Further measurements
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(already scheduled) of cells activity, including several data points between 2 and 18 hours,
will be able to confirm or contradict this result. A better sampling of the time-activity
curve is also expected to provide more accurate estimations of cell cumulated activities.
2.5.2 Interpretation of survival curves
Despite the experimental errors involved and the approximation introduced by the do-
simetric model, we have been able to establish curves expressing clonogenic survival as
a function of the nucleus absorbed dose. It was showed that, correcting clonogenic sur-
vival response for unlabelled mAb toxicity, modified the shape of absorbed dose-effect
relationship, with curves getting closer in the case of Ramos cells: this effect suggested
a certain degree of absorbed dose-effect correlation. Under this hypothesis, the rather
similar Ramos cells survivals obtained for the specific (177Lu-Rituximab and 177Lu-HH1)
and the non-specific (177Lu-Erbitux) antibodies, may be interpreted as an indirect val-
idation of the dosimetric model. This is particularly true for the simplest of the three
models, consisting of Ramos cells exposed to 177Lu-Erbitux. In this case, in fact, nucleus
absorbed dose almost exclusively depends on the radioactivity accumulated in the culture
medium. The dosimetric model is therefore extremely simple and hence more reliable (the
model depends on fewer a priori assumptions). Besides, in the case of 177Lu-Erbitux,
the cell killing mechanism is by definition purely radiative since Erbitux does not bind
to cells (or at least not significantly). At the same time, adding the complexity of the
cross-absorbed dose calculation (c.f. 177Lu-Rituximab and 177Lu-HH1) produces survival
curves close to those of 177Lu-Erbitux, which is the expected effect in case of absorbed
dose-effect correlation.
In order to determine the presence (or the lack thereof) of a absorbed dose-effect
correlation in Ramos cells experiments, survival curves were fitted with LQ model as it
is generally done in EBRT for low-LET radiation. The idea was to compare the LQ
curves and determine if the three mAbs survivals could be described by a single absorbed
dose-effect relationship. It was found that the differences between 177Lu-Rituximab and
177Lu-HH1 curves, and between 177Lu-HH1 and 177Lu-Erbitux curves were not signific-
ative (5% confidence level), while 177Lu-Erbitux curves were significantly different from
177Lu-Rituximab survival even after correction for cytotoxicity. In addition, according to
survival curves corrected for toxicity (figure 2.17, bottom), 177Lu-Erbitux seems to have a
higher therapeutic efficacy than the specific antibodies. This result clearly indicates that
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something is still missing in the model (a possible over-estimation of the cross-absorbed
dose) or in the biological interpretation of the data. Certainly, a better estimation of cell
cumulated activities could contribute, in the future, to reduce the uncertainties in the
absorbed dose calculation.
The same effect was found for DOHH2 cell lines. DOHH2 cells survival curves including
both cytotoxic and radiation induced effects indicated that the two specific 177Lu-mAbs
had approximately the same therapeutic efficacy, with 177Lu-Erbitux being less effective.
However, after correction, 177Lu-Erbitux presented a higher therapeutic efficaciy. This
outcome is somehow unexpected, as 177Lu-Erbitux is non-specific and hence it is not
significantly internalised by lymphocyte B cells.
A plausible explanation to this phenomenon is that lymphoma cells contain two sub-
populations with different sensitivities: a first population is sensitive to the genotoxic
effects of the treatment (indifferently of either mAb or 177Lu) and dies first, while a
second population is constituted of more resistant cells. Therefore, the greater the effic-
acy of the mAb alone, the lower the effect of radiation per Gy. This would suggest that
biological effects of unlabelled mAbs (HH1 and Rituximab) occur before the effects of ra-
diation are detectable. The plateaux observed after correction for cytotoxicity for DOHH2
cells treated with 177Lu-Rituximab and 177Lu-HH1 further corroborates this hypothesis.
In the case of DOHH2 cells, the increased efficacy of the non-specific antibody is even
more evident because of the higher sensitivity of these cell lines (α/β ratio was 29.7 Gy
for DOHH2 cell and 3.4 Gy for Ramos cells when considering 177Lu-Erbitux survivals).
Further experiments are currently ongoing in order to verify this assumption.
Another possible explanation of 177Lu-mAbs results would be the involvement of
bystander effects. This phenomenon consists in the death of cells that have not been
directly crossed by particles but are in proximity of irradiated cells. In this context, a
higher than expected cytotoxicity may be observed at low cell absorbed doses, while a
saturation effect may occur at higher absorbed doses.
All these data highlight the complexity of establishing absorbed dose-effect relation
in TRT. In particular, the nature of interactions between pure mAb-induced and pure
radiation-induced biological effects is unknown; it was thus showed that 177Lu-Erbitux
was more efficient per Gy in killing cells than 177Lu-HH1 or 177Lu-Rituximab. These
conclusions would not be different if synergy (instead of additivity) between mAb efficacy
and radiation effects was considered.
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2.6 Conclusions
In a context of clonogenic survival experiments for the evaluation of novel radiopharma-
ceuticals, an accurate assessment of cell absorbed dose is crucial to better understand cell
death mechanisms, and to evaluate the therapeutic efficacy in vitro. The calculation of
the absorbed dose in TRT is intrinsically more complex than in EBRT since it depends
on many variables. Especially when β-emitters are involved, particular attention should
be paid to the calculation of the cross-irradiation absorbed dose.
A realistic multi-cellular dosimetric model was developed for the calculation of aver-
age cell absorbed dose on the basis of experimentally determined parameters (cell size,
isolated cell/cluster density, cluster size, average cell cumulated activity). The model was
applied to the study of a novel 177Lu-labelled radiopharmaceutical targeting CD37 recept-
ors expressed by lymphoma B cells. This approach is generic and it can be useful for
the determination of the average cell absorbed dose in clonogenic survival experiments
involving any type of radiation.
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Chapter 3
Tumour dosimetry in α-particles
radioimmunotherapy
3.1 Introduction
Animal studies are a pre-requisite for the application of new drugs in human clinical
trials. This requirement is established by law in both Europe and USA. In preclinical
studies aiming at the evaluation of radiopharmaceuticals (radioactive agents), an accurate
dosimetry is essential for the observation of an absorbed dose-effect correlation, both for
efficacy and toxicity assessment. These need has been acknowledged by several scientists
working in this field (Pouget et al. 2011, Konijnenberg et al. 2011, Behr et al. 2000,
Konijnenberg et al. 2007).
Nevertheless, pre-clinical dosimetric models usually do not take into account tissue
and activity heterogeneity within organs and tumours. This goes usually on pair with
the way activity is determined. Conventional pharmacokinetics assessment is typically
performed by counting radioactivity (gamma counters) present in collected organs after
animal sacrifice, at various time points after the administration of the radiopharmaceutical.
This approach is limited (but simple to implement) as it only provides mean activity
concentration in a given sample, thus limiting absorbed dose determination to whole organs
or tumours (activity heterogeneity within the tissue/organ is not taken into account).
Other factors that may impair the reliability of the absorbed dose estimate are the
employment of incomplete pharmacokinetic models, and the imprecise measurement of
tumour volumes. In general, absorbed dose uncertainties of 20% or more can be observed
in these studies, and this can make the difference between establishing or not an absorbed
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dose-effect correlation (Konijnenberg et al. 2011).
Especially in the case of short range radiations (α-particles, Auger electron), the aver-
age absorbed dose delivered to the tumour is not necessarily a relevant parameter for the
evaluation of novel radiopharmaceuticals in terms of efficacy. In this case, in fact, if the
size of the organ/tumour considered is significantly larger than particle range in tissue,
the energy released by the radiopharmaceutical is deposited locally and the resulting ab-
sorbed dose distribution is almost as heterogeneous as the radioactivity distribution. In
this chapter, average and voxel-based tumour dosimetries are compared in the framework
of a alpha-particle radioimmunotherapy experiment.
In radioimmunotherapy (RIT), diffuse or metastatic cancer cells are killed by using
radiolabelled monoclonal antibodies (mAbs) against tumour-associated antigens. Several
studies in humans and animals have shown a potential indication of intraperitoneal ra-
dioimmunotherapy for the treatment of peritoneal carcinomatosis (2-3 mm in size) as an
adjuvant treatment after cytoreductive surgery in combination with or in replacement of
Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) (Aarts et al. 2007, Koppe et al.
2005, Santoro et al. 2009, Boudousq et al. 2010). However, the only phase III clinical trial
to evaluate intraperitoneal RIT for ovarian cancer using 90Y-HMFG1 mAb was rather un-
satisfactory (Verheijen et al. 2006). A possible explanation is the use of long range (10.1
mm in water) and low Linear Energy Transfer (LET = 0.2 keV/um) β particles. These
characteristics, combined to the reduced size of tumours treated, resulted in a too low
absorbed dose to the tumours (Oei et al. 2007). The use of α-particles, is therefore a
promising alternative: their short range (50 - 100 um) and high LET (80 - 300 keV/um)
make them much more deleterious locally than conventional β-emitters.
Recently, Boudousq et al. (2013) evidenced a lack of absorbed dose-effect correlation
in animal alpha-radioimmunotherapy (α-RIT) experiments of small volume peritoneal
carcinomatosis, when only the average tumour absorbed dose was taken into account. Most
of preclinical studies on RIT with 212Pb (Milenic et al. 2005, Milenic et al. 2007, Horak et
al. 1997, Tan et al. 2012, Milenic et al. 2008) have targeted the Human Epidermal growth
factor Receptor 2 (HER2). As anti-HER2 mAbs are internalized in the cytoplasm after
receptor binding (Hudis 2007), 212Pb-mAb internalization could contribute to both RIT
efficacy and toxicity. Their objective was hence to compare the efficacy and toxicity of
non-internalizing 212Pb-35A7 (anti-carcinoembryonic antigen, CEA) monoclonal antibody,
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which mostly remains at cell surface, and of internalizing 212Pb-trastuzumab (anti-HER2)
mAb, in RIT of small volume peritoneal tumours that express CEA and HER2 receptors.
They injected (intraperitoneally) three groups of swiss nude mice bearing 2-3 mm tumour
xenograft, with 1.48 MBq of 212Pb labelled mAbs: 212Pb-35A7, 212Pb-trastuzumab plus
a non-specific mAb (212Pb-PX) as a control. Subsequently, they built Mice Survival (MS)
curves over a period of 130 days (see figure 3.1) and calculated the Kaplan-Meier survival
estimates (Goel et al. 2010) for the three groups, plus a group of mice treated with
NaCl for control. A mediam MS of 94 days was found for mice treated with 212Pb-35A7,
while the median MS was not even reached for mice treated with 212Pb-trastuzumab,
indicating a higher therapeutic efficacy of the internalising mAb. Nonetheless, tumour
dosimetry, performed under the assumption of spherical tumour shape and homogeneous
radioactivity uptake (measured with a gamma counter after mice sacrifice), resulted in a
higher absorbed dose for the non-internalising mAb.
Figure 3.1: Survival curves obtained by Boudousq et al. (2013), for mice treated with 212Pb-
trastuzumab,212Pb-35A7, 212Pb-PX (irrelevant), and NaCl (for control).
The aim of this work is to apply more refined absorbed dose assessment techniques
to animal experiments carried out at IRCM (Institut de Recherche en Cance´rologie de
Montpellier) under the same conditions of those described in Boudousq et al. (2013). In
order to better understand the uptake mechanism of the three mAbs, the assessment of
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activity distribution heterogeneities at tumour level was carried out using beta imaging to
determine receptors distributions in vivo through autoradiography. tumour absorbed dose
distributions calculated on the basis of these images were in agreement with mice survival
curves determined in the previous work, confirming that the lack of absorbed dose-effect
correlation found by Boudousq et al. was due to approximate dosimetry.
3.2 Experiments
Experiments described in this section were performed by the Radiobiology and Targeted
Radiotherapy group at “Institut de Recherche en Cance´rologie de Montpellier”(IRCM),
U1194 INSERM, Montpellier, France.
3.2.1 Labelled antibodies
Trastuzumab (Herceptin, Genentech Incorporated, San Francisco CA, USA) is a human-
ized IgG1k internalizing mAb against the Human Epidermal Receptor type 2 (HER2)
expressed in vulvar squamous carcinoma A-431 cells. The non-internalizing murine IgG1k
mAb 35A7, specific for the CEA Gold 2 epitope (Pouget et al. 2008) was obtained from
hybridoma, kindly provided by Dr J-P Mach, Lausanne, Switzerland (Hammarstrom et
al. 1989). Affinity of 35A7 for CEA is 9.76 10−8 M (Robert et al. 1996) while affinity
of trastuzumab for HER2 is 0.16 10−9 M (Baselga et al. 1998). The non-targeting IgG1
mAb PX was purified from the ATCC mouse hybridoma P3X63Ag8 (Kohler et al. 1976)
and was used for control experiments. A summary of the properties of the three mAbs
used is reported in table 3.1.
antibody targeted antigen receptor binding
Trastuzumab HER2 internalising
IgG1k 35A7 CEA non-internalising
IgG1 PX - non-specific
Table 3.1: List of mAbs employed in this study and their characteristics.
Trastuzumab, 37A7 or PX were conjugated with TCMC (Macrocyclics, Dallas, TX,
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USA) using a 12-fold molar excess of ligand to mAb, as described in Milenic et al. (2005).
The 224Ra/212Pb generators were provided by AREVAMed SAS (Bessines-sur-Gartempes,
Haute-Vienne, France) and radiolabelling with 212Pb was performed as described by Tan
et al. (2012). Then, 1 mg mAb-TCMC was incubated with 37 MBq 212Pb at 37 oC for
1 hour and the reaction quenched with 4 mL, 0.1 M EDTA (Ethylenediaminetetraacetic
Acid Disodium Salt) solution. Specific activities were about 37 MBq/mg for the three
mAbs. The labeling yield (ratio 212Pb/212Pb-mAbs) was generally < 2%.
3.2.2 Animal experiments
Swiss nude mice (7 weeks old females) from Charles River were acclimated for 1 week before
experimental use. Subsequently, they were intraperitoneally (ip) grafted with 0.7 106
HER-2 positive vulvar squamous carcinoma A-431 cells, suspended in 0.3 mL DMEM
(Dulbecco’s Modified Eagle Medium), and transfected with CEA and luciferase genes.
Three days post-graft, tumour growth was determined by bioluminescence imaging to
separate mice in three homogeneous groups. The following day, mice received a single ip
injection of 212Pb-35A7 (anti-CEA), 212Pb-trastuzumab (anti-HER2) or 212Pb-PX (non-
specific) mAbs with an activity of 1.48 MBq (37 MBq/mg). The following nomenclature
was adopted for the three mice groups:
• G1: 6 mice treated with 212Pb-trastuzumab;
• G2: 5 mice treated with 212Pb-35A7;
• G3: 3 mice treated with 212Pb-PX;
Mice were eventually sacrificed at 4, 17 and 24 hours post-injection and tumours were
resected. Tumour mass (of the order of a few mg) was distributed among 6.2 ± 4.5
nodules/mouse. In figure 3.2, a typical tumour set extracted from a single mouse is
shown.
3.2.3 Tumour imaging
For each mouse, all resected tumours were quickly frozen in liquid nitrogen using a single
slide, for a total of 14 slides. Each slide was then cut in half along the longitudinal
axis in order to approximately access the central plane of the tumours. Two adjacent
10 um thick cryosections were selected for DAR (Digital AutoRadiography) imaging and
histopathology analysis.
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Figure 3.2: Typical tumour samples resected from a single mouse of this study. Courtesy of JP.
Pouget.
The BetaIMAGERTMdFine (Biospace Lab) was used to determine the spatial distri-
bution of 212Pb-mAbs with a spatial resolution of 10 – 25 um. The sample was covered
with a scintillating foil to convert electrons emitted by 212Pb, 212Bi and 208Tl into photons
that are detected by an intensified CCD (Charge-Coupled Devices) camera. Images were
acquired for a minimum time of 30 minutes for the early time points (4h) to a maximum
time of 2 hours for the latest (24 h), in order to account for count loss due to decay. Ima-
ging times were arbitrarily chosen to make it possible the scan of all cryosections within
the working day. Final data were stored in the form of binary images (20 × 20 × 10 um3
voxel size) of the Counts Per Minute (CPM) registered.
Adjacent tumour sections were also stained with Hematoxylin Erythrosine Saffron
(HES) and the general morphology was analyzed under a standard transillumination mi-
croscope. With this technique, both tumour areas with and without radioactivity uptake
were stained. In figure 3.3 and 3.4, DAR (left) and HES (right) images obtained for two
adjacent sections of tumours treated with 212Pb-Trastuzumab and 212Pb-35A7 are shown
as an example. Ten and eleven larger tumours can be identified in the 212Pb-Trastuzumab
and 212Pb-35A7 images respectively. On average, in the case of 212Pb-35A7 treatment,
the radioactivity was mainly present at tumour surface, while for 212Pb-Trastuzumab and
the non-specific antibody (not shown here) a quite homogeneous radioactivity distribution
was found. Necrosis did not occur in any of the nodules shown.
3.3 212Pb-mAbs pharmacokinetics
3.3.1 212Pb source
212Pb beta-decays into 212Bi that in turns decays into 208Tl and 212Po. In 212Pb-mAbs
radioimmunotherapy, the main α-particles emitted by 212Bi (6.09 MeV) and 212Po (8.78
MeV) are employed to deliver a short-range, lethal absorbed dose to tumour cells. The
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Figure 3.3: Example of DAR (left) and HES images (right) for tumours treated with 212Pb-
Trastuzumab (G1).
Figure 3.4: Example of DAR (left) and HES images (right) for tumours treated with 212Pb-35A7
(G2).
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radioactive decay scheme for 212Pb is shown in figure 3.5. It includes α- and β-particles
with energies going from a few hundred keV up to 8.78 MeV, corresponding to ranges in
tissue from micrometers to centimeters. The physical half-life of 212Pb is 10.64 h, while
Figure 3.5: 212Pb decay chain.
the half-lives of its daughters are 60 minutes or less, so the decay products are in transient
equilibrium with the parent radionuclide (Maiello and Hoover 2010). In figure 3.6 (left)
the decay curves of 212Pb and its daughters is obtained from the solution of Bateman
equations (McParland 2010) generalised to a decay chain of the form X1 → X2 → X3, X4:
A1(t) = A1,0 e
−λ1t (3.3.1)
A2(t) = A1,0
( λ2
λ2 − λ1
)(
e−λ1t − e−λ2t
)
(3.3.2)
Ai(t) = BRi A1,0
( λ2,iλi
(λ2,i − λ1)(λi − λ1)(λi − λ2,i)
)
×
(
(λi − λ2,i)e−λ1t − (λi − λ1)e−λ2,it + (λ2,i − λ1)e−λit
)
(3.3.3)
In equations 3.3.1, 3.3.2 and 3.3.3, λ1 and λ2 are respectively the decay constants of
212Pb
(λPb) and
212Bi (λBi). At the same time, λ2,i and BRi are the
212Bi decay constant and
the branching ratio for either the 208Tl (i = 3) or the 212Po (i = 4) channel, depending
on the decay chain the equation is applied to. Similarly, λi is the decay constant of either
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208Tl or 212Po to 208Pb. λ2,1 and BRi satisfy the relations:
λ2,3 = λBi→T l = BRBi→T l λBi (3.3.4)
λ2,4 = λBi→Po = BRBi→Po λBi (3.3.5)
with:
λ2 = λBi = λBi→T l + λBi→Po (3.3.6)
In figure 3.6 (right) the daughter–parent activity ratios for the three daughters of 212Pb
show that a transient equilibrium (constant ratios) is reached approximately at 10 hours for
212Bi and 212Po, while for 208Tl it takes approximately 24 hours. Despite many authors
(Baidoo et al. 2013, Howell et al. 1994, Boudousq et al. 2013) assume the transient
equilibrium is reached within 4-5 hours, at 5 hours, the ratio of 212Bi, 208Tl and 212Po
activities with respect to 212Pb activity is still 4%, 40% and 15% less than their ratio at
equilibrium. Therefore, any radioactivity measurement performed before 24 hours should
be interpreted with great care.
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Figure 3.6: Left: radioactive decay of 212Pb and its daughters. Daughters activity is normal-
ised to the the activity of the progenitor. Right: daughter/parent activity ratios. The transient
equilibrium is reached at approximately 24 hours.
105
Chapter 3. Tumour dosimetry in alpha-radioimmunotherapy
3.3.2 DAR imager calibration
The absolute 212Pb activity in 8/14 tumour slides was determined immediately after mouse
sacrifice and tumour sectioning. Using a previously calibrated gamma counter and select-
ing the 238.632 keV gamma of 212Pb, activities ranging from 2.87 to 45.38 Bq were found.
Since 212Pb activity is measured directly, without contamination from its daughters, the
values obtained are free from possible biases even for the earlier time points, when the
equilibrium is not reached.
The same plates were subsequently scanned with the BetaIMAGERTMdFine in order
to establish a calibration factor for the DAR images. The beta imager, mainly measures
β-particles from 212Bi and 208Tl. However, it should be noted that, for tumour slides cor-
responding to mice sacrificed at 4 hours, transient equilibrium was not reached, especially
for 208Tl. For the 17 hours time point, on the other hand, the ratio between 208Tl and
212Pb activity is only 3% lower than the same ratio at equilibrium.
Given the low radioactivity in the slides and the low acquisition times, the DAR images
obtained were quite noisy (see for example figures 3.3 and 3.4, left) with only few counts
per voxel, on average. Therefore, DAR images were first smoothed by averaging voxel
content over a 2 voxels radius, and then, all voxels outside tumour volume having less
than 2 counts per minute were arbitrarily put to zero applying a mask. In this way, it
was possible to suppress the background counts producing artificial halos around each
tumours. In figure 3.7, the processed DAR image corresponding to the tumour set of
figure 3.3 (left) is shown as an example.
212Pb and electron activities obtained from the two sets of measurements, were com-
pared to obtain a calibration curve for the DAR images. Since both measurements were
performed within approximately 1 hours after mouse sacrifice, the data were not corrected
for the physical decay of 212Pb in this time frame. In figure 3.9, the 212Pb activity of
the whole tumour section is plotted against DAR counts per minute (CPMDAR). Poisson
errors were considered for CPMDAR; error bars fall within the point size. Assuming a
linear response without offset, the following calibration factor (kDAR) could be inferred:
kDAR =
A(Bq)
CPMDAR
= 1.432 10−4 (3.3.7)
106
3.3. 212Pb-mAbs pharmacokinetics
Figure 3.7: DAR image corresponding to the tumour set of figure 3.3 (G1), post-processed for
activity determination.
3.3.3 Time activity curves
Single tumours in each DAR image were segmented by thresholding, in order to obtain the
total number of tumour voxels Nt in the slide. In most tumours treated with anti-CEA,
many voxels in the central region, did not present any uptake of radioactivity. In order
to include all tumour voxels in the segmentation, the “fill holes”function of the ImageJ
software1 was applied to the thresholded images. In both cases, the corresponding HES
image was used as a reference to visually validate the segmentation.
For each mouse, the specific activity At (Bq/g) in the tumour mass (including all
nodules) was calculated as
At =
CPMtotal k
Nt Mvoxel
(3.3.8)
where CPMtotal are the total DAR counts in the nodule segmented image and Mvoxel
is the voxel mass in grams. When multiple mice were available for a single data point
(c.f. G1 and G2), their specific activities were averaged. The resulting average specific
activities and standard deviations were hence employed to build time–activity curves for
each 212Pb-mAbs (see figure 3.9). Time activity curves were subsequently fitted assuming
a mono-exponential decay to extract the cumulated activities (A˜t) for the three groups.
1http://imagej.nih.gov/ij/
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Figure 3.8: DAR calibration curve.
Results are reported in table 3.4.
3.4 Tumour dosimetry
Two different techniques were used for the calculation of tumour absorbed dose on the
basis of DAR imaging. To a first approximation, average tumour absorbed dose was cal-
culated assuming a spherical shape and a homogeneous radiopharmaceutical distribution,
while in the second instance, radioactivity heterogeneity was taken into account to obtain
tumour absorbed dose distribution at the voxel level. With both approaches, only the self-
absorbed tumour dose was considered since the short range of 212Pb α-particles prevent
the irradiation from surrounding tissues. In both cases, the Monte Carlo technique was
applied using the GATE toolkit.
3.4.1 Simulation of 212Pb source
The Monte Carlo simulation of a radioactive source in Gate requires the definition of all
emitted radiations in terms of energy and emission probability. For convenience, the emis-
sions are usually categorised per particle type (mono-energetic electrons, mono-energetic
photons, β- and α-particles) to define separate macro-sources with different probabilities
of emission. At run time, the probability of an event coming from macro-source i, is
given by the sum of the emission probabilities (particles/Bq s) of all radiations included
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Figure 3.9: Time-activity curves obtained from DAR images of tumours treated with the three
212Pb-mAbs.
in the given macro-source. These probabilities, calculated using the decay data listed in
Eckerman and Endo 2008, are reported in table 3.2.
For the simulation of a radioactive decay chain as in the case of 212Pb, the relative
branching ratios (BR) of parent and daughter radionuclides should be taken into account.
Eleven separate macro-source were hence defined to include all type of emissions from the 4
radionuclides of the 212Pb decay chain. Their relative emission probability was calculated
as the product of the particle/Bq s emitted (as listed in Eckerman and Endo 2008) and
the BR (reported in table 3.2) of each macro-source. Recoil energy associated with the
212Bi and 212Po decays is ignored (Goddu et al. 1994).
3.4.2 Average tumour absorbed dose
Tumour nodules in the DAR images were analysed one-by-one to calculate their average
absorbed dose. Nodule masses were estimated under the assumption that i) they had a
spherical shape and that ii) the DAR image was taken at the tumour central slice. Their
radius was hence calculated as (A/π)1/3 where A is the tumour area in mm2 calculated
from DAR images. Average nodule masses were 0.6, 0.7 and 0.5 mg for G1, G2 and G3
respectively.
The Gate Monte Carlo toolkit was used to generate 212Pb S values for water spheres of
selected radii (from 0.1 to 1.0 mm). The standard hadron physics list (hadrontherapyStand-
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Particle/Bq s emitted by the 212Pb decay chain
Particle type 212Pb 212Bi 208Tl 212Po
photons 6.566219 4.268342 3.635647 0.000000
electrons 5.561768 4.013696 1.224487 0.000000
beta 1.000001 0.640600 1.000001 0.000000
alpha 0.000000 0.359400 0.000000 1.000000
BR 1.000000 1.000000 0.359400 0.640600
Table 3.2: Particles per Bq s emitted by 212Pb and its daughters: the values are given for each
type of emission. In the last line, the branching ratios (BR) of each radionuclide is also reported.
ardPhys.mac) available in the “example/example PhysicsLists ”folder of the Gate code was
used. The hMultipleScattering process was added to take into account α-particles mul-
tiple scattering. A range cut of 1.0 μm was selected. Five millions primary particles were
generated in order to obtain a negligible statistical uncertainty on the average absorbed
dose (< 0.1%). Resulting S values are shown in figure 3.10 as a function of sphere radius.
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Figure 3.10: Water sphere S values for 212Pb.
S values for any sphere size (ranging from the minimum to the maximum tumour
radius) were extrapolated by linear interpolation of simulated data, and then used to
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calculate the absorbed dose to each nodule taking into account its specific size (estimated
mass) and the specific cumulated activities (Bq s/g) obtained for the three groups. The
average tumour absorbed dose and the standard deviation obtained for each group is
reported in table 3.3.
Tumour-specific dosimetry Self-absorption approximation
Group Average mass (g) Abs. Dose (Gy) Std Dev (Gy) Abs. Dose (Gy)
G1 6.91 10−4 28.12 2.15 34.14
G2 8.39 10−4 36.16 2.66 43.48
G3 6.45 10−4 17.74 1.34 22.02
Table 3.3: Average tumour absorbed doses for the three groups, obtained using tumour-specific
S values (tumour-specific dosimetry) and assuming that all energy emitted by 212Pb is absorbed
within the tumour (self-absorption approximation). In the first case, the absorbed dose standard
deviation is calculated from the absorbed doses of all tumours resected. For the self-absorption
approximation, a unique absorbed dose, independent of tumour mass was achieved. Average
tumour mass estimated from 2D DAR images is also reported.
A priori, the hypotheses made to extract nodule masses from 2D DAR images may
lead to the use of the wrong S value for a given tumour: this may introduce a certain
level of error in the calculation of the absorbed dose. For this reason, an alternative
approach that does not take into account tumour mass was also considered (Boudousq
et al. 2013). The absorbed dose Dt was calculated assuming that all energy emitted in
the tumour (Edep=8.7 MeV/Bq s) is deposited within the tumour itself (self-absorption
approximation):
Dt(Gy) =
Edep(J)
mass(g) 10−3
A˜t(s/g) mass(g) (3.4.9)
The resulting total absorbed doses are shown in table 3.3 for the three groups. Considering
the tumour masses in this study, tumour absorbed dose calculated in the self-absorption
approximation was overestimated from 10% to 50%. As a matter of fact, for tumours
masses of about 0.5 g, the self-absorption hypothesis does not hold true.
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3.4.3 Voxel dosimetry
DAR images for the three groups showed heterogeneous radiopharmaceutical distributions
for most tumours, especially for what concerns those treated with anti-CEA mAb. The
calculation of the absorbed dose at the voxel level is therefore required if this heterogeneity
has to be be taken into account.
A representative tumour for each group dataset was selected and used as input for the
simulation of the voxel absorbed dose. In picture 3.11, from left to right, HES (top) and
DAR (bottom) images of selected tumours for the G1 (212Pb-Trastuzumab), G2 (212Pb-
antiCEA) and G3 (212Pb-PX) groups are shown.
Figure 3.11: HES (top) and DAR (bottom) images of G1, G2 and G3 (from left to right) tumours
selected for voxel dosimetry.
The obvious issue for the calculation of tumour absorbed dose from DAR images is to
extrapolate the 3D absorbed dose distribution on the basis of a 2D activity distribution.
This problem was overcome by performing two different MC simulations. In the first
(2D model) the tumour was modelled as bi-dimensional (XY plane) in order to assess the
penetration of 212Pb emissions in the third dimension (Z) . In the second, this information
was used to build a fictitious 3D model of the tumour (semi-infinite model). This approach
allowed taking into account, not only the absorbed dose due to the activity in the tumour
slice considered, but also the absorbed dose due to the activity in contiguous slices. For
both simulations, the same physics list settings adopted for the generation of the S values
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was employed. Nevertheless, a custom maximum step of 0.1 um was used instead of the
default value of 20.0 um. In a voxel geometry, in fact, this parameter (and the range cut)
should be set to values lower than the voxel size, in order to avoid artefacts in the energy
distribution. As a general rule of thumb, a maximum step equal to 1/20 of the voxel pitch
is generally considered appropriate. For each simulation, 5 milions primary events allowed
a voxel statistical uncertainty < 1% for all voxels considered.
3.4.3.1 2D model
A 2D 212Pb voxel source was simulated according to the activity distribution reported in
the DAR image selected. The thickness of the simulated source was 20 um. The absorbed
dose was scored in the XY plane defined by the image (at Z=0), as well as along the Z
axis, from -110 um to 110 um. The goal of this simulation was to assess the penetration
of 212Pb emissions. In figure 3.12 (left), the absorbed dose along the Z axis, normalised
to the absorbed dose at Z=0, is reported in the case of the tumour treated with 212Pb-
Trastuzumab. The red line represents the absorbed dose due to α-particles, while the
blue line represents the absorbed dose due to all emissions but alphas. In green, the total
absorbed dose is also reported. Equivalent results were obtained for the other two tumours
(G2 and G3). Since most of the absorbed dose is due to α-particles emitted by 212Bi and
212Po, the penetration in tissue of the 212Pb source is limited. This preliminary simulation
allowed demonstrating that the energy emitted in the central slice is almost completely
deposited within 105 um from the source.
3.4.3.2 Semi-infinite model
For each group, the 20 um tumour slice defined from the selected DAR image, was replic-
ated 11 times along the Z axis (from -110 um to 110 um) in order to model a fictitious 3D
activity distribution. In this geometry, the absorbed dose in the central slice is supposed
to account for all energy emitted in the 3D tumour volume. Obviously, edge effects due to
tumour radioactivity at top and bottom extremities are neglected in this approximation.
Nevertheless, this was considered the most accurate approach in the lack of experimental
data concerning the actual 3D activity distribution in the tumour.
In figure 3.12 (right), the total absorbed dose (green points) along the Z axis, norm-
alised to the absorbed dose at Z=0, is reported in the case of the tumour treated with
212Pb-Trastuzumab, together with the alpha (red points) and non-alpha contributions
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Figure 3.12: Absorbed dose in the axis perpendicular to DAR images (Z), normalised to the
absorbed dose at Z=0, obtained for a tumour of G1, in the case of 2D (left) and semi-infinite
models (right). The separate contributions of α-particles and other emissions are shown in red and
green respectively. Total absorbed dose is reported in blue.
(blue points). Obviously, the absorbed dose attains its maximum value in the central
slice; the other slices, in fact, are only reached by a fraction of α-particles emitted within
the semi-infinite tumour. In figure 3.13, the absorbed dose maps in the central slice, ob-
tained for the selected tumours of G1, G2 and G3 are shown on the same intensity scale
and with realistic relative sizes. As expected, the energy deposition for 212Pb is mainly
localised in the emission voxels. As a results, the spatial distributions of radiopharmaceut-
ical activity (DAR images) and absorbed dose were very similar, with the smoother look
of absorbed dose maps due to α-particle range in tissue. In figure 3.14, the Dose Volume
Histograms (DVHs) for the three groups, calculated in the central tumour slice, shows
that 30% of the tumour treated with anti-CEA receives a null absorbed dose, justifying
the lower therapeutic efficacy found in the previous study (Boudousq et al 2013).
Average absorbed doses for the three tumours considered, were established restricting
the calculation to the the central slice of the simulated absorbed dose distributions. Results
are reported in table 3.4 together with the estimated tumour massess and the relevant
cumulated activities. Water sphere S values corresponding to the three tumour masses are
also reported for validation: the difference between the average absorbed doses calculated
with the average and the voxel dosimetry approaches was below 4% for the three groups.
The average absorbed dose obtained via voxel dosimetry are also in agreement with those
found considering all tumours of this study (c.f. 3.3).
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Figure 3.13: Absorbed dose distributions obtained for the selected tumours of G1, G2 and G3
(from left to right).
Group Tumour S value
(Gy/Bq s)
Mass (g) Sphere S value
(Gy/Bq s)
A˜t (Bq s/g) A˜t (Bq s) Tumour
Abs. Dose (Gy)
G1 8.61 10−7 1.45 10−3 8.60 10−7 2.45 1010 3.55 107 30.54
G2 6.22 10−7 1.97 10−3 6.43 10−7 3.12 1010 6.15 107 38.23
G3 5.16 10−7 2.38 10−3 5.37 10−7 1.58 1010 3.77 107 19.44
Table 3.4: S values and average absorbed doses (Gy/Bq s and Gy) obtained for the G1, G2 and
G3 tumours selected for voxel dosimetry. S values for water spheres of the same mass of tumours
considered is reported for comparison. Tumour cumulated activities (expressed in Bq s/g and Bq
s) for the three groups are also listed.
3.5 Discussion and conclusions
The average absorbed dose delivered to the tumour is not necessarily a relevant parameter
for the evaluation of novel radiopharmaceuticals in terms of efficacy, as demonstrated
by previous experiments carried out at IRCM. In Boudousq et al. (2013), they estab-
lished survival curves for athymic nude mice bearing intraperitoneal tumour xenografts
and treated with 212Pb labeled anti-HER2 (internalizing) and anti-CEA (non-internalising)
mAbs. Their results demonstrated a higher efficacy of anti-HER2 mAbs with respect to
anti-CEA mAbs (figure 3.1). However, the higher average absorbed dose found for tu-
mours treated with anti-CEA seemed to indicate a lack of correlation between absorbed
dose and effect. Analysis of tumour slices at Digital AutoRadiography (DAR) evidenced
a non-uniform distribution of radioactivity in tumours treated with anti-CEA (figure 3.4).
Dosimetry performed on the basis of these images confirmed the higher average absorbed
dose for tumours treated with 212Pb-35A7, with values in agreement with the previous
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Figure 3.14: Dose volume histograms for the selected tumours treated with 212Pb-Trastuzumab
(red), 212Pb-35A7 (blue) and 212Pb-PX (green). About 30% of G2 tumour receives a null absorbed
dose.
study (28.12 Gy and 36.16 Gy, on average, for G1 and G2 tumours in this study, versus
27.6 and 35.5 Gy found in the previous study). Nevertheless, the absorbed dose distri-
butions obtained for two representative tumours of G1 and G2 indicate that, despite the
anti-CEA mAb exhibits a higher average absorbed dose, a high fraction of tumour volume
( 30%) receives an absorbed dose compatible to zero (figure 3.14).
The heterogenous irradiation achieved with 212Pb-35A7 mAb perfectly justifies its
lower therapeutic efficacy. For the G2 tumour considered, in fact, a large portion of tumour
cell is overkilled, with few voxels receiving an absorbed dose up to 180 Gy. On the other
hand, in the 30% of tumour volume not receiving any irradiation, tumour cells are allowed
to proliferate undisturbed. Clearly, this outcome is determined by the short range of α-
particles whose emitted energy is deposited locally: the same antibody (35A7) labelled
with a β-emitter, would have produced a rather uniform absorbed dose distribution in
the tumour (for the tumour size considered), but also a more important irradiation to
surrounding healthy tissues.
This work clearly demonstrates why dosimetry must be carried out at the scale at
which biologically relevant phenomena occurs. The implementation of inadequate dosi-
metry with predictive purposes could, for example, bias the conclusions of a preclinical
study, as in the case highlighted. As part of the optimisation of TRT in preclinical exper-
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iments, the evaluation of spatial heterogeneity may be crucial for the establishment of an
absorbed dose-effect correlation, depending on the pharmaceutical and the radionuclide
involved.
Here, the use of DAR imaging was chosen to derive both radiopharmaceutical pharma-
cokinetics and distribution in vitro. However, for 212Pb, this approach is still not optimal
considering the rather long time needed for the transient equilibrium to be reached. In
most works on 212Pb dosimetry (Baidoo et al. 2013, Howell et al. 1994, Boudousq et al.
2013), it is generally assumed that the equilibrium is reached within 4–5 hours: this hypo-
thesis, however, is not strictly verified for all 212Pb daughters, with 208Tl employing about
24 hours to achieve a constant activity ratio with respect to its progenitor. On the other
hand, this is not necessarily a problem when measuring 212Pb-mAbs radioactivity using
a gamma counter. In this case, 212Pb activity is evaluated directly, with only gammas
from 212Pb taken into account (typically using an energy window centered on the 238.632
keV emission); as a result, the measurement does not depend on the achievement of the
equilibrium condition.
On the contrary, in this work, radiopharmaceutical activity was assessed through beta
counting. As a matter of fact, β-particles from both the parent (212Pb) and two of its
daughters (212Bi and 208Tl) contributed to DAR signal: 212Pb activity was hence inferred
indirectly, through cross-calibration of the DAR imager and the gamma counter. While
this approach could lead to accurate activity determination when the relative contribution
of the three radionuclides is constant, its implementation should be avoided when the tran-
sient equilibrium is not reached. For the DAR images collected 4 hours post injection, in
fact, 212Bi and 208Tl activities were still changing at different rates during the acquisition,
providing a possible explanation for the scattered calibration points obtained. For images
acquired at 17 hours, instead, the ratio between 208Tl and 212Pb activity was only 3%
lower than the ratio at equilibrium.
If, on one hand, this may have biased the time-activity curves obtained, on the other,
the similarity of average absorbed doses obtained in this and in the previous experiment
leads to conclude that the error introduced is not so important to compromise the outcome
of the study. Also, it should be stressed that the conclusions drawn from the comparison of
12Pb-Trastuzumab and 212Pb-35A7 DVHs, still hold in the case of an incorrect determina-
tion of the cumulated activity. Any error introduced in the measurement of 212Pb activity
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at 4 hours post-injection, in fact, equally impacts the dosimetry of the three antibodies.
Obviously, it would not have been reasonable to procrastinate the acquisition of the
first image to wait for equilibrium: time-activity curve should, in fact, be sampled at
biologically relevant time points. However, a more rigorous approach would have consisted
of measuring all tumour slides at the gamma counter (and not only some of them) to
extract 212Pb-mAbs pharmacokinetics, and using DAR as a non-quantitative tool to assess
relative radiopharmaceutical distributions.
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Model-based versus specific
dosimetry in diagnostic context:
comparison of three dosimetric
approaches.
The importance of accurate radiopharmaceutical dosimetry in targeted radionuclide ther-
apy is nowadays generally acknowledged. In addition to being a legal requirement in
most countries, patient-specific clinical dosimetry enables TRT optimization. Several ap-
proaches have been proposed to better assess absorbed doses delivered during therapy,
and absorbed dose-effect correlations have been evidenced in a clinical context for sev-
eral applications (Buckley et al. 2009, Flux et al. 2010, Barone et al. 2005, Garin et
al. 2012, Ferrer et al. 2012, Strigari et al. 2014). On the other hand, diagnostic ra-
diotracer dosimetry is usually performed to assess the effective dose, in a context where
irradiation delivered to the patient is not inducing deterministic effects. According to
ICRP recommendations, absorbed doses should be determined for models rather than for
an actual patient. In this sense, the population-based approach accepts a certain degree
of approximation (the model never faithfully represents the actual patient), a price to pay
to be able to compare different tracers and diagnostic procedures. In ICRP 60 (ICRP
1991), ORNL models (Cristy and Eckerman 1987, Cristy 1980) were recommended: it is
generally accepted that the models and results presented in OLINDA/EXM (Stabin et
al. 2005) are equivalent to those recommended in the ICRP 60. Since ICRP 103 (ICRP
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2007), new computing models were introduced in ICRP 110 (ICRP 2009). On principle,
current reference dosimetry for diagnostic radiotracers should therefore be performed us-
ing the formalism introduced in ICRP 103 (separation of the absorbed dose computation
between male and female patients, use of new organ weighting factors) and models from
ICRP 110. However, neither absorbed fractions nor S Factors are currently available for
the ICRP 110 model. At this stage (and even though the situation is likely to evolve in the
future), the evaluation of the dosimetry for new radiopharmaceuticals should implement
ICRP 60 recommendations (through the use of OLINDA/EXM for example). Neverthe-
less, performing patient specific dosimetry with tools available from the TRT experience
is appealing since this may give an idea of the distance between population-based and
specific dosimetry.
The first aim of this study is to establish whether current dosimetric models are capable
to provide realistic absorbed dose estimations in Nuclear Medicine diagnostics with respect
to a more personalised approach to dosimetry. In the second instance, a more general goal
is to establish the impact of the calculation method on the patient’s absorbed dose and to
understand how much each step involved in the absorbed dose assessment chain can affect
the final result. In order to achieve these tasks, a comparison of the absorbed doses to
various organs computed with different dosimetric techniques, was performed for a cohort
of 6 patients administered with a novel PET radiotracer, Flutemetamol (18F) Injection.
Currently, there are three main approaches to the calculation of absorbed doses from in-
ternalized radiopharmaceuticals: phantom based dosimetry, Dose Voxel Kernel dosimetry
and Monte Carlo dosimetry.
Phantom based dosimetry is usually built on the widely acknowledged formalism pro-
posed by the Medical Internal Radiation Dose (MIRD) committee of the Society of Nuclear
Medicine (Bolch et al. 2009). At the organ scale, this formalism is based on the com-
putation of the S value (SrT←rS ), which is the mean absorbed dose to the target organ
(rT ), per unit of nuclear transition of the radionuclide of interest in the source region
(rS) considered (in Gy Bq
−1 s−1). The S value is then multiplied to the total number of
disintegrations in the source region (cumulated activity A˜ in Bq s) in order to obtain the
absorbed dose (Gy) to the target.
In the Dose Voxel Kernel (DVK) approach (Bolch et al. 1998, Dieudonne´ et al. 2010,
Amato et al. 2012, Fernandez et al. 2013) a 3D cumulated activity map is convolved with
pre-calculated absorbed dose kernels for the radionuclide of interest in order to obtain
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3D absorbed dose distributions. The DVKs are generated una tantum via Monte Carlo
simulation by considering a radionuclide voxel source and scoring the absorbed dose in a
voxellized homogeneous medium made of water or soft tissue.
In principle, the most accurate dosimetry can be obtained by performing a full MC
simulation considering patient-specific anatomy and radiopharmaceutical distribution on
the basis of morphological and functional 3D images.
In this work, the dosimetry obtained with a custom application based on the Gate MC
toolkit (Jan et al. 2011) was compared to those obtained with two commercially available
software applications based on the MIRD formalism at the organ level (OLINDA/EXM)
and on DVKs (STRATOS by Philips).
4.1 Materials and Methods
4.1.1 Patient data
In order to compare the three dosimetric approaches described, a pre-existing dataset
provided by GE Healthcare Ltd, was employed. In this paragraph, the data acquisition
and post-processing protocol implemented by GE is described.
Six healthy Caucasian patients have been enrolled in a Phase I study to assess the
toxicity of a novel PET radiotracer, Flutemetamol (18F) Injection, with the intent to
detect amyloid deposits in early Alzheimer disease. The study was approved by the local
Ethics Committee, and it was performed in accordance with the Declaration of Helsinki
and the International Conference of Harmonisation ICH-6 E6-Good Clinical Practice. All
subjects provided written informed consent before the study started. Flutemetamol (18F)
Injection is currently not approved in the EU.
The patients (5 male and 1 female, age range 51-74 y) were injected with an average
18F activity of 121.3 MBq (ranging from 95.8 MBq to 146.5 MBq). Patient demography,
including masses for the organs considered in this study, is summarized in table 4.1. ORNL
and ICRP 110 phantom data are reported for comparison. Each patient underwent from
8 to 10 whole body PET/CT scans in 3D acquisition mode with FORE (FOurier REbin-
ning) histogramming (Defrise et al. 1997), on a Biograph 16 by Siemens. PET images
were composed of 128 × 128 voxels of 3.81 × 3.81 mm2 size; slice thickness was 3.0 mm.
The first 8 PET scans were acquired dynamically starting immediately after the injection
(up to 1.3 hours a.i. on average), with the patients remaining on the bed in order to avoid
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image co-registration issues as much as possible. The remaining scans were acquired at
approximately 150 and 260 minutes post injection. PET images were iteratively recon-
structed using 8 subsets and correcting for random coincidences (delayed window method),
scatter (model based) and dead time. The attenuation correction was performed using the
CT image corresponding to each acquired PET series (one CT corresponding to the first
8 dynamic images, one for each of the 150 and 260 minutes scans). All CT images were
obtained with a 80 kVp tube potential and a variable pitch between 1 and 2. The tube
current (mAs) and the effective mAs were adjusted (according to body weight) in order
to give an estimated effective dose of 0.5 mSv. A trained physician manually segmented
eleven Regions Of Interest (ROI) (bladder, brain, gallbladder, heart, intestines, kidneys,
liver, lungs, spine, spleen, thyroid and injection arm) on the first PET scan of each patient.
Six organs displayed specific radiotracer uptake (bladder, gallbladder, intestines, kidneys
liver, and in minor part the brain), while the others can be considered as target organs.
Organ mass (g)
Age (y) Sex Weight (kg) Height (cm) Brain Kidneys Liver Lungs Spleen Thyroid
PA1 74 M 63.0 165 1835 493 1889 757 229 26
PA2 71 F 58.0 153 1812 430 1570 515 129 18
PA3 73 M 71.0 160 1829 531 1972 888 231 10
PA4 51 M 69.5 172 2219 502 1779 872 192 26
PA5 56 M 81.0 188 2185 473 2246 1029 405 13
PA6 63 M 80.0 174 1966 459 2244 1044 409 37
ORNL
- M 73.7 167 1420 299 1910 1000 183 21
- F 56.8 - 1200 275 1400 800 150 17
ICRP
- M 73.0 176 1450 310 1800 1208 150 20
- F 60.0 163 1300 275 1400 950 130 17
Table 4.1: Demographic data for the 6 patients of the cohort, the ORNL hermaphrodite phantom
and the ICRP 110 model. The masses of the 6 organs considered in this study, are also included.
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4.1.2 Absorbed dose calculations
The GE dataset was analyzed applying a model-based approach through the software
OLINDA/EXM (Stabin et al. 2005), a Dose Voxel Kernel (DVK) approach as implemented
in the commercial software STRATOS (version 3.0) by Philips, and performing a full MC
simulation for each patient on the basis of a custom application developed with the MC
toolkit Gate (version 6.2).
In order to highlight the differences associated to the absorbed dose calculation al-
gorithm, the same cumulated activities were used as input data for the three approaches.
Since in STRATOS it is not possible to import cumulated activity maps produced with
third party software, the use of maps as processed by STRATOS for the three dosimetric
approaches was unavoidable. This introduces an obvious bias, but it was felt to be the
most sensible way to evaluate differences induced by the absorbed dose computation al-
gorithm.
STRATOS
STRATOS has been recently validated on phantom and patient data, against OLINDA/EXM
and a home-made software based on DVKs, in the case of 177Lu dosimetry (Grassi et al.
2014). STRATOS can read repeated PET (or SPECT) scans of a single patient to determ-
ine patient specific pharmacokinetics at the voxel level. It also offers several co-registration
tools to align functional images before cumulated activity calculation. For this study, the
rigid co-registration tool was used to align the 9th and the 10th PET scans to the first CT.
No co-registration was necessary for the first 8 dynamically acquired PET scans. Cumu-
lated activity in each voxel was obtained by applying the parallelogram rule up to the last
imaging time point, and then extrapolating the curve to infinity assuming a simple phys-
ical decay, as this is the only procedure implemented in STRATOS 3.0. Before calculating
the cumulated activity maps, STRATOS resamples the PET images to a 4.42 × 4.42 ×
4.42 mm3 voxel size by default. The 3D cumulated activity maps were then convolved with
pre-calculated water DVKs for the radionuclide of interest, to obtain 3D absorbed dose
maps for each patient under the assumption of uniform propagating medium. In figure
4.1, a typical SRTATOS output is shown as an example. In the case of 18F, the DVK
provided by Philips were initially in a format of a 7 × 7 × 7 voxels matrix with a 4.42 mm
pitch, corresponding to a cube of 3.1 × 3.1 × 3.1 cm3. They were generated by Philips
from DPKs (Dose Point Kernels) computed at our institution using the MCNPX MC
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Figure 4.1: STRATOS output window.
code: the energy was scored in 50 microns concentric shells around a point source under
the assumption of a uniform water medium. The deposited energy relative uncertainties
in each shell were below 1%.
In addition, a supplementary absorbed dose calculation was performed for one patient
(PA6) using a DVK matrix of 15 × 15 × 15 voxels (on a 4.42 mm pitch), to study the
impact of the DVK matrix size on dosimetry. The 15 × 15 × 15 DVKs were computed in
house with Gate and then implemented in STRATOS. The simulation assumed uniform
water propagating medium and a 18F source placed in the central voxel. The maximum
statistical uncertainty was below 1.2 % for the farthest voxels from the source; a statistical
uncertainty of 0.7 % was obtained averaging over all voxels.
The relative percentage difference between the STRATOS DVKs and the 7 × 7 × 7
central voxels of the 15 × 15 × 15 DVKs generated with Gate was 0.6% on average (the
highest percentage difference of 8.8% was found for the farthest voxels) proving that the
two datasets are in good agreement. For both kernel sizes, the convolution of DVK and
cumulated activity took less than a minute for the whole body. The Regions Of Interest
(ROIs) provided with the GE dataset were adapted to STRATOS proprietary format
through a series of python scripts developed for the purpose. ROIs were subsequently
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imported in STRATOS and used to derive average absorbed doses in each organ and the
corresponding Dose Volume Histograms (DVH).
OLINDA/EXM
OLINDA/EXM allows mean absorbed doses computation to various organs on the basis
of predetermined S values calculated from the Cristy and Eckerman adult male phantom
(Cristy and Eckerman 1987) and the adult female phantom by Stabin et al. 1995 (see figure
1.4 in chapter 1). The user is required to input average cumulated activities normalised
for the injected activity (residence time) for each source organ; for this study, these values
were extracted from STRATOS. Differences in the segmentation of the ORNL model
and the GE patients required making some approximations when entering the cumulated
activities for some organs in OLINDA. In the case of the heart, that in OLINDA is split
between wall and content, it was not possible to achieve the same level of segmentation
from the PET images because of the limited spatial resolution of the imaging technique.
Hence, the cumulated activity in each component (wall and content) was calculated by
weighting the total cumulated activity in the whole organ with the mass of each component
according to ICRP 89 values (ICRP 2002). Similarly, the intestine region as segmented
in the GE dataset corresponded to the Lower Large Intestine (LLI), Small Intestine (SI),
Upper Large Intestine (ULI) and stomach content of the OLINDA/EXM phantom. Hence,
under the assumption of uniform activity distribution in this macro-region, the cumulated
activity in each sub-region was extrapolated by weighting with the ICRP 89 mass of
each component. For the other source organs, the average cumulated activity on the
corresponding GE region of interest was used. The segmented regions not matching any
OLINDA/EXM organ were included in the remainder of the body.
For the calculation of the absorbed dose, since the percentage differences of actual
patient organ masses (from CT images) and ORNL model ranged from -121% to +48%
(-23% on average), OLINDA organ masses were scaled to the actual patient organ masses
using the specific option in OLINDA. This option includes a linear term to scale the beta
absorbed dose in source = target configurations, and two non-linear terms to take into
account the effect of photon self- and cross-irradiation (Stabin et al. 2005). A calculation
using the original ORNL model masses was also performed, in order to establish the im-
pact of mass scaling on OLINDA dosimetry results.
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Gate
A custom application was developed to perform patient-specific internal dosimetry with
Gate. Gate is a simulation platform based on the Geant4 MC toolkit (Agostinelli et
al. 2003) and dedicated to the modelling of medical imaging devices and radiotherapy
experiments: Gate version 6.2 is based on Geant4.9.6 patch03. The use of Gate for
radiopharmaceutical dosimetry applications was validated by several authors (Mauxion et
al. 2013, Papadimitroulas et al. 2012, Maigne et al. 2011) however, this is the first time
it is used to implement whole body patient dosimetry. The application developed can
read a CT image of a patient in order to define the geometry for the MC simulation. Four
materials were implemented (soft tissue, lung, bone, air) according to Cristy and Eckerman
classification (Cristy and Eckerman 1987). STRATOS cumulated activity maps (voxel size
of 4.42 × 4.42 × 4.42 mm3) were used to define the spatial distribution of the radiotracer
in the simulation, and to obtain patient-specific 3D absorbed dose maps for each patient.
18F spectrum was defined according to (Eckerman and Endo 2008). With the generation
of 6 108 primary particles per patient, corresponding to 2 hours of simulation time when
using 100 cores the available cluster (20 MacPro multi-processor, Intel Xeon at 2.66 GHz
and with 16 Gb of RAM), a statistical uncertainty below 3.5% was achieved in each voxel
including voxels from non-source organs.
Moreover, in order to estimate, through an example, the impact of model geometry
on cross irradiation, the Gate application was used to calculate the Sthyroid←liver values
(where the liver is considered the source and the thyroid is the target) according to the
real anatomy of the 6 patients.
4.2 Results
4.2.1 Flutemetamol biodistribution
In table 4.2, residence times obtained for the 6 patients of the cohort are reported as they
were entered in the software OLINDA. They were obtained averaging at the organ level the
voxel cumulated activities calculated by STRATOS and adapting the GE segmentation to
the ORNL phantom geometry as specified in the materials and methods section. For PA2,
the gallbladder was not segmented in the original dataset and was hence not included in
the dosimetry. In figure 4.7a the time activity curves for the main source organs of PA6
are presented to provide a representative example of Flutemetamol biodistribution in vivo.
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In figure 4.2, the cumulated activity map obtained with STRATOS for the same patient
is also reported.
Figure 4.2: Coronal view of the cmulated acitivity map obtained with SRTRATOS for PA6.
4.2.2 Comparison of average absorbed doses
Because of the differences between the ORNL model and patient geometry, the comparison
will be restricted to the absorbed doses obtained for 6 organs (liver, brain, kidneys, lungs,
thyroid and spleen) whose geometry matched in the 2 datasets. Results obtained with Gate
were arbitrarily chosen as a term of comparison for the other approaches; the absorbed
doses obtained with OLINDA and STRATOS will be presented as ratios with respect to
Gate absorbed doses (Gate absorbed dose/OLINDA absorbed dose and Gate absorbed
dose/STRATOS absorbed dose).
In the vertical bar chart of figure 4.3a, the ratios between the Gate and OLINDA
absorbed doses are reported for the 6 patients and the 6 organs considered. These results
were obtained using the organ masses from OLINDA. The histogram does not show a clear
tendency, with some of the organs receiving a higher absorbed dose according to Gate and
others according to OLINDA. The average Gate/OLINDA ratio considering all organs is
127
Chapter 4. Model-based versus specific dosimetry in diagnostic context
Residence times (h)
Organs PA1 PA2 PA3 PA4 PA5 PA6
UB Cont 0.153 0.125 0.138 0.056 0.226 0.231
Brain 0.102 0.121 0.077 0.059 0.079 0.098
GB Cont 0.242 - 0.246 0.014 0.133 0.364
Heart Cont 0.010 0.012 0.010 0.006 0.003 0.013
Heart wall 0.007 0.008 0.007 0.004 0.002 0.009
LLI Cont 0.073 0.117 0.076 0.101 0.128 0.061
SI Cont 0.560 0.898 0.584 0.773 0.981 0.472
Stom Cont 0.132 0.212 0.138 0.183 0.232 0.112
ULI cont 0.118 0.189 0.123 0.163 0.207 0.100
Kidney 0.113 0.090 0.072 0.057 0.050 0.055
Liver 0.922 1.278 0.783 0.366 0.536 0.860
Lungs 0.121 0.119 0.128 0.067 0.112 0.123
Spleen 0.018 0.011 0.010 0.007 0.022 0.020
Thyroid 0.0008 0.0008 0.0003 0.0008 0.0003 0.0125
Rem Body 0.111 0.154 0.114 0.068 0.157 0.108
Table 4.2: Residence times for the source organs considered in this study as enetered in the
OLINDA/EXM software (UB= Urinary Bladder, GB = GallBladder, LLI = Lower Large Intestine,
SI = Small Intestine, ULI = Upper Large Intestine). For PA2, the GallBladder was not segmented
in the GE dataset.
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1.23 ± 0.59 σ, ranging from 0.81 to 4.1: data were averaged over the 6 patients and all
the organs.
When considering the actual organ masses in OLINDA calculation (figure 4.3b), ab-
sorbed doses calculated with Gate are higher than those calculated with OLINDA for all
organs, with the exception of the lungs in one patient. The spread of the ratios in the
cohort is also reduced; the average Gate/OLINDA ratio considering all organs is 1.38 ±
0.34 σ, ranging from 0.93 to 2.23. Even in this case data were averaged over the 6 patients
and all the organs. The higher Gate/OLINDA ratios obtained when performing mass cor-
rection suggests that dosimetric differences between OLINDA and Gate do not depend on
organ mass differences between the MIRD phantom and the actual patients. If considering
the ratios of OLINDA absorbed doses averaged over the 6 patients and calculated with
and without mass scaling (figure 4.4a), the mass scaling approach increases the differences
between the two datasets. This tendency is confirmed by the lack of correlation between
Gate/OLINDA ratios (without mass scaling for OLINDA) and the ratios between actual
and ORNL’s organ masses. In figure 4.4b, in fact, a twofold difference on mass may corres-
ponds to absorbed dose ratios close to one. In general, the differences between OLINDA
and Gate are rather pronounced only when the actual organ mass is smaller than MIRD’s.
The Gate/OLINDA ratios averaged over the 6 patients for each organ are summarized
in table 4.3. The discrepancies between OLINDA and Gate are particularly high for the
thyroid, with an average Gate/OLINDA ratio of 1.97 ± 0.83 σ for the 6 patients. This
disagreement is confirmed by Sthyroid←liver values calculated for the six patients of the
cohort. The average thyroid-liver distance (measured at the barycentre of the organs) for
the cohort was 23.6 cm ± 2.8 cm (σ), while in the ORNL model it is 56% larger (36.9
cm). The average ratio of the OLINDA and Gate S values for the 6 patients is 8.57 ±
2.72 σ (ranging from 5.12 to 11.75), confirming the significant impact of anatomy on the
absorbed dose for target organs located far from the source.
In figure 4.5, the ratios between Gate and STRATOS absorbed doses are presented
for the STRATOS calculation performed with the 7 × 7 × 7 voxels DVK matrix. The
Gate/STRATOS ratios averaged over the 6 patients and all the organs considered is 2.51
± 1.21 σ, ranging from 1.09 to 6.06. The larger discrepancy is found for the lungs: the
average ratio for the 6 subjects is 4.76 ± 2.13 σ. The Gate/STRATOS ratios averaged for
each organ over the patients from the cohort are summarized in table 4.3.
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Figure 4.3: Ratios between Gate and OLINDA absorbed doses for the 6 patients (from PA1 to
PA6 going from left to right) of the cohort and the 6 organs considered. In a), OLINDA dosimetry
is performed using the ORNL phantom organ masses, while in b) actual patient organ masses are
used
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Figure 4.4: Left: Ratios between Gate and OLINDA absorbed doses averaged over the 6 patients
with and without mass scaling in OLINDA calculation. Results are reported for the 6 organs
considered in this study. Right: Lack of correlation between Gate/OLINDA ratios (OLINDA
calculation performed without mass correction) and the ratios of actual and ORNL phantom organ
mass.
Figure 4.5: Ratios between Gate and STRATOS absorbed doses for the 6 patients (from PA1 to
PA6 going from left to right) of the cohort and the 6 organs considered.
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Gate/OLINDA Gate/OLINDA MS Gate/STRATOS
Mean St Dev Mean St Dev Mean St Dev
Brain 0.87 0.36 1.18 0.49 1.59 0.69
Kidneys 0.98 0.41 1.48 0.61 2.08 0.97
Liver 1.09 0.47 1.15 0.49 1.58 0.72
Lungs 1.23 0.52 1.08 0.45 4.76 2.13
Spleen 1.12 0.52 1.43 0.60 2.61 1.16
Thyroid 2.11 1.28 1.97 0.83 2.46 1.07
Mean 1.23 0.67 1.38 0.59 2.51 1.22
Table 4.3: Average absorbed dose ratios in the cohort and corresponding standard deviations for
the 6 organs considered in this study. In the second column the ratios between Gate and OLINDA
absorbed doses are obtained using ORNL organ masses, while in the fourth column OLINDA
absorbed doses are scaled to the actual target organ masses (MS = Mass Scaled). In the sixth
column the ratios between Gate and STRATOS absorbed doses is presented.
4.2.3 Impact of kernel size on DVK dosimetry
One patient (PA6) dataset was analysed using both the 7 × 7 × 7 voxels kernel matrix
provided by Philips and the generated in-house 15 × 15 × 15 matrix. The results are
compared in figure 4.6a in which Gate/STRATOS ratios are reported for the two kernel
sizes. The ratio between Gate and STRATOS absorbed doses goes from an average of 2.44
± 0.66 σ obtained with the 7 × 7 × 7 DVKs to an average of 1.38 ± 0.37 σ obtained with
the 15 × 15 × 15 kernel: both values are obtained averaging the absorbed doses over all
organs for the patient considered. The reduction of the differences between STRATOS and
Gate when using the largest DVK matrix is more obvious in the case of brain, kidneys and
liver, considered as source organs in the GE dataset. Conversely, for target organs such
as lungs, spleen and thyroid, the use of a 15 × 15 × 15 kernel is not sufficient to achieve
an absorbed dose ratio close to 1. This behaviour suggests that the high Gate/STRATOS
ratios obtained with the 7 × 7 × 7 kernel is related to the 511 keV gamma absorbed dose.
In order to confirm this hypothesis, and to exclude at the same time that STRA-
TOS and GATE differences come from tissue heterogeneity that are neglected in the
DVK approach, two additional simulations were performed for PA6 under the following
assumptions: a) patient body was only composed by soft tissue; b) patient body was
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Figure 4.6: Left: Comparison of Gate/STRATOS absorbed dose ratios obtained with the 7 ×
7 × 7 and the 15 × 15 × 15 kernel matrices for PA6. Right: Gate/STRATOS absorbed dose
comparison for a standard Gate simulation (left) and assuming an homogeneous medium (centre)
without photon generation (right). In all cases STRATOS absorbed doses were calculated with
the 7 × 7 × 7 kernel.
only composed by soft tissue and photons were not generated. Indeed, while it was not
feasible to take into account all photons deposited energy in STRATOS (the generation
of large size DVK for STRATOS was beyond the scope of this work), it was possible to
suppress their contribution in Gate for comparison purposes. Computed absorbed doses
were compared to those obtained from 7 × 7 × 7 DVKs and reported in the histogram of
figure 4.6b. The assumption of tissue homogeneity only impacts lungs absorbed dose (as
expected). However, when photon generation is suppressed in Gate, absorbed dose ratios
are much closer to 1. The average ratio between Gate and STRATOS is, in this case,
0.84 for the 6 organs considered; the ratio is obviously lower than 1, since in the Gate
simulation no photons were generated, while in STRATOS a small fraction of the photon
energy is deposited anyway.
4.2.4 Voxel dosimetry
While OLINDA results are limited to average organ absorbed doses, STRATOS and Gate
dosimetry offer the additional possibility of obtaining absorbed dose distributions. In figure
4.7 the Dose Volume Histograms (DVHs) obtained for PA6 with Gate (b) and STRATOS
implementing the 7 × 7 × 7 (c) and the 15 × 15 × 15 DVKs (d) are reported. The
shift towards low absorbed doses in STRATOS 7 × 7 × 7 DVHs reflects the STRATOS
underestimation of the average absorbed dose as reported in the previous section. DVHs
obtained with the 15 × 15 × 15 kernels are in closer agreement to those obtained with
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Gate; in this case, the liver absorbed dose is slightly higher for the STRATOS calculation,
in accordance with the values reported in the histogram of figure 4.6a.
Figure 4.7: Time activity curves (a) for a selection of source organs in PA6, as obtained from
STRATOS software. Dose volume histograms for PA6 and the 6 organs considered in this study
calculated with Gate (b), STRATOS using the 7 × 7 × 7DVKs (c) and the 15 × 15 × 15 DVKs
(d)
4.3 Critical aspects
One of the most critical feature of the GE dataset consisted in the approximate nature
of the provided organ contours. Organ segmentation was manually performed by GE col-
laborators on the coronal projections of the first acquired PET scan. This approach is
in many ways questionable. First, PET spatial resolution is about ten times worse than
CT spatial resolution. Therefore, organ delineation is usually carried out on CT images
(or morphological images in general) when those are available. In addition, the spatial
sampling of tomographic images is typically larger along patient axis than in the trans-
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verse plane. As a result, a coronal segmentation is by nature, far from being optimal. A
direct consequence of the reduced spatial resolution, is that PET images are more prone
to partial volume effect, which makes a precise delineation of organ boundaries more dif-
ficult. Besides, the determination “by eye”of organ edges on a PET image is known to
depend on the contrast parameters selected in the visualisation software used. In general,
when the average absorbed dose to an organ is demanded, the impact of inadequate organ
segmentation is minimal: few voxels may be erroneously neglected or included in the Re-
gion Of Interest (ROI), only slightly shifting the average absorbed dose value. Conversely,
when performing voxel dosimetry, results could be biased, and therefore they should be
interpreted with care.
GE organ segmentation was particularly poor in the case of brain and liver. In figure
4.8 the worst case segmentation of the brain (occurring for PA1) is shown, superposed,
from left to right, to the patient CT scan, his cumulated activity map, and the absorbed
dose distributions obtained from Gate and STRATOS. In all cases the skull is clearly
included in the ROI, resulting in an underestimation of the average absorbed dose in the
brain for the two dosimetric techniques. For both STRATOS and Gate dosimetry in fact,
the extra voxels lie in a region of lower cumulated activity with respect to actual brain,
and therefore they contribute considerably less to the locally absorbed dose. In addition,
Gate absorbed dose is even further underestimated, since it is scored in the actual tissue
(bone in this case), while STRATOS considers a uniform propagating medium made by
soft tissue. If the only difference between the two dosimetric methods was in the way
they handle tissue heterogeneity, one would expect lower average absorbed dose for Gate.
However, the comparison performed in this work demonstrated that STRATOS absorbed
doses are systematically lower than Gate’s, suggesting that organ segmentation erros only
minimally impact on the dosimetric results.
A more accurate brain segmentation performed by applying a threshold on PA1 CT
image (region growing technique) revealed that approximately 10388 additional voxels (on
a total of 41657) were included in the ROI from GE, when applying the segmentation to
the absorbed dose maps (voxels size of 4.42 × 4.42 × 4.42 mm3). In terms of differen-
tial absorbed dose volume histograms (see picture 4.9), this error could be approximately
corrected by applying a cut to the 10388 lowest entries in both Gate and STRATOS his-
tograms. The generation of dDVHs (differential DVHs) with the custom ROI evidenced
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Figure 4.8: From left to right, an example of GE brain segmentation superposed to the patient
CT image, to the cumulated activity map obtained from STRATOS, and to the absorbed dose maps
calculated by direct Monte Carlo simulation and with STRATOS. Absorbed doses are reported in
arbitrary scales.
a shift on the average absorbed dose: from the 1.60 10−2 mGy/MBq obtained with GE
ROI to 1.83 10−2 mGy/MBq in the case of Gate dosimetry (14%); and from 0.93 10−2
mGy/MBq to 1.13 10−2 mGy/MBq in the case of STRATOS dosimetry (21%). Indeed,
with a more accurate segmentation, the Gate/STRATOS ratio for the Brain in PA1 would
have been about 5% lower (from 1.71 to 1.62). It should also be noted that in figure 4.9,
Gate and STRATOS dDVHs are presented with a very different bin size. This is a direct
consequence of the discrete absorbed dose levels generated by STRATOS: this discretisa-
tion is clearly visible form the absorbed dose maps (i.e. figure 4.8. first from the right). A
possible explanation for this issue is a bad internal handling of data types by STRATOS,
that determines a loss of resolution.
Another example of a possibly problematic segmentation in the GE dataset, is the
liver. In figure 4.10, the worst case liver segmentation (occurring for PA4) is shown
superposed to PA4 CT image and to the corresponding cumulated activity map (first and
second images from left respectively). On the right, absorbed doses obtained with Gate
and STRATOS are also presented. In this case, the liver ROI included extra voxels from
the lung, resulting in an overestimation of the average liver absorbed dose calculated with
Gate. In the direct MC simulation, in fact, the absorbed dose in the extra voxels is scored
in a lower density material (lung tissue) instead of soft tissue. As a result, the absorbed
dose is artificially high, even for voxels with a low cumulated activity.
This effect directly depends on patient breathing and movement during acquisition
and it is typically encountered in the calculation of voxel absorbed dose via direct MC
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Figure 4.9: Top: brain dDVHs obtained with Gate implementing the GE ROI (left) and a custom
ROI (right). Bottom: brain dDVHs obtained with STRATOS implementing the GE ROI (left)
and a custom ROI (right).
simulation. A whole body CT scan, in fact, only last few second, and generally reflects
patient anatomy corresponding to a single respiratory cycle (at least for what concerns
the thorax). The PET acquisition, on the other hand, is considerably longer, and it
thus registers internalised radioactivity through many respiratory cycles. Patient-specific
dosimetry at liver/lung interface is particularly sensible to breathing artefacts: in the
absence of a gated PET acquisition, it is impossible to avoid the spill out of liver activity
in the lung. In the Gate absorbed dose distribution (figure 4.10), this effect is clearly
visible at liver/lung interface. Nevertheless, an adequate organ segmentation could avoid
including the artefacted voxels in the determination of the average organ absorbed dose
and the organ dDVH. In this specific case, the dDVH obtained with Gate presents an
artificial tail at high absorbed doses (figure 4.11) that is not present in STRATOS data.
Cutting of the contribution of these voxels, the liver average absorbed is shifted from
7.00 10−2 mGy/MBq to 6.94 10−2 mGy/MBq (0.8%).
In contrast, STRATOS absorbed dose is slightly lowered by patient breathing and
movement. Since the spilled out liver cumulated activity is scored in soft tissue, the
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Figure 4.10: From left to right, an example of GE liver segmentation superposed to the patient
CT image and to the cumulated activity map obtained from STRATOS. The absorbed dose maps
calculated by direct Monte Carlo simulation and with STRATOS are also shown for the same
patient. Absorbed doses are reported in arbitrary scales.
absorbed dose in the extra voxels is very low (because the cumulated activity is also very
low). As a results, the additional voxels contribute increasing histogram counts in the
lower absorbed dose region ( figure 4.11b).
4.4 Discussion
Previous works demonstrated that OLINDA and the DVK approach can produce reliable
absorbed doses in specific therapeutic scenarios (Grassi et al. 2014, Divoli et al. 2009,
Dieudonne´ et al. 2013). Some of them focus on the calculation of the absorbed dose to lim-
ited regions of the body; in this case, even if a gamma emitter is taken into consideration,
the calculation of the absorbed dose is limited to source organs (self-absorbed dose) or to
organs in their proximity. Other works consider pure β-emitters such as 90Y; in this case
only source organs receive a measurable absorbed dose because of β-particles short range.
Hence, in these studies, the effect of photon cross-irradiation for distant organs, relevant
in a diagnostic scenario, is not investigated. Consequently, in both contexts, model- and
the DVK-based approaches are capable to provide sound dosimetric results.
A completely different conclusion should be drawn in the case of photon absorbed
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Figure 4.11: Top: liver dDVH obtained with STRATOS. Bottom: liver dDVHs obtained with
Gate before (left) and after (right) cutting of the voxel contribution at lung/liver interface.
doses in non-source organs. This work demonstrates that the choice of the absorbed dose
calculation algorithm is critical for non-source organs when gamma emitters are considered;
average absorbed doses to target organs can be underestimated by up to a factor 3 (i.e
the Gate/STRATOS ratios for the spleen) according to the algorithm.
The comparison between OLINDA and Gate dosimetry shows average Gate/OLINDA
absorbed dose ratios of 1.23 ± 0.67 σ and 1.38 ± 0.59 σ when the model and the actual
patient masses are considered respectively. The mass scaling procedure, instead, shifts
OLINDA absorbed doses by 12% on average, while reducing the standard deviation of the
average absorbed dose ratios within the cohort.
The mass scaled data also exhibit a clear trend, with OLINDA absorbed doses lower
than Gate’s for all organs. This trend is somehow expected considering the geometry of
the ORNL model whose inter-organ distances are in general overestimated (Lamart et
al. 2011, Zankl et al. 2003). The use of an approximate geometry for energy scoring
during the MC simulation may have a major impact on photon ballistics. The number
of photons generated in a source organ and reaching a certain target, strictly depends
on the relative organ position. For large source-to-target distances, the relative number
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of photons reaching the target decreases because of the reduced solid angle. This is
confirmed, for example, by the fact that on average, the OLINDA Sthyroid←liver value is
underestimated by 86% for male patients, while the liver–thyroid distance is 56% lower in
the actual patients than in the ORNL model. As a result, thyroid absorbed dose calculated
with Gate is on average two times that computed by OLINDA. It must be pointed out,
however, that a factor 2 in absorbed dose only translates in a factor 0.05 × 2 (according
to ICRP 60 tissue weighting factor) or 0.04 x × (according to ICRP 103) when calculating
the effective dose.
Most of the issues arising from an approximate anatomical representation of the patient
could be overcome in the future by adopting new models as a standard. With this aim, the
ICRP has proposed two voxel-based computational models (adult male and female) whose
anatomy is representative of the average man and woman (ICRP 2009, ICRP 2002). At
this stage, however, pre-calculated absorbed dose factors for the ICRP 110 models are not
available, and the implementation of ICRP recommendations would require an extensive
preliminary work for the MC generation of S values for the radionuclides of interest. In
order to overcome this issue, in our institution we are planning to compute absorbed doses
for different radionuclides according to ICRP 103, implementing direct radiation transport
on the ICRP 110 model.
Different comments should be made on DVK dosimetry. The comparison between
STRATOS and Gate resulted in a mean Gate/STRATOS absorbed dose ratio of 2.51
± 1.22 σ. Clearly, the absorbed dose to the lungs should be considered apart, since in
standard DVK convolution (and STRATOS) specific tissue densities are not accounted for.
However, the Gate/ STRATOS ratio remains high (2.06) even if lungs are not included
in the sample. For other organs, the STRATOS assumption of unit density propagation
medium is expected to produce discrepancies of less than 20% (Divoli et al. 2009) on the
absorbed dose. On the other hand, increasing the DVK matrix has a major impact on
the dosimetry in a diagnostic scenario, as was demonstrated for a patient of the cohort.
When the DVK matrix size is doubled, the average Gate/STRATOS ratio for the 6 organs
considered, goes from 2.44 ± 0.66 σ obtained with the 7 × 7 × 7 matrix to 1.38 ± 0.37 σ,
suggesting that the lower absorbed doses found in STRATOS most likely depend on the
limited kernel matrix size implemented. Also, the improvement in the results is higher
for brain, kidneys and liver (source organs in the GE dataset) whose absorbed dose less
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depends on cross irradiation.
Grassi et al. (2014) found an agreement within few percents between 177Lu absorbed
doses calculated for physical-phantoms with STRATOS and a home-made DVK software
(VoxelMed). Their results are not in disagreement with ours as 177Lu has a significantly
lower gamma contribution (∼16%) and energies (112.9 and 208.4 keV) with respect to
18F (∼80% of gamma emissions). Moreover, the DVKs implemented in VoxelMed have
an overall size comparable to those implemented in Stratos (between 2.4 × 2.4 × 2.4 cm3
and 4.3 × 4.3 × 4.3 cm3 according to the voxel sizes used in their study).
The use of small kernel matrix is not an inherent limitation of STRATOS and the
DVK approach. DVK matrices modelling energy deposition in larger volumes could be
generated to appropriately score photon energy in the whole body. Nevertheless, the
implementation of larger DVKs matrices is recommendable in diagnostic dosimetry, es-
pecially for radioisotopes having a higher fraction of gamma emissions. In the lack of an
appropriate kernel size, the higher the gamma contribution (as in 18F and 131I), the more
would the current DVK underestimate absorbed doses with respect to a full MC method.
In analogy, radionuclides presenting higher gamma energies (as 131I, 18F and 124I) result in
a higher photon absorbed dose, due to the increased energy of the Compton recoil electron,
and should be treated with DVKs of relevant size.
On the other hand, differences between Gate and OLINDA/EXM are mostly due to
geometry and ballistics. Since OLINDA/EXM already considers photon contribution to
the absorbed dose, these differences are expected to increase for radionuclides having
higher gamma contributions.
In this work, the dosimetry performed with Gate is arbitrarily considered as the refer-
ence as it tries to explicitly consider morphological changes within patients and it imple-
ments detailed radiation transport in heterogeneous media (Marcatili et al. 2013, Hobbs et
al. 2009, Dewaraja et al. 2010). In addition, Gate has already been validated for internal
dosimetry (Mauxion et al. 2013, Papadimitroulas et al. 2012, Maigne et al. 2011) against
data from the literature, and other MC codes. However, even the full MC approach is not
free from limitations. As long as the input data (the 3D cumulated activity map in this
case) used for the MC simulation are accurate, the user will obtain reliable results. The
main issue arises when input data are not adequate, thereby introducing errors that are
propagated in the MC calculation.
In this study the calculation of cumulated activity was not considered, as any error
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introduced at this stage would impact the three techniques investigated approximately
at the same level. However, it should be mentioned that the calculation of cumulated
activity at the voxel level might indeed be critical, since it strictly depends on the accur-
acy of functional images co-registration. On the contrary, the assessment of an average
cumulated activity in each organ is less prone to error, but this comes at the price of neg-
lecting activity heterogeneities and therefore absorbed dose gradients. In this study, the
co-registration errors have been minimized by acquiring the first 8 PET scans dynamically,
and then accurately repositioning the patients for the last 2 scans.
Another major element to consider, concerns the time required to perform the dosimet-
ric calculation with each approach. A great advantage of DVK and model based methods
is that absorbed doses to various organ can be obtained very quickly (few seconds for
OLINDA and less than 1 minute for STRATOS) while a whole body MC simulation may
require many hours without adequate computer resources. Depending on the application
and on the radionuclide, the user should evaluate which dosimetric approach is the most
appropriate in terms of benefits and effort. For example, when photon contribution to the
absorbed dose is of importance, MC calculation, even if longer, may be warranted.
All these comments generally stand for the intrinsic comparison of the computational
approaches here considered. The availability of a complete dataset as the GE one, provided
the opportunity to assess the inherent differences between these three dosimetric methods
in the case of a radionuclide including both short and long range emissions. The conclu-
sions drawn are therefore pertinent to other isotopes and applications (i.e. therapy with
131I). However, in the specific case of diagnostic dosimetry, they must be further contex-
tualised. Since the aim of diagnostic dosimety is to obtain an order of magnitude of the
effective dose to infer population-based information and ensure safe level of patient irra-
diation, accuracy is not its main objective. Using a model to perform dosimetry is in this
case accepted as it allows ensuring traceability of the dosimetric procedure. Even when
approximate phantom geometry produces imprecise absorbed dose estimations, the im-
pact on the effective dose may be significantly reduced depending on the tissue weighting
factor for the organ considered. Nevertheless, the absorbed dose computation should in
principle be performed with the best available tools. In the lack of absorbed dose factors
for more accurate digital models (i.e. ICRP 110), the possibility of performing patient
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specific absorbed dose computations for the patient enrolled in the trial was explored;
the dosimetric results obtained could in principle be averaged to infer population-based
effective doses.
4.5 Conclusions
The comparison of full MC dosimetry to those obtained using two commercially available
software applications has illustrated how the choice of the absorbed dose calculation al-
gorithm may introduce a bias when gamma radiations are of importance. Considering
the full MC dosimetry as a term of comparison, it was observed that absorbed doses ob-
tained with OLINDA could be underestimated up to a factor 2, while those obtained with
STRATOS could be even smaller.
This study suggests that, when cross-organ irradiation is predominant, an exhaustive
approach as MC may provide more reliable dosimetric results.
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Chapter 5
Multi-resolution hybrid models for
targeted radionuclide therapy
dosimetry
5.1 Introduction
In recent years several models were developed for radiopharmaceutical dosimetry in clinical
and preclinical settings. Currently, computational phantoms are available in three different
formats: stylized, voxel and hybrid models. For a more detailed review on digital models
please refer to chapter 1 and to Xu and Eckerman 2010.
Stylized phantoms (Cristy 1980, Snyder et al. 1975) are based on 3D surface mathem-
atical equations and, despite they are widely employed for reference dosimetry, they offer
limited realism.
Voxel based phantoms (Kramer et al. 2006, ICRP 2009, Zubal et al. 1994) were
developed to reach a level of realism that could not be achieved by mathematical models.
They are generally based on segmented tomographic images for which each voxel is tagged
in order to univocally identify an organ, and thus they reflect the spatial sampling of the
original image. Even though CT or MRI in-plane resolutions may be sufficient to show
detailed organ boundaries, the sampling along the z axis for these techniques is typically
quite coarse (few millimetres) resulting in the appearance of stair-stepped artifacts on the
organ contours that compromise the realism of the model.
Finally, “hybrid”phantoms (Segars et al. 2010b, Lee et al. 2010 , Xu et al. 2007,
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Na et al. 2010, Cassola et al. 2010), based on polygonal mesh geometry and/or NURBS
(Non Uniform Rational Basis-Splines) representation, allow the highest level of realism as
well as a further degree of versatility by offering the possibility to finely tune each model
according to various parameters. Unfortunately, the direct implementation of such models
in a Monte Carlo (MC) code is not currently envisaged since the time necessary to navigate
the many facets of a polygonal mesh linearly scales with their number. For example, in
the case of very detailed geometries typical of human phantoms, it has been demonstrated
that the simulation of a tessellated solid in Geant4 can be up to two order of magnitudes
slower than the simulation of the equivalent Constructed Solid Geometry (CSG) (Kim et
al. 2011, Poole et al. 2012). Even if specific classes have been recently developed to allow
faster simulation in polygonal mesh geometries (Han et al. 2013), these techniques may
not be practical when the absorbed dose distribution inside the mesh organ is requested.
In this case, in fact, the definition of a fine scoring grid reproducing as precisely as possible
the polygonal mesh contours is required if the model realism is not to be lost. However,
the implementation of a very thin scoring grid could in turn affect significantly simulation
performances. Therefore, even hybrid models usually require the generation of a voxel
version for MC simulation of radiation transport. Nevertheless, their implementation in
MC simulations imposes strict constraints in terms of geometry definition. Since absorbed
dose simulation time is strictly related to spatial sampling, a compromise should be made
between model realism and simulation speed. In particular, the total number of voxels
employed in a MC model is limited by the amount of memory needed to store the geometry
before simulation. This trade-off between accuracy and calculation feasibility, leads on one
side, in an overestimation of the size of small radiosensitive structures such as the skin
or hollow organs’ walls and, on the other, to unnecessarily detailed voxelization of large,
homogeneous structures.
While reference models are valuable for defining idealised exposures conditions and
for developing dose coefficients for radiological protection purposes, a completely differ-
ent approach to radiopharmaceutical MC dosimetry in a therapeutic context, consists in
directly employing 3D anatomical patient images for the computation of the absorbed
dose (Marcatili et al. 2013, Dewaraja et al. 2010, Hobbs et al. 2009, Chiavassa et al.
2006). While this strategy offers the clear advantage of being more patient-specific than
using models, it is prone to the same lack of anatomical realism of voxel phantoms when
structures of small size need to be considered.
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Since the simulation of very highly-sampled whole body absorbed dose distributions
does not seem feasible using currently available computational resources, an alternative
approach to MC dosimetry is proposed. This approach is built on the observation that,
in most clinical applications, the degree of spatial accuracy required depends on the ana-
tomical region. Typically, in radiotherapy applications, only the absorbed dose to a few
organs (organs at risk) is of clinical interest. While in external beam radiotherapy, all
these organs are grouped in the anatomical volume intersecting the collimated radiation
beam, in Targeted Radionuclide Therapy (TRT) they are distributed all over patient’s
body. Therefore, for the MC computation of radiopharmaceutical absorbed dose, the
whole patient body must be taken into consideration, meaning that a huge number of
elements are needed to describe the simulation geometry.
The aim of this work is to develop flexible computational tools to implement multi-
resolution models for Geant4 in order to better characterise energy deposition in selected
anatomical structures, while preserving reasonable computation times. Some efforts have
already been made by other groups (Kumada et al. 2011, Taschereau et al. 2008, Hubert-
Tremblay et al. 2006) to reduce the trade-off between spatial accuracy and calculation
speed using multi-resolution approaches. Here, the use of different voxel sizes to describe
different anatomical areas is proposed. A fine voxelization can be used to describe small
structures, organ walls and to achieve realistic organ’s shape, while a coarser voxellization
can be employed to describe organs whose anatomical structure is not of interest for the
selected application. In this work, the tools developed are presented and validated through
the implementation of a proof of principle example involving a limited number of organs.
The ultimate goal is to apply the same strategy to whole body absorbed dose simulations
merging 3D patient data and accurate organ models obtained with the proposed approach.
5.2 Material and Methods
The realisation of the multi-scale hybrid Monte Carlo model involved two main develop-
ment stages: the construction of a multi-resolution digital model using the Visualization
ToolKit (VTK) (Schroeder et al. 2006) and the effective implementation of multi-scale
geometries in Geant4 (Agostinelli et al. 2003). The working principles behind these two
pieces of software are described in details in the following sections and through a practical
example.
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5.2.1 Multi-scale digital model
The Python module of the Visualization ToolKit (VTK) was used to develop a pipeline for
the construction of multi-resolution geometries on the basis of CT images or reference voxel
models. The pipeline allows to extrapolate a polygonal mesh representation of each organ
and to choose different sampling to build the corresponding voxel model. The software has
been conceived with a modular structure allowing the user to select the optimal sequence
of operations to built a realistic organ model for a given clinical application.
The first mandatory step of this process consists in the creation of a polygonal mesh
starting from a segmented 3D medical image or a digital phantom (Image2Mesh module).
Initially, the standard “discrete marching cubes”algorithm (Lorensen and Cline 1987) is
applied to the 3D image matrix, then the resulting polygonal mesh is smoothed (Smoothing
module) in order to minimise the stair-step artefacts commonly associated to the low
spatial sampling of the original image. The effect of the smoothing process is to “relax”the
mesh, making the cells better shaped and the vertices more evenly distributed.
The optional VolumeDeformation module allows to adjust the polygonal mesh volume
to match the user-established value. Volume deformation is performed through uniform
erosion or dilation along the mesh normals; each deformation operation is an iterative
process in which acceptance criteria of relative error (typically 0.5%) in the adjusted
organ volume is used. The main function of this module is to reproduce the organ size of
a specific patient or to generate organ models complying to standards (i.e. ICRP 2002).
In any case it can also be used to compensate for the volume shrinking naturally induced
by the smoothing process.
When multiple organs are considered, the MeshIntersection module permits to handle
mesh organ intersections applying boolean filters (Quammen et al. 2011) and selecting
which organ the intersecting voxels must be assigned to.
The OrganWall module allows the user to build walls in the presence of hollow organs.
Starting from the whole organ (wall plus internal part) polygonal mesh, the wall is created
performing a uniform erosion along the mesh normals: the stopping criterion is given by
the wall thickness or volume selected by the user. Two separate polygonal meshes, the
organ wall and the inner organ, are thus generated.
The second mandatory module (Voxelization module) generates a High Resolution
(HR) voxel model starting from the organ polygonal mesh previously processed according
to user requirements. At this stage the user may opt for a standard voxelization imple-
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menting a single voxel size, or for a multi-scale voxelization involving voxels of two different
sizes. In the second case, voxels dimensions can be chosen arbitrarily but they should be
one the multiple of the other. This multi-scale approach allows maintaining a realistic
organ shape even after the voxelization process, while keeping the total number of voxels
necessary to describe the organ low. Typically, each organ will be modelled by definying
two geometrical elements. First, as many “big voxels”as possible are used to reproduce
the internal part of the organ; then, “small voxels”are used to fill the organ volume up to
its surface, thereby maintaining a realistic shape. The model built is then supposedly free
from the typical artefacts introduced by the poor spatial sampling of the original images,
and can be used to achieve a more accurate dosimetry.
In the case where multiple organs are considered, intersecting voxels are assigned to
a single organ using a dedicated module (VoxelIntersection module), before generating a
Geant4 input file for each organ. In the Geant4 input file, the voxel sizes implemented
and the list of voxel coordinates are specified.
Most of the modules here described are fully automated with the exception of theMesh-
and Voxel-Intersection modules that require the user feedback for an optimal result.
5.2.2 Multi-scale geometry in Geant4
The use of the Monte Carlo technique in radiotherapy applications is usually limited by
the lack of adequate computational resources. When dealing with the MC simulation of
anatomical data extracted from medical images or digital models, two main aspects should
be considered in order to make the simulation feasible: memory consumption to store the
geometry and simulation time.
The most general way of representing voxel geometries in Geant4 is through the defin-
ition of an independent volume (through the G4Box class) to model each voxel, and to
assign this volume a specific position and material composition. Since the definition of a
single volume in Geant4 may require almost 200 bytes (Hubert-Tremblay et al. 2006), it is
easy to understand why the use of this approach in geometries involving a huge number of
voxels (typically ∼ 107 in medical images), would not be feasible in terms of memory con-
sumption. On the other hand, timing performances in this scenario are quite satisfactory,
since the application only needs a simple access to the vector storing volumes information
(position, size and material) in order to establish the particle position during tracking.
In order to improve the navigation speed in constructed solid geometries, Geant4 uses
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by default an optimisation technique called SmartVoxels (Schu¨mann et al. 2012). The
simulation space is sliced along one or three axes creating virtual voxels (smart voxels)
containing only a limited number of volumes each. Smart voxels are then used at sim-
ulation time to efficiently locate the next hit voxel through a hierarchical search on the
virtual grid. The granularity of the voxelization is defined by the “smartless”parameter:
the smaller the value, the coarser the optimisation. The use of SmartVoxels requires the
allocation of additional memory to store the geometry; the amount of memory needed
increases as the virtual grid becomes thinner.
Because of the large use of the MC technique in medical imaging and dosimetry ap-
plications, many MC toolkits offer specific tools for the implementation of voxelized geo-
metries. In order to improve navigation speed and memory usage, Geant4 supports the
use of parametrized volumes: with this feature only a volume is created in memory but,
at simulation time, it appears to have different positions and material compositions. For
a more detailed description of Geant4 parametrization options please refer to Schu¨mann
et al. 2012.
G4PhantomParametrization is one of the two parametrizations recommended by Geant4
for use in tightly packed 3D voxel geometries completely filling a parallelepiped space. The
primary advantage of this class is that it has its own navigator (G4RegularNavigation)
which allows faster voxel navigation using knowledge of a voxel’s position within the 3D
matrix in order to predict the next voxel to be hit. The voxel search is done through the
ComputeMaterial method invoked at each step. The option of skipping voxel frontiers
between equal materials can be selected to further reduce simulation time (Arce et al.
2008). This approach is expected to dramatically improve memory usage since it requires
the placement of a single voxel volume instead of the several millions needed to describe
a typical CT image. In any case, simulation time is strictly related to the the spatial
sampling chosen for the geometry. On one hand, in fact, navigation time increases with
the number of voxels, on the other, smaller voxels require the simulation of more primary
events in order to achieve adequate statistical uncertainties at the voxel level. There-
fore, in specific scenarios, G4PhantomParametrisation may not be the most performant
approach.
Since a specific technique for handling multi-resolution voxel geometries in Geant4 does
not yet exist, a dedicated approach based on the use of the G4Box and G4AssemblyVolume
classes is proposed. It is based on the hypothesis that the reduced number of voxels needed
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to describe the multi-resolution organ model may in part overcome memory issues arising
from the implementation of independent voxel volumes. This hypothesis confirmed, the use
of the G4Box class would intrinsically imply faster particle tracking performances with re-
spect to phantom parametrization approach. Indeed, while in G4PhantomParametrization
a specific method should be called at each step to locate the particle, with standard volume
placements, the application only needs to access the vector storing volumes information.
Reading the Geant4 input files generated for each organ by the VTK application, a
template voxel volume (LogicalVolume) of the right size and material composition was
defined in the form of a G4Box. Then, as many logical volumes as indicated in the
input file are added to a G4AssemblyVolume allowing for all the voxels to be positioned
as a single entity (including translation, rotation and reflection operations) according to
the coordinates listed in the file. A different assembly volume is generated for each organ
included in the simulation. In terms of memory consumption, for each organ the definition
of one G4Box volume (48 byte), one material composition (92 byte) and many physical
volumes (56 bytes each) placed in different positions is required. Reasonable memory usage
is expected based on the fact that i) the multi-scale organ model intrinsically uses less
voxels than the corresponding high resolution parametrized volume, and that ii) with this
approach only voxels actually belonging to the organ are defined, while in parametrized
volumes, surrounding voxels should be considered as well. In order to reduce simulation
time, voxel navigation is optimised activating the SmartVoxel option (typically using the
default smartless value of 2). To further improve simulation performances, a specific
G4Region is defined to bundle together voxels of the same dimensions, allowing for optimal
definition of production cuts for particle tracking.
5.2.3 Multi-scale voxel sources in Geant4
The simulation of multiple voxels sources confined inside a specific organ is a typical
scenario in radiopharmaceutical dosimetry applications. Generally the source distribution
is either uniform within the organ volume, or derived from functional images (PET or
SPECT) whose sampling pitch varies between few millimetres to about one centimetre.
In both cases, the definition of a voxel source is necessary to reproduce the contours of
the voxelized organ and hence, the same sampling as for the geometry should be used.
While for low sampling models the definition of a voxel source does not present particular
issues, with high resolution models memory and time performances problems may be
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encountered due to the huge number of voxel sources implemented. For this reason, the
multi-resolution approach is applied to the source definition as well. Therefore, when
a radioactive distribution is associated to an organ modelled using two voxel sizes, two
independent sources are generated, each including only voxels of a single size. Two separate
simulations are run in this case, and the results are merged a posteriori, weighting for the
relative contribution of each source in terms of total activity.
5.2.4 Proof of principle example
Model generation. In this work the potential advantages of implementing multi-resolution
MC simulations is investigated through the use of a practical example. The digital female
phantom provided within the ICRP 110 report (ICRP 2009) was chosen for convenience as
a starting dataset, since it is already segmented and organ masses comply with reference
values listed in the ICRP 89 report (ICRP 2002). Specifically the female model was
considered because it presents a finer spatial sampling (voxels of 1.775 x 1.775 x 4.84
mm3) than the male model (see figure 1.5 in chapter 1). The choice of modelling the
bladder (wall and interior) and the uterus was made to test the different features of the
VTK and Geant4 applications developed. In this example, the bladder wall represents
the clinically interesting anatomical structure for which an accurate dosimetry is required.
With an average thickness of 3.2 mm (Hakenberg et al. 2000), the bladder wall is typically
very badly represented in digital models and cannot be identified in patient CT images. In
the ICRP female model, the spatial sampling along the z axis is so coarse that the bladder
wall is not even a closed structure (figure 5.2a. The bladder wall, in the coronal plane, is
indicated in light blue). However, uniformly improving the spatial sampling of the entire
bladder would produce a very detailed description of the inner bladder (in pink) which
has no clinical interest. For these reasons, the bladder was considered a relevant organ
to evaluate the multi-scale approach developed. In addition, being the bladder a hollow
organ its allows validating validate the OrganWall module developed in VTK. The uterus
(in red) has been added to the model in order to test the Mesh- and the Voxel-Intersection
modules.
Using the software tools described in section 5.2.1, a realistic polygonal mesh model
was generated for the three structures selected as illustrated in figure 5.1. Since in the
ICRP 110 report only the mass/volumes of the organs are indicated and bladder wall
thickness is not specified, first, a polygonal mesh describing the whole bladder was gen-
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Figure 5.1: VTK pipeline for the generation of bladder and uterus polygonal meshes. From
left to right and from top to bottom: coronal projection of ICRP 110 model with and without
bladder wall explicitly segmented; uterus and bladder polygonal meshes as obtained from marching
cube algorithm and after smoothing and mass scaling implementation; polygonal meshes including
bladder wall.
erated using the Image2Mesh module (figure 5.1, a). Then, using the Smoothing and the
VolumeDeformation modules the whole bladder mesh was recursively eroded until the res-
ulting mesh volume was equal to the inner bladder volume (figure 5.1, d): the bladder wall
mesh was obtained by subtraction of the whole bladder and the inner bladder meshes (5.1,
e). The final polygonal mesh volumes for the three structures considered, are compatible
to the volumes listed in the ICRP report within 5% after smoothing and correcting for
organ intersections (MeshIntersection and VoxelIntersection modules). In fig. 5.2b, a 3D
representation of the three polygonal meshes obtained is shown: the uterus is represented
in red, the inner bladder in blue, and the bladder wall in white wireframe.
In order to implement this realistic model into a Geant4 simulation two high resolu-
tion voxel models were generated using cubic voxels of a single size (0.2 mm) and of two
different sizes (0.2 mm and 2.0 mm). From here on, the first will be designated as High
Resolution Single-Scale (HR–SS) model (shown in figure 5.2c) and the second as High
Resolution Multi-Scale (HR–MS) model (shown in figure 5.2d). In the HR–MS model,
the need of maintaining realistic organ shapes during the voxelization process resulted in
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Figure 5.2: Coronal projections of the three selected organs (bladder, bladder wall and uterus)
from a) the ICRP 110 female phantom (LR–MS model), b) the polygonal mesh model, c) the
HR–SS and d) the HR–MS models.
the generation of five different structures. The bladder wall (in light blue in figure 5.2d)
was sampled using 0.2 mm voxels while the inner bladder and the uterus were split in
two regions each: the edge voxels having a size of 0.2 mm, and the internal voxels, having
a size of 2.0 mm. In figure 5.2d, the inner bladder “big voxels”are represented in pink,
and the “small voxels”in orange; the uterus “big voxels”are represented in red and “small
voxels”in light red. The HR–MS model is composed of about 4 times less voxels than the
HR–SS model (8386424 voxels against 28862039 voxels).
Geant4 simulations. Three separate simulations have been set-up on Geant4.9.6-patch01,
for the calculation of the absorbed dose in the two high resolution models (HR–MS and
HR–SS models) and in the original ICRP 110 bladder-uterus model (from now on indicated
as Low Resolution Single-Scale — LR–SS — model). All organs are considered made of
soft tissue according to Cristy and Eckerman (1987) material definition and surrounded
by water. For each simulation, a uniform radioactive source inside the inner bladder is
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defined, and the absorbed dose to the bladder, the bladder wall and the uterus is scored.
The source spatial distribution in the LR–SS model coincided with the bladder voxels. For
both high resolution models, the source optimisation procedure described in section 5.2.3
was implemented in order to achieve reasonable simulation times for the HR–SS model.
For this proof of principle example two different radionuclides sources (90Y and 131I) were
implemented as they provide beta emissions of very different endpoint energies (2.28 MeV
for 90Y and 606.31 keV for 131I ) well covering the range of beta energies typically used
in TRT. These sources also offer the possibility of comparing the dosimetric impact of
a pure β-emitter as 90Y, and a beta/gamma emitter as 131I (main gamma emission at
364.49 keV). Sources were generated using the General Particle Source module in Geant4
and the G4Ion class (Marcatili S. et al. 2013). For the three geometries the same physics
list (G4EmStandardPhysics option4 ) was used, implementing Livermore models (Chauvie
et al. 2004) for the simulation of electromagnetic interactions down to 250 eV. These
models have already been validated by several authors for Targeted Radionuclide Therapy
applications (Amato et al. 2013, Mauxion et al. 2013, Papadimitroulas et al. 2012, Maigne
et al. 2011), and they are based on the evaluated tables from LLNL (Lawrence Livermore
National Laboratory): EPDL97 (Cullen et al. 1997), EEDL (Perkins et al. 1991a) and
EADL (Perkins et al. 1991b). Specific cuts, consistent with the voxel size implemented
have been applied. The voxel statistical uncertainty (standard deviation of the mean) was
calculated at simulation time by considering the actual number of particles releasing their
energy in the voxel (Nv) and it scales as 1/
√
Nv(Nv − 1) (Visvikis et al. 2006).
The only difference between the three simulations consisted in the approach adopted
to define the voxel geometry in Geant4. For the LR–SS (voxels of 1.775 × 1.775 × 4.84
mm3) and the HR–SS (voxels of 2 × 2 × 2 mm3) models a G4PhantomParametrization
was implemented with production cuts of 0.1 and 0.01 mm respectively, for electrons and
photons. The dedicated G4RegularNavigation algorithm was used, with the option of
skipping voxels of equal materials enabled. The implementation of the HR–SS model as
a parametrized volume required the definition of 560 × 570 × 360 voxels including the
water voxels surrounding the actual organs.
On the other hand, the five structures generated for the HR–MS model were imple-
mented in Geant4 in the form of five independent G4AssemblyVolumes. A total of 9791981
voxels were used to describe the three organs. Voxels of 2 mm size were added to the “big
voxels”G4Region and production cuts of 0.1 mm were defined for electrons and photons;
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voxels of 0.2 mm size were added to the “small voxels”G4Region were refined production
cuts of 0.01 mm were set. The SmartVoxel optimisation along a single axis was used with
a default smartless value of 2. Different smartless values were tested without significant
improvement in computation speed. A three-dimensional optimisation was excluded to
avoid excessive memory usage at simulation set-up. For each source 2.94 108 radionuclide
decays were simulated in the case of high resolution models, and 7.50 107 events for the
LR–SS model.
5.2.5 Tests performed
5.2.5.1 Validation of multi-scale geometry in Geant4.
Absorbed dose distributions were calculated for the three organs selected in this example
and the three models implemented. The comparison between the two high resolution
dosimetries allowed the validation of the proposed multi-scale approach in Geant4 with
respect to the well established phantom parametrization method. The comparison of high
and low resolution models, on the other hand, permitted to investigate the possible benefits
of high resolution dosimetry.
5.2.5.2 Simulation performances
Simulation times for the two high resolutions models were evaluated in the case of a cubic
source of 2 × 2 × 2 mm3 placed inside the bladder. Mono-energetic electrons (energy from
0.1 to 2.5 MeV) and photons (from 10 keV to 2 MeV) of different energies were employed
in order to distinguish the effect of particle type on simulation speed. 105 primary events
were simulated for each particle energy.
The memory and time needed to store the geometry for the three models was also
estimated simulating a 300 keV geantino (the Geant4 non-interacting particle) cubic source
(2 × 2 × 2 mm3) at the center of the inner bladder, and generating a single primary event.
5.3 Results and Discussions
The proof of principle example described in this work was selected to investigate the
possible advantages of implementing a multi-scale approach in the detailed MC simulation
of small anatomical structures. In this perspective, results concerning the bladder wall
(the selected target organ) are discussed more in details as they served as a validation
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benchmark for the multi-scale approach. Uterus absorbed dose distributions are also
presented to discuss the different statistical convergences of HR–SS and HR–MS models.
5.3.1 Validation of multi-scale geometry in Geant4: bladder wall dosi-
metry
Absorbed dose distributions were generated for the three organs considered and the three
models selected. In figure 5.3 the transverse distributions obtained for the bladder wall
are shown as an example. Absorbed dose maps corresponding to 90Y sources are displayed
on top, while those corresponding to 131I sources are shown at the bottom. From left to
right, absorbed dose distributions were obtained through MC simulation of the LR–SS, the
HR–SS and the HR–MS models respectively. The pronounced visual similarity between
absorbed dose distributions obtained with the two high resolution models offers a first level
of validation for the G4AssemblyVolume approach with respect to the well acknowledged
G4PhantomParametrization technique. On the other hand, the inaccuracy of the Low
Resolution (LR) absorbed dose distributions confirms the need for more detailed organ
modelling.
Figure 5.3: Bladder wall transverse absorbed dose distributions for the three models simulated
(LR–SS, HR–SS and HR–MS from left to right) and the two sources considered (90Y on top and
131I below). The same vertical scale is used for the three distributions corresponding to each source.
In figure 5.4 absorbed dose profiles along the bladder wall thickness are shown for the
two high resolution models, in the case of a 90Y (left) and a 131I (right) source. The
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standard deviation associated to the average absorbed dose is smaller than the point size
and hence it is not visible in the plot. These profiles are generated considering expanding
shells (of 0.2 mm thickness) along the bladder surface normals, and by averaging absorbed
doses in these regions. The shells were created through dilation of the bladder voxel
model using the Visualization Toolkit. The vertical scales in the two plots were set to the
same ymax/ymin ratio in order to highlight the differences in absorbed dose delivery for
the two radionuclides. From the 131I profile, the different contributions of the β-particle
(EβEndPoint = 606.31 keV) and the main photon (Eγ = 364.49 keV) can be distinguished.
The first produces a steep slope next to the source edge (corresponding to X axis origin
in the plot) extending up to about 1 mm, which is compatible to the Continuous Slowing
Down Approximation (CSDA) range of 2.3 mm (Lanconelli et al. 2012) expected for 131I.
The latter, is responsible for the slowly decreasing tail. On the contrary, 90Y, being a pure
β-emitter (EβEndPoint = 2.28 MeV, maximum beta CSDA range of 10.1 mm (Lanconelli et
al. 2012)) produces a more continuous absorbed dose profile. As a general trend, the 131I
profile shows a faster absorbed dose decrease as the radiation penetrates in the tissues.
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Figure 5.4: Bladder wall 3D absorbed dose profiles for the two high resolution models and the
two sources simulated. 90Y profiles are shown on the left and 131I on the right.
In order to further validate the multi-scale approach, the average absorbed dose and the
average statistical percentage error for the bladder wall were derived for the three models.
The errors were calculated averaging the statistical percentage errors (standard deviation
of the mean) over the voxels composing the organ. The results, reported in table 5.1 for
both 90Y and 131I sources, show a high level of agreement between the two high resolution
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models. The percentage differences ((HR–SS – HR–MS)/HR–SS) between the average
absorbed doses are in this case below 1% for both radionuclides considered. The average
absorbed dose percentage differences between the HR–SS model and the LR–SS model
((HR–SS – LR–SS)/HR–SS) are higher (7.70 % and 6.38% for 90Y and 131I respectively)
but not huge, suggesting that the use of a low resolution model may be adequate if only the
average absorbed dose to the organ is needed. The advantage of using the LR–SS model,
in this specific case, lies in its faster statistical convergence. The statistical errors listed
in the table correspond to 2.94 108 events run for the MC simulation of high resolution
models, and to 7.50 107 primary events in the case of the LR–SS model. Hence, despite the
simulation of about 4 time less events, the low resolution model generates much smaller
statistical uncertainties.
90Y 131I
Model AADose % Error AADose % Error
HR–SS 1.82 10−13 0.69 2.35 10−14 5.13
HR–MS 1.81 10−13 0.70 2.36 10−14 5.26
LR–SS 1.68 10−13 2.81 10−4 2.21 10−14 3.07 10−3
AADose percentage differences
HR–MS vs. HR–SS 0.55 -0.43
LR–SS vs. HR–SS 7.70 6.38
Table 5.1: On top, average absorbed doses (AADose) in Gy/Bq s, and average statistical errors
(in percentage) in the bladder wall in the case of 90Y and 131I sources. Below, AADose percentage
differences between the two high resolution models (HR–MS vs. HR–SS), and between the LR–SS
and HR–SS models, for 90Y and 131I.
On the other hand, the choice of a high resolution approach presents clear advantages
when an accurate absorbed dose distribution is required. In order to highlight the differ-
ences between the absorbed dose distributions obtained with the three models, the bladder
wall differential Dose Volume Histograms (DVH) was generated for each of them. For both
90Y and 131I sources ( figure 5.5) the histograms for the two high resolution methods, in
blue and red, appear perfectly superposed and present a well-defined shape reflecting the
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non-uniform energy deposition along the bladder wall thickness. On the contrary, LR–SS
model histograms (here normalised to the integral of the other two histograms) are quite
coarse and, if in the case of 90Y source the overall trend is in agreement with the high res-
olution models, for 131I source the low resolution histogram appears “compressed”causing
a remarkable miscalculation of the minimum and maximum absorbed dose delivered to the
organ. Even though an appreciable discrepancy between the low and the high resolution
DVHs was expected, this “shrinking”effect is mainly induced by the low spatial sampling
of the LR–SS model rather than the geometry itself. It is in fact acknowledged that
increasing the thickness of the absorbed dose scoring grid produces an averaging effect
resulting in the compression of the differential DVH around the average absorbed dose
value (Taschereau et al. 2008). In order to appreciate the sole effect of unrealistic organ
modelling on the LR–SS DVH, a similar voxel size should be used to score the absorbed
dose in the HR–MS and the LR–SS models: reducing the voxel linear dimension of the
LR–SS model by a factor 8 in all directions, voxel dimensions of 0.219 × 0.219 × 0.60 mm3
are achieved, comparable to those of the HR-MS model in the transverse plane. In figure
5.6 LR–SS model DVHs obtained with the original sampling, and with a finer scoring
grid (LR–SS/8) are reported for 90Y and 131I respectively. The HR–MS model DVH is
also reported as a term of comparison. As can be observed from these plots, if the ab-
sorbed dose is scored on a finer voxel grid, the LR–SS and the HR-MS histograms for 131I
shows a more similar shape than the corresponding histograms for 90Y. This qualitative
observation highlights that the consequences of using low resolution organ models may be
different for different sources. In order to better understand figures 5.6 and the bladder
wall thickness in the HR–MS and the LR–SS models should considered. While the first
presents a uniformly thick wall of 5.6 mm, in the LR-SS model the bladder wall thickness
is very irregular. If the transverse plane 3D image of the ICRP bladder is considered, the
wall is always modelled using two voxels (hence it has an average thickness of about 3.55
mm); however, considering the coronal images, we discover that the wall is represented
with a number of voxels varying between 0 and 4 (hence, between 0 and 19.36 mm). This
“exceeding”thickness has clearly a negligible impact on 131I absorbed dose distributions,
since most of the energy emitted by this radionuclide is absorbed within the first 2 mm
anyway. On the contrary, for a radionuclide as 90Y, emitting energetic β-particles (with a
CSDA range in water of 10.1 mm), it causes an excess of voxels receiving a low absorbed
dose.
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Figure 5.5: 90Y (top) and 131I (bottom) differential DVHs in the bladder wall for the LR–SS
(in green), the HR–SS (in red) and the HR–MS (in blue) models, for a uniform source in the
bladder. In the legend, the number of entries, the mean values and the Root Mean Square (RMS)
values are reported for the three histograms. The number of entries matches the number of voxels
implemented in the corresponding organ model.
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Figure 5.6: 90Y (top) and 131I (bottom) differential DVHs in the bladder wall generated from the
LR–SS model with different scoring grids: one reproducing the original sampling (1.775 × 1.775
× 4.84 mm3), the other having 8 times smaller voxels (0.219 × 0.219 × 0.605 mm3). In red, the
HR–MS model DVH is shown as a term of comparison. In the legend, the number of entries, the
mean values and the Root Mean Square (RMS) values are reported for the three histograms. The
number of entries matches the number of voxels implemented in the corresponding organ model.
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5.3.2 Statistical uncertainty: uterus dosimetry
With a CSDA range in water of 10.1 mm, most of 90Y β-particles emitted in the bladder
deposit their energy in the 5.6 mm thick bladder wall. As a results, despite the large
number of primary particles generated in the Monte Carlo simulation (2.94 108 events for
the HR models), most of uterus voxels remain unfired by 90Y radiation. In this context,
the average organ absorbed dose is not necessarily a relevant parameter. Even the inter-
pretation of the absorbed dose distribution (dDVH) is not straightforward; in particular,
it is hard to say to which extent the heterogeneity depends on statistical uncertainty or on
particle ballistics. A better understanding of this issues would therefore require a dedic-
ated analysis which is beyond the scope of this work. For all these reasons, 90Y dosimetry
for the uterus will not be discussed here. Nevertheless, the 90Y absorbed dose distribution
obtained with the HR-SS model is shown in figure 5.7, left for reference. Here, the ab-
sorbed dose map is resampled to 2.0 × 2.0 × 2.0 mm3 voxels in order to reduce statistical
fluctuations and highlight the effect of limited particle range.
Figure 5.7: 90Y (left) and 131I (right) absorbed dose distribution obtained with the HR–SS model
resampled to a voxel size of 2.0 x 2.0 x 2.0 mm3.
In contrast, photons emitted by 131I could, in principle, produce a measurable energy
deposition in any voxels of the uterus model. However, depending on the voxel size
chosen for the uterus representation, a partial irradiation may be achieved within the
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simulation, regardless of the huge number of primary particle generated. In the case of
the HR-SS model, for example, about 8% of the voxels are not hit by any radiation.
As a consequence, the average statistical error for the voxel absorbed dose is quite high
(18.26%) limiting the reliability of the absorbed dose distribution. In figure 5.8 the uterus
absorbed dose map (left) obtained with the HR–SS model is shown together with the
correspondant distribution of statistical percentage error (right). For the latter, the peak
at 100% corresponds to the voxels not fired, and the peak at about 50% corresponds to the
voxels receiving a single hit. As expected, the LR–SS and the HR-MS models performed
much better in terms of statistical convergence. For the first, a 0.02% average statistical
error was obtained with a limited number of simulated events (7.50 107). For the multi-
scale model, a 0.04% average statistical error was obtained for the inner part of the uterus
(representing about 80% of the total volume) and a 19.06% for the edge voxels.
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Figure 5.8: 131I absorbed dose map (left) obtained with the HR–SS model, and the corresponding
statistical error distribution in the uterus (right).
Also for what concerns the uterus dDVHs, the LR and the HR approach led to quite
different results. In figure 5.9 (top), the 131I dDVHs are presented for the three models, and
normalised by the area of the HR–SS model to account for the different number of voxels
fired by radiation. In this case, the HR–MS dDVH is much closer to the LR–SS dDVH
than to the HR–SS model, while, again, the average absorbed doses (listed in the legend
of figure 5.9 as “mean”) to the organs are in good agreement: the differences between the
HR–SS model and the HR–MS and the LR-SS models are 4.6% and 6.3% respectively:
the difference between the HR–MS and the LR–SS models is, instead, of only 1.8%.
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Considering the higher statistical uncertainty afflicting the HR–SS data, one might
attribute the different shape of the HR–SS dDVH to the lack of convergence of the Monte
Carlo simulation. However, a simple comparison of the dDVHs obtained from the HR–SS
model with the 0.2 × 0.2 × 0.2 mm3 voxel size, and from the same model resampled to 2.0
× 2.0 × 2.0 mm3 voxels, demonstrates that the difference actually depends on sampling
(see figure 5.9, bottom). Here, the same input data produce totally different absorbed
dose distributions simply using different voxel sizes. As a reference, in figure 5.7 (left), the
131I absorbed dose map is shown for the HR–SS model resampled to 2.0 × 2.0 × 2.0 mm3
voxels in order to reduce statistical fluctuations due to sampling. The two absorbed dose
distributions in figure 5.7 are presented using the same intensity scale to further highlight
the differences between 90Y and 131I.
All the considerations made regarding the statistical convergence of the Monte Carlo
simulation at the voxel level should not be applied to the interpretation of the average
absorbed doses obtained. The convergence of the mean absorbed dose value, in fact, is
much faster. According to conventional error propagation rules, the error on the mean
absorbed dose is calculated as the squared sum of the voxel errors (ei), divided by the
number of voxels composing the organ model (N). Under the hypothesis that all voxel
errors are the same, the error on the mean absorbed dose is given by the voxel error divided
by N, and it is hence much smaller than ei. As a consequence, the average absorbed dose
calculated for the uterus remains relevant for the three models implemented.
5.3.3 Simulation performances
All the simulations for this study could be run on a 3.1 GHz Intel Core i5 computer with
12 GB of RAM without using the SWAP memory. As expected, the G4AssemblyVolume
presented a higher memory consumption for geometry storage (see table 5.2). However,
in this example, a 3.6 times increase in memory usage is not critical as it leaves the total
memory consumption for the HR–MS model at 3.21 GB, a value that can be easily handled
by any modern desktop computer.
The times needed to simulate a single geantino (the non-interacting Geant4 virtual
particle used to test transportation processes) in both high resolution models are reported
in table 5.2. Since the geantino navigation takes less than 0.01 seconds in both simulations,
these values can be interpreted as the times necessary to build and store Geant4 geometry.
No significant difference is found for the set-up time of the HR–MS and the HR–SS models.
165
Chapter 5. Multi-resolution hybrid models for TRT dosimetry
HR-SS model
Entries  9060998
Mean  8.458e-15
RMS  8.171e-15
Absorbed dose (Gy/Bq s)
0 5 10 15 20 25 30 35 40 45 50
-1510×
# 
vo
xe
ls
0
100
200
300
400
500
600
310×
Differential DVH Uterus - 131I
HR-MS model
Entries  9674721
Mean  8.07e-15
RMS  4.958e-15
LR-SS model
Entries  5094
Mean  7.925e-15
RMS  3.872e-15
HR-MS model
HR-SS model
LR-SS model
inner uterus - 0.2 mm3
Entries  9060998
Mean  8.458e-15
RMS  8.171e-15
Absorbed dose (mGy/MBq)
0 5 10 15 20 25 30 35 40 45 50
-1510×
# 
vo
xe
ls
0
100
200
300
400
500
600
310×
dDVH Uterus HRSS model - 131I
inner uterus - 2.0 mm3
Entries  9825
Mean  7.345e-15
RMS  4.17e-15
0.2 mm voxels
2.0 mm voxels
Figure 5.9: Top: 131I uterus dDVHs obtained with the three models. Bottom: 131I uterus dDVHs
obtained from the HR–SS model with the 0.2 x 0.2 x 0.2 mm3 voxel size (red line), and from the
same model resampled to 2.0 x 2.0 x 2.0 mm3 voxels (blue line).
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In both cases these times seem negligible considering, for example, that the simulation of
a few millions of 90Y decays in the same geometry would take about 1 hour on a standard
desktop computer.
HR–MS HR–SS
Time for geometry definition (s) 48 53
Memory to store geometry (GB) 3.21 0.88
Table 5.2: Geant4 time and memory performances at geometry set-up, for the HR–MS and the
HR–SS models.
The evaluation of MC simulation times for the two high resolution models indicates
that the simulation of multi-scale geometries in Geant4 according to the proposed method,
is faster for both electrons and photons sources (see figure 5.10). For mono-energetic
electrons the G4AssemblyVolume approach allows to speed up the simulation by a factor
2.1 on average with respect to the G4PhantomParametrization technique. In this case,
the speed-up factor does not depend on particle energy because the number of voxels seen
by electrons (energy from 0.1 to 2.5 MeV) during navigation is limited to few surrounding
elements at any energy. Since for this test the source is placed at the centre of the bladder,
the faster navigation in the HR–MS model is directly correlated to the larger voxel size
in the HR–MS bladder. On the other hand, the speed-up factor in case of photon sources
strictly depends on photon energy, with time ratios (TimeHR−SS/TimeHR−MS) going from
1.5 to 4.9 in the selected energy range (from 10 keV to 2 MeV). This behaviour reflects
the dramatically increasing number of voxels seen at navigation by a gamma ray as its
energy increases: since the total number of voxels in the HR–MS model is 3.9 times lower
(excluding surrounding voxels) there is a gain in simulation time of the same order of
magnitude.
Even considering more realistic simulations implementing extended radionuclide sources,
the multi-resolution approach remains the fastest. For the simulation set-up described in
section 5.2.3 (Geant4 simulations), a speed-up factor of 2.27 was obtained for 90Y and of
1.90 for 131I when comparing the HR–MS model to the HR–SS.
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Figure 5.10: Simulation times for 105 electrons (on the left) and photons (on the right) of different
energies, in the case of HR–MS and HR–SS models.
5.4 Conclusions
The accuracy of radiopharmaceutical absorbed dose distributions computed through MC
simulations, is limited by the low spatial resolution of the 3D imaging techniques used
to define the simulation geometry. This issue also persists with the implementation of
realistic digital models, as they require to be simulated in their voxel form in order to
reduce computation times. While for most organs the typical spatial sampling adopted
to build the MC voxel geometry (few millimetres at best) is adequate, for small anatom-
ical structures, the low sampling results in unrealistic organ shapes which may produce
inaccurate dosimetry.
In this work a novel approach is proposed to adapt the spatial sampling of MC ab-
sorbed dose maps in different organs to the level of accuracy required by a specific clinical
application, while maintaining the simulation time low. The software tools developed
will eventually allow merging 3D patient images and accurate voxel models of selected
organs, to perform multi-scale absorbed dose simulations with Geant4. Here the proposed
approach is validate towards the recommended Geant4 technique to simulate 3D voxel
geometries, using organ models of different spatial resolutions.
The comparison of two high resolution bladder models showed no significant differences
in the dosimetry, both at the voxel and at the organ level, providing a validation of
the multi-scale approach. At the same time, the comparison of high and low resolution
dosimetries supported the need for high resolution models of small anatomical structures
when an accurate knowledge of the absorbed dose distribution is required. In this case,
in fact, the shape of resulting DVHs strictly depends on the model spatial resolution
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as well as on the average range of the main emissions of the radionuclide considered.
Here, for example, it was observed a significant bias in 90Y dDVH shape caused by the
unrealistic bladder thickness in the LR–SS model, which is not substantial in 131I dDVH.
Significant differences were also found in the shape of uterus dDVHs obtained with fine
(HR–SS model) and coarse sampling (LR–SS and HR–MS models). The high statistical
uncertainty associated to small size voxels suggests that a low resolution or a multi-scale
approach is recommended for dosimetry of target organs far from the source (with respect
to particle range). All these effects clearly indicate that spatial sampling of the anatomical
model should be chosen with great care, not only to match the suited spatial resolution,
but also accordingly to the radiation source selected.
On the other hand, relative differences between the average absorbed doses for the HR
and the LR models were of the order of few percent. This discrepancy is not remarkable
and suggests that a high resolution approach may not be necessary when only the av-
erage organ absorbed dose is needed. As a matter of fact, simply using a different MC
toolkit implementing different physics models, or changing the binning of the radionuclide
spectrum for the simulation of the source, would probably result in similar percentage
differences for the average absorbed dose (Lanconelli et al. 2012).
It was also demonstrated that the proposed approach based on G4AssemblyVolumes
allows reducing simulation times for the simplified geometry here discussed. The speed-up
factor, of the order of 2 in this example, depends on the radionuclide emissions con-
sidered and on the relative number of voxels needed to describe the HR–SS and the
HR–MS models. For the simulation of whole body geometries including selected HR or-
gan models, even better time performances are anticipated with respect to the standard
G4PhantomParametrization approach. As expected, the Geant4 memory usage to store
the multi-scale model was higher than the memory needed for the single scale model.
However, for limited size geometries, the reduced number of voxels necessary to describe
the same anatomical area contributes to keep its amount to values that can be handled by
standard desktop computers. In future works, memory consumption will be maintained
low enough even in the case of whole body simulations using parallel worlds in Geant4 (En-
ger et al. 2012). In this scenario, the 3D whole body image of a patient could be modeled
using G4PhantomParametrization in the main world, while the detailed multi-scale model
could be implemented as a G4AssemblyVolume in the parallel world.
169
Chapter 5. Multi-resolution hybrid models for TRT dosimetry
170
Conclusions and future
perspectives
The MIRD formalism is by essence valid at any scale (from cellular to clinical studies) as
long as the mean absorbed dose is the relevant parameter to assess. However, key factors
need to be considered, as spatial resolution conditions (and sometimes limits) the relevance
of a given dosimetric approach. In the past decades, limitation in computing power has led
to the generation of dosimetric models of limited accuracy. Human and animal anatomy
were represented using simple volume shapes as spheres, ellipsoides and so on. The advent
of modern computers and the development of medical imaging techniques allowed the
digital sampling of the volumes of interest, resulting in a refinement of geometry definition.
This led to the generation of voxel-based and BREP models for both man and small
animals. The implications of an improved geometry definition seems obvious at first sight:
if the model geometry better matches the in-vivo or in-vitro biological system considered,
a more realistic computation of the S factor can be implemented, and the dosimetric
approach will be more accurate.
However, this is only one aspect of the problem. The overall accuracy of a given
dosimetric approach depends on the accuracy of both parameters in the MIRD equation.
Increasing the precision in the determination of the S value is fruitful only if the cumulated
activity can be determined with the same level of accuracy. It is hence crucial to take
into account spatial distribution of radioactivity, as it may vary even at the intra-cellular
scale. This heterogeneity, combined with the range of radiations, induces absorbed dose
gradients that directly impact the biological efficacy of the treatment. This is true for
all particles involved in TRT (alpha, beta, Augers), depending on the size of the bio-
logical system they interact with. An important parameter to consider are the relative
dimensions of particle range and propagation medium. In this sense, the spatial resolution
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at which the activity should be quantified depends on the experimental context. In the
presence of short-range emitters, dosimetry should consider events occurring at the tissue
and even at the cellular scale. Conversely, for beta emitters, the assessment of activity
variability within the organ volume is considered appropriate for most applications. Thus,
while sometimes the use of the most refined imaging technologies is required to obtain
dosimetric results of adequate accuracy, in other cases an approximate, but simpler ap-
proach may be implemented. In this work, examples of dosimetric calculations performed
with different levels of detail have been discussed at the cellular, animal and clinical scales.
In chapter 2, the development of dedicated software tools has allowed the creation of
virtual cell colonies on the basis of experimentally determined parameters. The generation
of a realistic multi-cellular model was indeed necessary for the establishment of the ab-
sorbed dose-effect relationship in the case of 177Lu labelled antibodies. Typical β-particles
range in tissue can cover hundreds of cell radii; this means that the absorbed dose to a
given cell in the culture is affected by the internalisation properties and actual spatial po-
sitions of thousands of cells. For the experimental conditions considered in this study, the
cross-irradiation contribution was, in many cases, higher than self-absorption. This result
strictly depends on how the experiment was conceived: cross-irradiation was relevant only
before cells were seeded in different dishes for the formation of colonies (0 - 18 hours),
while cell self-irradiation was continuos over the whole experiment time (0 - 336 hours).
Hence, for in-vivo applications, as for example tissue dosimetry investigated at the cellular
level, the cross-absorbed dose is in principle expected to contribute considerably more to
the average cell absorbed dose. As a consequence, the implementation of realistic distribu-
tions and randomised cell properties is inevitable to obtain sound dosimetric results. This
thesis is also supported by the high standard deviations (∼24% on average) found for the
cell average cross-absorbed dose, that reflects the high level of heterogeneity of the various
parameters characterising the colony. In this perspective, performing a single dosimetric
calculation for a given geometrical configuration and for a given average cell cumulated
activity, could have resulted in absorbed dose values considerably distant from the mean.
All these considerations stand on the assumption that the cellular model developed
is correct and appropriate. Even if there are no ground-truth data to benchmark the
proposed approach, the establishment of an absorbed dose-effect correlation for Ramos
cells may be considered indirect proof of its consistency. In particular, the similar surviv-
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als achieved for the two specific (177Lu-HH1 and 177Lu-Rituximab) and the non-specific
(177Lu-Erbitux) mAbs is encouraging. For the latter, the absorbed dose is almost only
due to non-specific irradiation from radioactivity in the culture medium. This makes the
associated dosimetric model very simple and hence less prone to errors, as it depends on
fewer parameters and assumptions. On the other hand, the lack of absorbed dose-effect
correlation found for DOHH2 cells is most probably due to bystander effect (as observed
in experiments performed at IRCM and not discussed in this thesis).
In chapter 3, the average tumour absorbed dose was shown not to correlate with
treatment efficacy, in the case of α-RIT of small volume carcinomatosis. This study ori-
ginated from a previous work carried out at IRCM with the aim of comparing the efficacy
and toxicity of two different radiopharmaceuticals. In their work, Boudousq and col-
leagues established mice survival in relation to the treatment with two internalising (212Pb-
Trastuzumab) and non-internalising (212Pb-35A7) mAbs. The internalising mAb showed
significantly increased mice survival, however, the average absorbed dose was higher for
tumours treated with the non-internalising mAb. In a second experiment, the acquisition
of DAR images of tumour cryosections demonstrated that the non-internalising (at the
cellular level) antibody, presented a very heterogeneous uptake at the tumour level. On
the basis of these images, it was possible to assess the absorbed dose distribution with a
spatial resolution of few micrometers. The resulting dose volume histograms evidenced
that, despite the higher average absorbed dose found, a large part of tumours treated
with the non-internalising mAb received a null absorbed dose. Tumour cells in these areas
could hence freely proliferate, which explains the low efficacy of 212Pb-35A7 treatment,
and restores a correlation between absorbed dose delivered and therapeutic effect.
A more general conclusion regarding this study, concerns the pertinency of methods
currently employed for the assessment of absorbed dose in small-animal experiments. The
standard approach, based on organ/tumour biopsy and subsequent counting, only provides
a measure of the average activity, neglecting sub-organ uptake heterogeneities. So, while
this strategy has been proven reasonable for short range β-emitter dosimetry, for which
particle range produces a smoothing effect on the absorbed dose distribution, it is a priori
inappropriate for α-particles. A further demonstration that dosimetry may be unreliable
when it is not carried out at the relevant scale (with respect to particle range and biolo-
gical phenomena involved).
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However, the implementation of the most refined dosimetric techniques is not always
required, as seen in chapters 4 and 5 for two different clinical applications. In chapter
4, three different dosimetric approaches have been compared for the analysis of the same
dataset acquired in the framework of a previous study. The aim of the original work, was
to assess the effective dose for a novel PET radiotracer, 18F-Flutemetamol. In the context
of this thesis, the same dataset was used to derive more general conclusions regarding the
accuracy of phantom-based, DVK and personalised MC dosimetry. Absorbed dose values
for a sub-sample of organs was significantly different for the three methods. Values ob-
tained with the phantom-based approach were up to two times lower than those obtained
with Monte Carlo; DVKs (as implemented in STRATOS) absorbed doses were up to 3
times lower. Certainly, in a therapeutic context, these differences would not be acceptable,
especially if regarding organs that are considered at risk for the treatment. However, the
same conclusion does not hold in the context of diagnostic dosimetry. In this case, in fact,
the aim is to obtain an order of magnitude for the effective dose to ensure safe levels of
irradiation to the general population. Dosimetry does not need to be patient-specific and
hence accuracy is not its main objective. Indeed, even a two- or threefold error in the
determination of the absorbed dose, only slightly shifts the corresponding effective dose,
because of the very low values of tissue-specific weighting factors (ICRP 1991, 2007). Still,
this study has contributed to highlight how the choice of the computational method can
impact patient dosimetry.
Even within the same treatment planning, the accuracy needed may vary for different
anatomical structures. In chapter 5, a method to perform Monte Carlo based, multi-
resolution dosimetry is proposed. It allows increasing the dosimetric accuracy for selected
structures while keeping simulation time low.
As for EBRT, predictive dosimetry in TRT requires establishing the absorbed dose to
a few organs that are considered at risk for the treatment. In EBRT, where radiation
beams are collimated, these organs are included in a limited region of the body. For
this reason, the dosimetric calculation is rather fast, even for MC methods (Sarrut et al.
2014). On the contrary, organs at risk in a TRT treatment may be very distant from
one to another, since the irradiation is diffuse and isotropic. As a result, the dosimetric
calculation may be considerable time-consuming as it should cover, in principle, the whole
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body. In this sense, increasing the spatial resolution of the modelled geometry (in order
to increase the accuracy of the absorbed dose distribution) seems unfeasible, as it would
further compromise the calculation timing performances. A possible solution, however, is
to improve the spatial sampling for the organ(s) of interest, while maintaining a coarse
sampling for the rest of the body. Following this approach and through a proof of principle
example, it was demonstrated that model spatial resolution may significantly affect the
dosimetric endpoints obtained, and the shape of the absorbed dose distributions. The case
discussed involved the dosimetry of the bladder wall for homogeneous 90Y or 131I sources
in the bladder. For this configuration, for example, the maximum 131I absorbed dose to
the bladder wall predicted by the high resolution model was about four times higher than
the value predicted by the low resolution one; a difference that is not certainly negligible
for the determination of the activity to administer. On the other hand, however, using
a fine voxellization was proven counterproductive for uterus dosimetry. In this example,
in fact, the uterus was only partially irradiated by β-particles (and photons in the case
of 131I) generated in the bladder and, as a consequence, the MC convergence was very
slow. In the specific case of 90Y, most of uterus voxels remained unfired for both low and
high resolution models, because of limited particle range. Nevertheless, in the case of 131I
source, the low- and the multi-resolution approaches (that used a coarse sampling for most
of uterus voxels) performed much better than the high resolution single scale model, due
to the larger volume of voxels implemented.
Another important aspect to consider for TRT optimisation, concerns the absolute
quantification of radioactivity both in vivo and ex vivo. Being able to assess uptake het-
erogeneity, does not guarantee alone, achieving more accurate dosimetry. It is in fact
crucial to establish the absolute value of cumulated activity with the highest possible
precision. In chapter 3, for example, the choice of using DAR to quantify 212Pb activity
before transient equilibrium was achieved, may have partially biased the absolute absorbed
doses obtained for tumours of the three groups (but the relative comparison of the three
radiopharmaceutical still holds). At the same time, in the work discussed in chapter 2,
a finer temporal sampling of the time-activity curves, would have resulted in smaller ab-
sorbed dose errors. A more accurate determination of activity was, in principle, possible
for some of the dosimetric studies performed in the framework of this thesis. However,
the optimisation of activity quantification procedures was beyond the scope of this work
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that focused, instead, on the computational aspect of the dosimetric assessment process.
Through four practical examples, this thesis provided hints for the optimisation of ab-
sorbed dose calculation at different scales, separately. This multi-scale approach was felt
necessary as a better determination of the absorbed dose-effect correlation in preclinical
experiments, ultimately participates to the improvement of TRT treatments efficacy. In
perspective, the integration of the dosimetric knowledge obtained at different scales may
also contribute establishing more accurate predictive dosimetry for therapy. In a clinical
setting, in fact, the scale at which biological information can be accessed is limited by
the spatial resolution of currently available medical imaging scanners (from 1 to 10 mm
depending on the technique). However, the biological efficacy of a given radiopharmaceut-
ical ultimately depends on microscopic processes. Present-day clinical dosimetry simply
neglects the complexity and heterogeneity that characterise living tissues at the cellular
or multi-cellular level.
In principle, information obtained at a smaller scale can be used as a template for
larger scale dosimetric calculations. This concept can be applied at different levels. For
example, if the activity distribution pattern is assessed ex vivo (via autoradiography or
using an alpha camera, with a spatial resolution of 10-50 um), the goal could be to inject
this knowledge in the absorbed dose determination performed in vivo on animals (even if,
at that scale, activity is determined with a spatial resolution of about 1 mm). Another
application could consist in establishing radiobiological parameters via clonogenic survival
assays and use this information to model DNA damages within the Monte Carlo compu-
tations of patient absorbed dose. This strategy could also be applied to the calculation of
bone marrow absorbed dose, taking into account microscopic parameters. Patient images
can be combined with macroscopic and microscopic representations of bone marrow mer-
ging voxel and analytical models, and then used to perform direct radiation transport as
seen in chapter 5.
The application of this multi-scale approach requires the development of specific soft-
ware tools that is currently on going at CRCT (Centre de Recherche en Cance´rologie de
Toulouse).
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Le formalisme du MIRD est, par de´finition, valide a` toute les e´chelles, des e´tudes cellu-
laires aux e´tudes cliniques, tant que la dose absorbe´e moyenne est le parame`tre d’inte´reˆt.
D’autres facteurs cle´s sont cependant a` prendre en compte dans la mesure ou` la re´solution
spatiale conditionne (et parfois meˆme limite) la pertinence de la me´thode dosime´trique
choisie. Jusqu’a` une e´poque tre`s re´cente, la puissance de calcul a` disposition e´tait le facteur
limitant de la pre´cision des mode`les dosime´triques. L’anatomie humaine et de l’animal
e´tait donc repre´sente´e par une combinaison de volumes simples, comme des cubes, des
sphe`res ou des ellipso¨ıdes. Les progre`s re´cents en informatique et en imagerie me´dicale ont
permis l’e´chantillonnage digital a` haute pre´cision des volumes mesure´s, et donc l’obtention
de mode`les ge´ome´triques raffine´s. Ces avance´es ont mene´es au de´veloppement des mode`les
ge´ome´triques voxelise´s et des mode`les hybrides (BREP), tant pour l’homme que pour le
petit animal. Les avantages d’une de´finition plus pre´cise de la ge´ome´trie peuvent sem-
bler e´vidents a` premie`re vue : si le mode`le ge´ome´trique correspond mieux a` la re´alite´ du
syste`me biologique e´tudie´, que ce soit in vivo ou in vitro, le calcul du facteur S sera mieux
imple´mente´, et l’approche dosime´trique plus pre´cise.
Cependant, ceci n’est que l’un des aspects du proble`me. En effet, ame´liorer le cal-
cul du facteur S n’est utile que si l’activite´ cumule´e peut eˆtre de´termine´e avec un niveau
de pre´cision similaire. La prise en compte de la distribution spatiale de la radioactivite´
est cruciale car celle-ci peut-eˆtre tre`s he´te´roge`ne meˆme a` l’e´chelle intracellulaire. Cette
he´te´roge´ne´ite´, combine´e a` la longueur d’interaction de la radiation, induit des gradients
dans la distribution de la dose absorbe´e, qui impactent directement l’efficacite´ biologique
du traitement. Ce phe´nome`ne est observe´ pour tous les types de particules rencontre´s
en RIV (alpha, beta, e´lectrons Auger), selon les dimensions caracte´ristiques du syste`me
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biologique conside´re´. Le parame`tre important est en fait la dimension relative du libre
parcours moyen de la particule par rapport aux dimensions caracte´ristiques du milieu de
propagation. La re´solution spatiale a` laquelle l’activite´ doit eˆtre quantifie´e de´pend donc
du contexte expe´rimental. En pre´sence d’e´metteurs a` courte longueur d’interaction, la do-
sime´trie doit eˆtre re´alise´e a` l’e´chelle du tissu, voir meˆme de la cellule. En revanche, pour
les e´metteurs beta, qui ont une plus grande longueur d’interaction, l’e´chelle de l’organe
est suffisante pour obtenir une dosime´trie correcte dans la plupart des cas. En re´sume´,
si l’utilisation de techniques d’imagerie avance´es est parfois indispensable pour obtenir
des re´sultats dosime´triques fiables, dans d’autres cas, l’imple´mentation d’une ge´ome´trie
approximative dans le cadre d’une approche plus simple peut eˆtre suffisant. Dans cette
the`se, divers exemples de calcul dosime´trique, re´alise´s a` diffe´rents niveaux de de´tails, ont
e´te´ pre´sente´s et analyse´s aux e´chelles cellulaire, animale et clinique.
Le chapitre 2 a pre´sente´ le travail re´alise´ pour le de´veloppement d’un outil informatique
de´die´ a` la cre´ation de colonies cellulaires virtuelles dont les parame`tres correspondent aux
mesures expe´rimentales fournies en entre´e. La ge´ne´ration d’un mode`le multi-cellulaire
re´aliste a en effet e´te´ ne´cessaire pour e´tablir la relation dose absorbe´e-effet dans le cas
d’anticorps marque´s au lute´tium 177 (177Lu). La longueur d’interaction des particules
β dans le tissu biologique couvre typiquement plusieurs centaines de rayons cellulaires,
ce qui implique que la dose absorbe´e par une cellule donne´e dans la culture de´pend des
capacite´s d’internalisation et de la distribution spatiale des milliers de cellules environ-
nantes. Dans les conditions expe´rimentales e´tudie´es dans ce travail, la contribution de
l’irradiation par tirs croise´s e´tait, dans un grand nombre de cas, plus importante que celle
de l’auto-absorption. Cependant, ce re´sultat de´pend de manie`re stricte des conditions
expe´rimentales choisies : l’irradiation par tirs croise´s n’e´tait importante que dans la phase
initiale, avant que les cellules ne soient de´pose´es dans les boˆıtes pour la formation des
colonies (0 – 18 heures), alors que l’irradiation par auto-absorption a e´te´ continue pendant
toute la dure´e de l’expe´rience (0 – 336 heures). Ainsi, dans le cas des applications in vivo,
par exemple pour la dosime´trie d’un tissu e´tudie´ au niveau cellulaire, on s’attend a` ce que
l’irradiation par tirs croise´s ait une contribution significative a` la dose absorbe´e moyenne
par cellule. L’imple´mentation de distributions re´alistes, pour l’e´talement spatial et les
proprie´te´s des cellules, est donc indispensable pour obtenir des re´sultats dosime´triques
acceptables. Cette the`se est aussi supporte´e par la grande valeur observe´e de la de´viation
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standard (∼24%) de la dose absorbe´e par irradiation par tirs croise´s, reflet du haut niveau
d’he´te´roge´ne´ite´ des divers parame`tres caracte´risant les colonies. Pour ce type d’e´tude, une
dosime´trie re´alise´e en utilisant une unique instanciation de la ge´ome´trie, et pour une valeur
donne´e de l’activite´ moyenne par cellule, aurait fournie des doses absorbe´es e´loigne´es de
la moyenne re´elle.
Ces conside´rations ne restent e´videmment valides que sous la condition que le mode`le
de colonie cellulaire de´veloppe´ soit correct et adapte´. Bien qu’il n’y ait pas de donne´es
de re´fe´rence pour valider cette nouvelle approche, le fait de trouver une corre´lation dose
absorbe´e-effet pour les cellules Ramos peut eˆtre conside´re´ comme un preuve indirect de
sa consistance. En particulier, des courbes de survie tre`s similaires sont obtenues pour
les anticorps monoclonaux spe´cifiques (177Lu-HH1 et 177Lu-Rituximab ) et non spe´cifiques
(177Lu-Erbitux) e´tudie´s, ce qui est tre`s encourageant. Pour ce dernier, la dose absorbe´e est
presque uniquement due a` l’irradiation non spe´cifique lie´e a` la radioactivite´ dans le milieu
de culture. Le mode`le dosime´trique associe´ ne de´pend donc que d’un nombre limite´ de
parame`tres et d’hypothe`ses, ce qui le rend relativement simple et limite le risque d’erreur.
Par ailleurs, l’absence de corre´lation dose absorbe´e-effet obtenue pour les cellules DOHH1
est tre`s probablement due a` l’effet bystander, comme observe´ lors d’expe´riences re´alise´es
a` l’IRCM et non pre´sente´es dans cette the`se.
Dans le chapitre 3, il a e´te´ de´montre´ que la valeur moyenne de la dose absorbe´e par
la tumeur n’est pas forcement corre´le´e a` l’efficacite´ du traitement dans le cas de la ra-
dioimmunothe´rapie α des carcinoses de volume re´duit. Cette e´tude prend son origine
dans un travail pre´ce´demment re´alise´ a` l’IRCM et ayant pour but la comparaison de
l’efficacite´ et de la toxicite´ de deux radiopharmaceutiques diffe´rents. Dans leur travail,
Boudousq et ses colle`gues ont e´tabli les courbes de survie de souris traite´es par deux anti-
corps diffe´rents, l’un internalisant (212Pb-Trastuzumab) et l’autre non internalisant (212Pb-
35A7). L’anticorps internalisant donnait des taux de survie significativement plus e´leve´s,
alors que la dose absorbe´e moyenne a` la tumeur e´tait pourtant plus e´leve´e pour l’anticorps
non internalisant. Lors d’une seconde expe´rience, les images de coupes cryoge´niques de
la tumeur, obtenues par autoradiographie digitale, ont montre´ que l’anticorps non inter-
nalisant (au niveau cellulaire) e´tait absorbe´ de manie`re tre`s he´te´roge`ne au niveau de la
tumeur. Ces images ont en outre permis d’extraire la distribution de la dose absorbe´e avec
une re´solution spatiale de quelques microme`tres. Les histogrammes dose volume de´rive´s
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ont mis en e´vidence le fait que, malgre´ la grande valeur moyenne de la dose absorbe´e,
une grande partie de la tumeur traite´e avec l’anticorps non internalisant recevait en fait
une dose quasiment nulle. Les cellules tumorales de ces zones non traite´es pouvaient donc
prolife´rer librement ; ce qui explique la faible efficacite´ du traitement au 212Pb-35A7, et
permet aussi de restaurer la corre´lation dose absorbe´e-effet the´rapeutique.
D’un point de vue plus ge´ne´ral, cette e´tude apporte un nouveau regard sur la per-
tinence des me´thodes utilise´es actuellement pour de´terminer la dose absorbe´e dans les
expe´riences sur le petit animal. La proce´dure standard, base´e sur la biopsie de l’organe
ou de la tumeur suivie du comptage des photons gamma, ne procure qu’une mesure moy-
enne de l’activite´, et ne donne aucune information sur l’he´te´roge´ne´ite´ de la radioactivite´
a` l’inte´rieur de l’organe meˆme. Alors que cette strate´gie est tout a` fait raisonnable pour
faire de la dosime´trie avec des e´metteurs β, pour lesquels la longueur d’interaction non
ne´gligeable produit un effet de lissage de la distribution de la dose absorbe´e, elle est a
priori inadapte´e en pre´sence de particules α. Ceci est une autre de´monstration du fait
que la dosime´trie ne peut pas eˆtre fiable si elle n’est pas e´tablie a` la bonne e´chelle, soit,
celle conside´rant la longueur d’interaction des particules en rapport aux dimensions ca-
racte´ristiques des phe´nome`nes biologiques e´tudie´s.
L’imple´mentation d’un mode`le dosime´trique tre`s raffine´ n’est cependant pas toujours
utile, comme cela est de´montre´ dans les chapitres 4 et 5, pour deux applications cli-
niques diffe´rentes. Dans le chapitre 4, trois approches dosime´triques diffe´rentes ont e´te´
compare´es pour l’analyse d’un meˆme jeu de donne´es, obtenu dans le cadre d’une e´tude
pre´ce´dente. L’objectif du travail initial e´tait d’e´tablir la dose efficace pour un nouveau
radiotraceur pour la TEP, le 18F-Flutemetamol. Dans le contexte de cette the`se, ce meˆme
jeu de donne´es a e´te´ utilise´ pour de´river des conclusions plus ge´ne´rales sur la pre´cision des
diffe´rentes techniques dosime´triques : dosime´trie base´e sur les fantoˆmes, VDK et Monte-
Carlo personnalise´e. Les valeurs de dose absorbe´e obtenues pour un e´chantillon des organes
se sont re´ve´le´es eˆtre tre`s diffe´rentes d’une me´thode a` l’autre. La dosime´trie base´e sur les
fantoˆmes a fourni des valeurs de dose absorbe´e jusqu’a` deux fois plus petites que celles
obtenues par dosime´trie Monte-Carlo, alors que la dosime´trie VDK (via l’outil STRATOS)
donnait des valeurs trois fois plus petites. Dans un contexte the´rapeutique, ces diffe´rences
ne seraient certainement pas acceptables, en particulier sur les organes conside´re´s a` risque
pour le traitement. Cependant, dans le cadre d’une dosime´trie a` vise´e diagnostique, elles
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ne sont plus vraiment proble´matiques. En effet, dans ce cas, l’objectif est de de´river l’ordre
de grandeur de la dose efficace permettant d’assurer un niveau d’irradiation acceptable
pour une population de patients. La dosime´trie n’a alors pas besoin d’eˆtre spe´cifique a` un
patient donne´, et la pre´cision n’est plus l’objectif principal. En re´alite´, meˆme une erreur
d’un facteur deux ou trois sur la valeur de la dose absorbe´e n’est plus un proble`me car
cela ne correspond qu’a` une diffe´rence minimale sur la dose efficace, en raison des valeurs
tre`s faibles des facteurs de ponde´ration des tissus (ICRP 1991, 2007). L’e´tude pre´sente´e
ici a tout de meˆme le me´rite de contribuer a` souligner l’importance de l’impact du choix
de la me´thode de calcul sur la dosime´trie personnalise´e.
Meˆme pour pour un plan de traitement donne´, la pre´cision dosime´trique ne´cessaire sera
a priori diffe´rente pour chaque structure anatomique. Dans le chapitre 5, une me´thode
s’appuyant sur des simulations Monte-Carlo est propose´e pour re´aliser une dosime´trie
multi-re´solution. Cette me´thode permet d’ame´liorer la pre´cision de la dosime´trie pour les
structures choisies, tout en contenant les temps de calcul.
Tout comme pour la radiothe´rapie externe, la dosime´trie pre´dictive en RIV requiert
l’estimation de la dose absorbe´e pour les organes conside´re´s a` risque dans le cadre du
traitement. En radiothe´rapie externe, ou` le faisceau de radiation est collimate´, ces or-
ganes sont compris dans une zone anatomique limite´e. C’est pour cette raison que les
calculs dosime´triques sont relativement rapides meˆme si l’on utilise une me´thode Monte-
Carlo (Sarrut et al. 2014). En revanche, en RIV, les organes a` risque peuvent eˆtre tre`s
distants les uns des autres, car la source de radiation est diffuse et isotrope. Les cal-
culs dosime´triques peuvent alors prendre un temps conside´rable car ils doivent en principe
prendre en compte le corps entier. L’augmentation de l’e´chantillonnage spatiale du mode`le
ge´ome´trique (pour ame´liorer la pre´cision sur la distribution de la dose absorbe´e) semble
comple`tement irre´aliste, a` cause de l’allongement des temps de calcul induit. Une solution
possible est d’ame´liorer la re´solution spatiale pour les organes d’inte´reˆt, tout en mainten-
ant un e´chantillonnage grossier du reste du corps. Cette approche a e´te´ imple´mente´e sur
un exemple particulier servant de preuve de principe, afin de de´montrer que la re´solution
du mode`le spatial peut impacter significativement les re´sultats de la dosime´trie, ainsi que
la forme de la distribution de la dose absorbe´e. L’exemple choisi consiste a` re´aliser la
dosime´trie de la paroi d’une vessie contenant une source homoge`ne d’yttrium 90 (90Y) ou
d’iode 131 (131I). Dans cette configuration, pour l’iode 131, le dose maximale absorbe´e
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a` la paroi de la vessie est quatre fois plus grande pour le mode`le haute re´solution, que
pour le mode`le basse re´solution. C’est une diffe´rence certainement non ne´gligeable pour
la de´termination de la valeur de l’activite´ a` administrer. En revanche, pour la dosime´trie
de l’ute´rus, la voxe´lisation fine de la ge´ome´trie s’est re´ve´le´e eˆtre contre-productive. Dans
l’exemple imple´mente´, l’ute´rus n’e´tait en effet que partiellement irradie´ par les particules
β (et des photons pour l’iode 131) provenant de la vessie, ce qui rendait la convergence
de la simulation Monte-Carlo tre`s lente. Pour le cas spe´cifique de l’yttrium 90, la plupart
des voxels de l’ute´rus ne recevait aucun coup tant pour les mode`les haute re´solution que
pour le mode`le basse re´solution, a` cause de la faible longueur d’interaction des partic-
ules. Ne´anmoins, pour l’iode 131, les approches a` basse re´solution et multi-re´solutions
(entraˆınant un e´chantillonnage grossier de l’ute´rus) ont donne´ de meilleurs re´sultats que
le mode`le a` tre`s haute re´solution, en raison du volume plus important des voxels qui a
permis d’obtenir une meilleur statistique en terme de coups.
Un autre aspect important a` conside´rer pour l’optimisation de la RIV, concerne la
quantification absolue de la radioactivite´, a` la fois in vivo et ex vivo. De´terminer correcte-
ment l’he´te´roge´ne´ite´ de l’absorption de la radioactivite´ n’est pas suffisant pour garantir
l’obtention d’une dosime´trie plus pre´cise. Il est en effet aussi crucial de de´terminer
avec autant de pre´cision que ne´cessaire la valeur absolue de l’activite´ cumule´e. Dans
le chapitre 3 par exemple, le choix d’utiliser des images acquises par autoradiographie di-
gitale, pour quantifier l’activite´ du plomb 212 (212Pb), avant meˆme que l’e´quilibre se´culaire
ne soit atteint, a peut eˆtre partiellement biaise´ la valeur absolue des doses obtenues pour
les tumeurs des trois groupes (mais la comparaison relative des trois radiopharmaceutiques
reste elle correcte). Dans le meˆme ordre d’ide´e, pour le travail pre´sente´ au chapitre 2, un
meilleur e´chantillonnage temporel des courbes d’activite´ aurait permis de re´duire signi-
ficativement l’erreur finale sur la dose absorbe´e. En fait, certaines e´tudes dosime´triques
mene´es durant cette the`se auraient pu, en principe, be´ne´ficier d’une mesure plus pre´cise
de l’activite´ cumule´e. Cependant, les proce´dures pour l’optimisation de la quantification
de l’activite´ e´taient trop e´loigne´es du cadre de ce travaille, plutoˆt focalise´ sur les aspects
computationnels du process dosime´trique.
Ce travail de the`se pre´sente plusieurs pistes pour l’optimisation du calcul de la dose
absorbe´e a` diffe´rentes e´chelles, et ceci a` travers quatre cas pratiques. Cette approche
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multi-e´chelle est apparue ne´cessaire car une meilleure de´termination de la corre´lation dose
absorbe´e-effet dans les expe´riences pre´cliniques, peut contribuer in fine a` l’ame´lioration
de l’efficacite´ des traitements RIV. De plus, l’inte´gration du calcul dosime´trique obtenu
a` diffe´rentes e´chelles pourrait aussi aider a` e´tablir une dosime´trie pre´dictive plus pre´cise
pour la the´rapie. En effet, dans un contexte clinique, l’e´chelle a` laquelle on peut acce´der a`
l’information biologique est limite´e par la re´solution spatiale des scanners pour l’imagerie
me´dicale actuellement disponibles (entre 1 et 10 mm selon les techniques). Hors, l’efficacite´
biologique d’un radiopharmaceutique donne´ de´pend pourtant de processus microscopiques.
La dosime´trie clinique pratique´e aujourd’hui ne´glige malheureusement la complexite´ et
l’he´te´roge´ne´ite´ qui caracte´risent le tissu biologique vivant aux e´chelles cellulaire et multi-
cellulaire.
En principe, les informations obtenues a` petite e´chelle peuvent servir de mode`le pour
les calculs dosime´triques a` plus grande e´chelle. Ce concept peut en fait eˆtre applique´ a`
diffe´rents niveaux. Par exemple, si le pattern de la distribution de l’activite´ est de´termine´
ex vivo (par autoradiographie ou en utilisant une came´ra alpha ayant une re´solution spa-
tiale de 10 a` 50 μm), cette information pourrait eˆtre utilise´e pour la de´termination de
la dose absorbe´e aux animaux in vivo (bien qu’a` cette e´chelle, l’activite´ ne puisse-t-eˆtre
mesure´e qu’avec une re´solution spatiale de 1 mm). Une autre application pourrait eˆtre
de de´river des parame`tres radiobiologiques via des expe´riences de survie clonoge´nique,
afin d’exploiter ces re´sultats pour mieux mode´liser les dommages a` l’ADN dans les cal-
culs Monte-Carlo de dosime´trie personnalise´e. Cette strate´gie pourrait aussi permettre
d’ame´liorer le calcul de la dose absorbe´e a` la moelle osseuse en prenant en compte les
parame`tres microscopiques. Les images du patient peuvent eˆtre associe´es avec des repre´sentations
micro et macroscopiques de la moelle osseuse en combinant des mode`les analytiques et
voxelise´s, et ensuite utilise´es pour re´aliser un transport direct de la radiation comme cela
a e´te´ vu au chapitre 5.
L’application de cette me´thode multi-e´chelle requiert le de´veloppement d’outils in-
formatiques spe´cifiques, travail qui est actuellement mene´ au sein du CRCT (Centre de
Recherche en Cance´rologie de Toulouse).
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MULTI-SCALE DOSIMETRY FOR TARGETED RADIONUCLIDE THERAPY
OPTIMISATION
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Abstract
Targeted Radionuclide Therapy (TRT) consists in killing tumour targets by using radiolabeled
vectors (radiopharmaceuticals) that selectively bind to tumour cells. In a context of TRT opti-
mization, a better determination of energy deposition within biologic material is a prerequisite
to the definition of the absorbed dose-effect relationship and the improvement of future can-
cer treatment. This requires being able to quantitatively assess activity distribution (with the
most appropriate molecular imaging technique) and perform radiation transport at the scale at
which biologically relevant phenomena occur. The methodologies that should be applied and
the problematic to be faced strictly depend on the scale (cell, tissue, body) of the application
considered, and on the type of radiation involved (photons, electrons, alpha). This research
work consisted in developing dedicated dosimetric techniques (single-scale dosimetry) capable
of taking into account the peculiarity of different experimental scenarios (cellular, pre-clinical,
clinical TRT).
Keywords: Targeted radionuclide therapy – Cellular dosimetry – Preclinical dosimetry – Clin-
ical dosimetry – Monte Carlo modelling – Multi-scale dosimetry.
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Re´sume´
La Radiothe´rapie Interne Vectorise´e (RIV) consiste a` de´truire des cibles tumorales en utilisant
des vecteurs radiomarque´s (radiopharmaceutiques) qui se lient se´lectivement a` des cellules tu-
morales. Dans un contexte d’optimisation de la RIV, une meilleure de´termination du de´poˆt
d’e´nergie dans les tissues biologiques est primordiale pour la de´finition d’une relation dose ab-
sorbe´e - effet biologique et pour l’optimisation des traitement du cancer. Cela ne´cessite une
e´valuation quantitative de la distribution de l’activite´ (avec la technique d’imagerie mole´culaire
la plus approprie´e) et d’effectuer le transport du rayonnement a` l’e´chelle a` laquelle se produisent
les phe´nome`nes biologiques pertinents. Les me´thodologies a` appliquer et les proble´matiques a`
e´tablir de´pendent strictement de l’e´chelle (cellule, tissu, organe) de l’application conside´re´e, et du
type de rayonnement en cause (photons, e´lectrons, particules alpha). Mon travail de recherche
a consiste´ a` de´velopper des techniques dosime´triques de´die´es (dosime´trie mono-e´chelle) et in-
novantes, capables de prendre en compte la particularite´ de diffe´rents sce´narios expe´rimentaux
(cellulaire, pre´-clinique, RIV clinique).
Mots-cle´s : Radiothe´rapie interne vectorise´e - dosime´trie cellulaire - dosime´trie pre´clinique -
dosime´trie clinique - mode´lisation Monte Carlo - dosime´trie multi-e´chelle.
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